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Short description and aim of the present thesis
Botanicals and botanical preparations such as plant food supplements (PFS) 
are widely marketed within the European Union (EU). However, procedures 
for safety assessments of PFS have not been legally harmonized at the EU 
level and are therefore governed by national legislation and manufacturer’s 
procedures (Silano et al., 2011). To adequately support the safe use of PFS, 
the validity of existing procedures for risk and safety assessment need to be 
demonstrated and procedures need to be harmonized at the European level. 
While many consumers equal ‘natural’ with ‘safe’, PFS may contain compounds 
that are of concern for human health. One of the major bottlenecks in the safety 
assessment of botanicals and botanical ingredients, and thus also for PFS, is 
the fact that some botanicals may contain compounds that are both genotoxic 
and carcinogenic. The risk assessment of such compounds is complicated and 
an international scientific agreement on the best practices for risk assessment 
of these type of compounds is currently lacking (EFSA, 2005). Therefore, the 
present thesis aimed at testing new concepts that could be of use for the risk 
and safety assessment of PFS focusing on finding adequate ways to judge the 
risk or safety of PFS that may contain compounds that are both genotoxic 
and carcinogenic. The concepts tested include the Margin of Exposure (MOE) 
approach, a mode of action based approach and a matrix effect approach. 
These concepts, described below, address the most important issues in risk and 
safety assessment of PFS according to dedicated bodies such as the European 
Food Safety Authority (EFSA). Considering that risk management actions can 
only be based on adequate safety evaluations, this work should ultimately give 
a better idea on when risk management actions would be needed, but also for 
which PFS there is no reason for concern even though they do contain limited 
amounts of compounds that may be genotoxic and carcinogenic. 
Plant Food Supplements (PFS)
Definition of PFS 
According to the EU Directive on Food Supplements (2002/46/EC), the term 
“food supplement” covers a wide range of nutrients and other ingredients 
such as vitamins and minerals, amino acids, essential fatty acids, fiber and 
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various plants and herbal extracts. Food supplements can be defined as “… 
foodstuffs the purpose of which is to supplement the normal diet and which 
are concentrated sources of nutrients or other substances with a nutritional or 
physiological effect, alone or in combination, marketed in dose form, namely 
forms such as capsules, pastilles, tablets, pills and other similar forms, sachets of 
powder, ampoules of liquids, drop dispensing bottles, and other similar forms 
of liquids and powders designed to be taken in measured small unit quantities” 
(Directive 2002/46/EC). Food supplements prepared from botanicals are 
generally referred to as PFS (acronym of plant food supplements). 
Market structure and consumer behavior towards PFS 
To date, the market volume for botanicals and botanical preparations including 
PFS is rapidly expanding. Reportedly, in 1999 the global market for herbal 
supplements was worth $15 billion (Glaser, 1999) and the predicted sales of 
herbal supplements and remedies will reach $93 billion by 2015 (Vargas-Murga 
et al., 2011). This robust growth has been linked to the fact that PFS are within 
easy reach of consumers as they are sold over the counter in supermarkets, 
drugstores, health-food shops, pharmacies and via Internet (EFSA, 2004). In fact, 
the number of web shops marketing PFS online is still increasing and the sale of 
PFS via Internet is expected to be of growing importance (Vargas-Murga et al., 
2011). Resulting from the increasing market volume of PFS, including the sale 
of PFS from countries were PFS are not regulated, the need for stricter control 
and safety testing of such products becomes more important in order to protect 
consumers against adverse effects. 
Additional causes of the increasing market volume are the ageing 
population, a lack of confidence in conventional medical practice, increasing 
awareness of consumers to take charge of their health and well-being by self-
medication and the fact that botanicals and products made thereof generally 
have a high consumer acceptance (Egan et al., 2011; Vargas-Murga et al., 2011). 
Although available consumer studies focus predominantly on the use of dietary 
supplements in general, and as a result data on consumer attitudes and beliefs 
about PFS are limited, the available studies suggest that the people consuming 
PSF, for example products consisting of echinacea, ginkgo biloba, ginseng, 
green tea extract, St. John’s Wort and valerian amongst others, are generally 
female, have a higher education and relatively high income and are middle-
aged (Egan et al., 2011 and references therein).
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Concerns related to the quality and safety of PFS
Although botanicals and products made thereof including PFS are widely 
marketed and generally have a high consumer acceptance, some botanicals and/
or botanical preparations may contain toxic compounds that are of concern for 
human health. Previously, EFSA expressed some general concerns related to the 
quality and safety of botanicals and botanical preparations such as PFS (EFSA, 
2004). It was stated, amongst others, that chemical and microbial contamination 
of botanicals and botanical preparations, for example those originating from 
Asia, can be a problem. In fact, a variety of selected traditional Ayurverdic 
herbal preparations on the Dutch market sampled between December 2004 
and June 2007 were found to be contaminated with mercury, lead and arsenic 
resulting in daily intakes at levels that would exceed the established safety limits 
following use at dose levels recommended by the respective manufacturer 
(Martena et al., 2010). In addition, Martena et al. (2007) reported that despite 
the ban on aristolochic acids in herbal preparations worldwide, a number of 
Chinese traditional herbal preparations on the Dutch market were found to be 
contaminated with aristolochic acids. In fact, relatively high levels up to 1676 
mg aristolochic acid/kg herbal preparation were found (Martena et al., 2007). 
The claimed quantity and stability of the active ingredients in botanicals 
and products made thereof is another possible concern (EFSA, 2004). EFSA 
indicated that the occurrence of any efficacy following the use of botanical 
products can often be ascribed to the presence of one or more secondary 
plant metabolites. However, the patterns and concentrations of such secondary 
metabolites are highly dependent on biotic and abiotic factors causing stress 
(EFSA, 2004). As a result, differences can occur between botanicals that belong 
to the same species and variety, especially for botanicals grown in the wild. Such 
differences make it difficult to guarantee consistency of the composition of the 
botanical or the product made thereof (EFSA, 2004). 
Another concern expressed by EFSA is the presence of naturally 
occurring toxic compounds in botanicals (EFSA, 2004). Especially the use of 
highly concentrated plant material is of concern. Additionally, some botanicals 
or their ingredients are of possible concern because of their interactions with 
prescription drugs. Such contra-indications are often not mentioned on the 
label of botanical products including PFS (EFSA, 2004). Another issue of concern 
is the intentional addition of synthetic drugs to botanical preparations. An 
example is the intentional addition of sildenafil, the active ingredient of Viagra®, 
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to dietary supplements used for erectile dysfunction (FDA, 2009). However, 
the presence of Viagra® or its active ingredient might be of potential concern 
for human health especially for men taking prescription drugs that contain 
nitrates. Nitrate-containing drugs are often prescribed to persons suffering 
from diabetes, high blood pressure, high cholesterol, or heart diseases which 
are common conditions in persons with erectile dysfunction (FDA, 2009). The 
concomitant use of prescription drugs rich in nitrates and sildenafil might 
result in a marked lowering of blood pressure and should therefore be avoided 
(FDA, 2009). These existing concerns related to the quality and safety of PFS, 
underline the need for uniform and well accepted procedures for risk and safety 
assessment of PFS as well as for quality control. 
Concepts tested in the present thesis 
MOE approach 
Several approaches exist for the safety evaluation of compounds that are 
both genotoxic and carcinogenic, which may be applied in the risk and safety 
assessment of botanicals and/or botanical products containing these type of 
compounds. However, a general framework for the risk and safety assessment 
of PFS is not in place and rules for safety testing of PFS are subjected to national 
law. An overview of different approaches available for the risk and safety 
assessment of PFS is presented in Chapter 2 of the present thesis and includes 
the history of safe use, the tiered approach proposed by EFSA, the Threshold of 
Toxicological Concern (TTC) and the MOE concept. 
Regulatory and advisory bodies might use qualitative or quantitative 
approaches in the risk assessment of genotoxic carcinogens (Barlow and 
Schlatter, 2010). In the quantitative risk assessment of carcinogenic food-borne 
chemicals, animal data are often used to predict the risk for human health as 
data from human epidemiological studies are often not available or are difficult 
to obtain. Thus, the assessment of human cancer risk includes extrapolation 
from data obtained in animal studies and this may introduce uncertainty in the 
interpretation of the human cancer risk. 
One of the approaches to quantitatively assess the potential risk for 
human health, is linear extrapolation of the animal carcinogenicity data to 
obtain a virtual safe dose (VSD) at which the additional lifetime cancer risk would 
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be one in a million. When extrapolating animal data to a VSD that gives a one 
in a million extra risk for developing cancer upon lifetime exposure, a variety of 
models can be used including models that are based on simple extrapolation 
and models that are mathematically more complicated (EFSA, 2005). However, 
low-dose linear cancer risk extrapolation has been widely used and has been 
reported to be a worst case extrapolation method resulting in the lowest 
possible VSD but is, in spite of this, currently not generally accepted (EFSA, 
2005). Moreover, it is often unknown if the selected model adequately describes 
the underlying biological process associated with tumor development and risk 
estimates of a particular compound may vary orders of magnitude depending 
on the model applied (EFSA, 2005; O’Brien et al., 2006). Moreover, the effect of 
species differences in metabolism and the effects of genetic polymorphisms 
and lifestyle factors are not taken into account since rodent tumor data are 
converted to a VSD without incorporating uncertainty factors for interspecies 
or interindividual variation (Rietjens et al., 2011). Thus, better approaches are 
required for cancer risk assessment of compounds that are both genotoxic and 
carcinogenic. 
One of such approaches is based on the so-called Margin of Exposure 
(MOE). EFSA previously prepared an opinion on the MOE as a harmonized 
approach in the risk assessment of compounds that are both genotoxic and 
carcinogenic (EFSA, 2005). The MOE is a dimensionless ratio between (1) a 
reference point obtained from epidemiologic or experimental data on tumor 
incidence and (2) the estimated daily intake in humans (Barlow et al., 2006; EFSA, 
2005). The BenchMark Dose (BMD) approach is the preferred method to derive 
the reference point. The BMD can be obtained by fitting mathematical models 
to the observed data without extrapolation (Barlow et al., 2006). The BMDL, that 
is the one-sided 95% lower confidence limit of the BMD, is considered to be the 
preferred reference point, because it takes statistical uncertainties in the value 
of the BMD into consideration (Barlow et al., 2006). Using the BMD approach, 
reference points can be obtained for treatment-related tumor types occurring 
at a specific site or for the total number of tumors (Barlow et al., 2006). BMD and 
BMDL values can be calculated for a pre-defined increased tumor incidence 
compared to the background level, that is, the BenchMark Response (BMR), 
including a 1%, 5% or 10% incidence of tumors (EPA, 1995). Generally, the use 
of a BMDL10 (i.e. a 10% increase in tumor incidence) is preferred since the use 
of lower incidences will increase uncertainty as 1% and 5% may be outside 
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the experimentally observed incidences (Barlow et al., 2006). Figure 1 illustrates 
how the BMD and BMDL values are derived when a BMR of 10% is selected. 
To allow calculation of a BMDL value, studies are required that are performed 
using a control group and at least two exposure levels for which a treatment-
related dose-response relationship is observed. Whenever carcinogenicity data 
are insuffi  cient to derive a BMDL, also other relative potency estimates can be 
used as an alternative to derive a reference point allowing the calculation of an 
MOE (EFSA, 2005). An example of such an alternative is the T25, that is, a 25% 
tumor incidence in tested animals after lifetime exposure (Dybing et al., 1997).
Figure 1. Dose-response curve illustrating how the BenchMark Dose (BMD) and BMDL value (the one-
sided 95% lower confi dence limit of the BMD) are obtained for a BenchMark Response (BMR) of 10%.
Previously, several regulatory and advisory bodies including EFSA, the 
World Health Organization (WHO) and the International Life Sciences Institute, 
European Branch (ILSI Europe), concluded that the MOE concept is the preferred 
approach in risk assessment of compounds that are both genotoxic and 
carcinogenic (Barlow et al., 2006; EFSA, 2005; JECFA, 2005; O’Brien et al., 2006). 
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In fact, during an international conference organized by EFSA, the WHO and ILSI, 
it was concluded that “… the MOE approach was a useful and pragmatic option 
for risk assessment of substances that are both genotoxic and carcinogenic. 
It has the potential to improve the advice provided to risk managers, since it 
allows comparison between compounds and prioritization of risk management 
actions, especially if the MOE is accompanied by an appropriate narrative 
explaining inherent uncertainties" (Barlow et al., 2006). 
EFSA has suggested that an MOE lower than 10,000 is considered as 
a priority for risk management actions and would be of concern for human 
health provided that the MOE is based on a BMDL10 from animal data (EFSA, 
2005). The value of 10,000 takes into account uncertainties in the MOE including 
(1) a factor 100 for species differences and human variability in kinetics and 
dynamics, (2) a factor 10 for inter-individual human variability in cell cycle 
control and DNA repair, and (3) a factor 10 for the reason that the BMDL
10
 
when used as a reference point is not identical to a no observed adverse effect 
level (NOAEL) (EFSA, 2005). When using a reference point other than a BMDL
10
 
value, the MOE should be interpreted differently. For example, the T25 value 
represents an increased tumor incidence of 25% compared to the background 
incidence while the BMDL
10
 value is related to a 10% increased cancer incidence. 
In other words, the T25 value indicates a risk that is at least 2.5 times higher 
than the risk represented by the BMDL
10
 (Dybing et al., 2008). Therefore, an MOE 
value of 25,000 is proposed to be used to denote the level of concern when 
comparing a T25 value with estimated daily intake levels instead of an MOE of 
10,000 (Dybing et al., 2008). It is important to note that EFSA previously stated 
that risk managers, and not risk assessors, are responsible to judge what MOE 
value would be considered acceptable (EFSA, 2005). In addition, whenever 
MOE values are determined to be 10,000 or higher, this should not preclude 
the application of risk management actions to reduce human exposure (EFSA, 
2005). 
In addition to the carcinogenicity data that are required for calculating 
BMDL10 values, adequate human exposure data are required as well to calculate 
the MOE. Moreover, MOE values can be calculated for different exposure 
scenarios. For example, estimated daily intakes, and thus the MOE, can be 
calculated for the whole population, the mean and median intakes, or individuals 
that are highly exposed (EFSA, 2005). The MOE approach can thus be applied to 
compare the potential risk for human health resulting from different exposure 
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scenarios e.g. exposure to a botanical compound from the use of herbs and 
spices, compared to the use of PFS. 
Mode of action based approaches 
A major limitation of the MOE approach is the fact that this approach requires 
carcinogenicity data to define the BMDL
10
, whereas for many botanical 
ingredients such carcinogenicity data are not available. Therefore, mode of 
action based approaches may be used to perform a read across from one 
compound to another and still perform a risk assessment for compounds for 
which tumor data are absent. The US Environmental Protection Agency (EPA) 
previously defined the term mode of action as “…a sequence of key events and 
processes, starting with interaction of an agent with a cell, proceeding through 
operational and anatomical changes, and resulting in cancer formation. A “key 
event” is an empirically observable precursor step that is itself a necessary 
element of the mode of action or is a biologically based marker for such an 
element.” (EPA, 2005). It is important to note that genotoxic compounds can 
exert different modes of action. For example, such compounds can bind directly 
to the molecular target or it might require bioactivation to a reactive metabolite 
that can interact with the molecular target (Paini, 2012). To describe key events 
leading to the development of tumors, one should take into account physical, 
chemical, and biological information (EPA, 2005) including kinetics (absorption, 
distribution, metabolism and excretion) and dynamics (events leading to tumor 
formation). 
To derive a mode of action based approach, physiologically based 
kinetic (PBK) modeling may be used. PBK models allow to mathematically 
describe the absorption, distribution, metabolism and excretion (ADME) of 
chemicals. These mathematical equations are principally based on physiological 
parameters (e.g. tissue blood flow rates, tissue volumes and cardiac output), 
physico-chemical parameters (e.g. blood-tissue coefficients) and metabolic 
parameters (e.g. kinetic constants for metabolic conversions) (Chiu et al., 
2007; Clewell and Clewell, 2008; Krewski et al., 1994; Rietjens et al., 2011). The 
outcomes of these equations can give insight in possible dose-dependent 
changes in metabolism with increasing levels of exposure to a chemical 
(Rietjens et al., 2011). Moreover, blood and tissue concentrations of a particular 
chemical or its active metabolite(s) can be monitored over time (Rietjens et al., 
2011). The parameters used in PBK modeling can be substituted for parameters 
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for a species of interest allowing interspecies extrapolation (Andersen, 1994). 
Additionally, PBK modeling can give an insight in interindividual differences 
by including kinetic constants for metabolic conversion by human individuals 
and for specific isoenzymes (Bogaards et al., 2000; Punt et al., 2010; Rietjens 
et al., 2011; Rostami-Hodjegan and Tucker, 2007). The development of PBK 
models consists of six different steps i.e. (1) definition of the conceptual model, 
(2) translation into a mathematical model, (3) defining parameter values, (4) 
solving the equations, (5) evaluation of model performance and (6) making 
predictions, which are extensively described by Rietjens et al. (2011). In short, 
in the first step several compartments should be defined representing organs 
and tissues that are relevant for the ADME characteristics of the compound 
of interest. The remaining organs and tissues can be pooled in compartments 
representing slowly (e.g. bone, muscle and skin) or richly (e.g. adrenals, brain 
and heart) perfused tissues. Moreover, an additional compartment for fat can 
be added if the compound of interest is relatively lipophilic. All compartments 
will be mutually connected through the systemic circulation. Figure 2 provides 
a schematic overview of a basic PBK model consisting of several compartments. 
In the next step, mathematical equations need to be defined describing the 
kinetic processes, including ADME characteristics, of the compound of interest. 
For each compartment, a set of mathematic equations needs to be defined. In 
addition to the definition of mathematical equations for each compartment, also 
parameter values need to be defined. Such parameters include (1) physiological 
and anatomical parameters, (2) physico-chemical parameters and (3) kinetic 
parameters as described above. After the mathematical model has been defined, 
the equations need to be solved to obtain concentrations of the compound of 
interest and its metabolite(s) in the relevant compartment or the body. This can 
be done using a variety of software packages such as Berkeley Madonna (Macey 
and Oster, UC Berkeley, CA, USA), acslXtreme (AEgis Technologies Group), and 
MATLAB (The MathWorks). Subsequently, an evaluation of model performance 
has to be made. This can be done by comparing the model outcomes to available 
in vivo data supporting the validity of the model. Moreover, a sensitivity analysis 
can be performed to provide a quantitative evaluation of how the input 
parameters of the model influence model output. Based on such an analysis it 
can be concluded whether the model output is directly or inversely related to a 
specific parameter. When the PBK model adequately predicts in vivo observed 
data, the model can be used to make predictions for different exposure scenarios. 
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For example, the concentration of an unstable reactive intermediate can be 
predicted which generally remains undetected in conventional toxicity studies. 
To describe the dynamic processes resulting in cancer formation, PBK models 
can even be extended to physiologically based dynamic (PBD) models. Some 
examples of dynamic characteristics that can be included in the PBD model 
to describe the mode of action of the compound of interest are DNA-adduct 
formation and DNA repair and ultimately tumor formation (Paini, 2012). 
Figure 2. Schematic overview of a PBK model. 
Matrix eff ect approach 
Generally, risk assessment of botanicals and botanical preparations is performed 
using data obtained from rodent studies which use high dose levels of the 
botanical compound administered by gavage in the absence of a natural 
botanical matrix (Rietjens et al., 2008). However, the presence of a botanical 
matrix might alter the toxicity of the botanical compound(s) of interest (Rietjens 
et al., 2008). In fact, the bioavailability of the compound of interest may be 
reduced when consumed in the presence of a matrix resulting from a slow or 
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incomplete release of the active principle from the matrix (Schilter et al., 2003). 
Another example is that specific intestinal carriers involved in active uptake 
of an ingredient might be inhibited by the matrix (Rietjens et al., 2008). These 
examples indicate that the ADME characteristics of a botanical compound of 
interest might be modulated by additional compounds present in the botanical 
or the product made thereof. As a result, the use of data from rodent studies 
conducted using the pure compound may not represent an adequate basis for 
risk assessment (Rietjens et al., 2008). This suggests that (experimental) data are 
essential to demonstrate the importance of matrix-derived combination effects 
for risk assessment of individual compounds. However, marked differences in 
composition can occur between botanicals that belong to the same species 
and variety, especially for botanicals grown in the wild (EFSA, 2004). Such 
differences make it difficult to guarantee consistency of the composition of 
the botanical or the product made thereof (EFSA, 2004). In addition, a wide 
variety of manufacturing methods for preparing PFS are available resulting 
in compositional differences of the final product. Clearly, this complicates the 
performance of risk and safety assessments of such botanical products in a 
generic manner. Therefore, a full toxicological assessment should preferably 
be performed for each individual botanical or botanical product. However, it 
would be impossible to perform toxicity studies for all specific botanicals and 
botanical preparations available. It is therefore of importance to develop and 
validate new science-based approach(es) to take matrix-derived combination 
effects into account without the need of animal testing. 
Previously, Rietjens et al. (2008) proposed to study the matrix-derived 
combination effects on a case-by-case basis based on analytical characterization 
of the major compound(s) responsible for this effect. Recently, this proposed 
approach was applied by Alhusainy and colleagues who identified the major 
compounds responsible for the matrix modulation of the bioactivation of the 
alkenylbenzene estragole based on in vitro data (Alhusainy et al., 2012). In 
addition, the possible in vivo effects were predicted by means of PBK modeling 
taking into account the relative ratio between the active principle (i.e. estragole) 
and the major compound responsible for this effect (i.e. nevadensin). Moreover, 
the importance of the matrix-derived combination effect in vivo was validated 
and confirmed in an in vivo rat study (Alhusainy et al., 2013). 
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Alkenylbenzenes, the model compounds tested in the 
present thesis 
Background
To test the use of the MOE concept, the mode of action concept and the matrix 
concept for the risk and safety assessment of PFS, compounds from the group of 
alkenylbenzenes were selected as model compounds. Chapter 3 of the present 
thesis describes the process underlying this selection of the alkenylbenzenes, 
as an important group of compounds that may be present in PFS and that exert 
genotoxic and/or carcinogenic properties. In short, this selection was based 
on (1) information on genotoxic and carcinogenic botanical ingredients as 
listed in the EFSA compendium (EFSA, 2012), (2) data from studies performed 
by the National Toxicology Program (NTP) providing evidence of genotoxicity 
and/or carcinogenicity of botanical compounds, and (3) the expert judgment 
from partners collaborating under the PlantLIBRA project (acronym PLANT 
food supplements: Levels of Intake, Benefit and Risk Assessment), a European 
collaborative project under the Seventh Framework Programme. Important 
compounds that were judged to be present in PFS, and are genotoxic and 
carcinogenic, were found to belong to the group of alkenylbenzenes (e.g. 
estragole, methyleugenol, safrole, β-asarone and elemicin) and the group of 
unsaturated pyrrolizidine alkaloids (e.g. riddelliine and monocrotaline). To date, 
compounds belonging to the group of unsaturated pyrrolizidine alkaloids are 
regulated and not allowed in PFS. For this reason, compounds belonging to 
the group of alkenylbenzenes were selected as the model compounds tested 
in the present thesis. 
Alkenylbenzenes including estragole, methyleugenol, safrole and 
β-asarone but also elemicin, apiol, myristicin, trans-anethole, eugenol and 
isosafrole (Figure 3) are naturally occurring compounds that contribute to 
the characteristic taste and fragrance of herbs and spices. Several herbs and 
spices such as anise, nutmeg, fennel, mace and basil contain combinations 
of alkenylbenzenes (SCF, 2001a, 2001b, 2002). However, within the same 
botanical, differences may occur in the levels of the different alkenylbenzenes 
present depending on geographical origin, the plant maturity at harvest and 
techniques used for harvesting, storage conditions, processing methods such 
as drying, and the distribution of alkenylbenzenes within the plant (Smith et 
al., 2002). Although humans are widely exposed to alkenylbenzenes through 
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the consumption of traditional foods, not much is known concerning the 
possible adverse impact on human health. A number of rodent carcinogenicity 
assays reveal the hepatocarcinogenic effects of the alkenylbenzenes estragole, 
methyleugenol and safrole (SCF, 2001a, 2001b, 2002). Moreover, a genotoxic 
mode of action has been suggested for these compounds (SCF, 2001a, 
2001b, 2002). These adverse effects have been linked to the conversion of 
the alkenylbenzenes to their carcinogenic metabolites. Figure 4 presents an 
overview of the metabolic pathways of estragole which are also relevant for 
the other alkenylbenzenes. The observed genotoxic and carcinogenic effects 
of alkenylbenzenes have been linked to their bioactivation by cytochrome 
P450 enzymes and sulfotransferase (SULT)-enzymes, resulting in the formation 
of 1’-sulfoxymetabolites and corresponding carbocations formed upon 
degradation of the 1’-sulfoxymetabolites (Anthony, 1987; Drinkwater et al., 
1976; Miller et al., 1983; Sangster et al., 1987; Solheim and Scheline, 1973; 
Wiseman et al., 1987).
Figure 3. The structural formulas of several alkenylbenzenes.
Genotoxicity
The alkenylbenzenes estragole, methyleugenol, safrole, elemicin, myristicin, and 
apiol have previously been given priority by JECFA for evaluation of their risks 
resulting from consumption of botanicals and botanical preparations (JECFA, 
2009). Estragole, methyleugenol and safrole have been tested in a number 
of in vitro and in vivo genotoxicity assays. However, the alkenylbenzenes 
elemicin, myristicin and apiol are less well studied and consequently only 
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limited genotoxicity studies are available. An overview of genotoxicity studies 
performed using estragole, methyleugenol and safrole is presented in Tables 1-3. 
 Based on the mode of action of the alkenylbenzenes, positive responses 
would be only expected in test systems containing appropriate enzymes and 
their cofactors required for bioactivation. Estragole (Table 1) and methyleugenol 
(Table 2) were found to be non-mutagenic in a number of studies using 
bacterial cells. This can be explained by the lack the sulfonation pathway in 
these test systems. In fact, a positive response for mutagenicity was recently 
demonstrated for methyleugenol in a reverse mutation test using Salmonella 
typhimirum TA100 expressing different SULT enzymes required for sulfonation 
of methyleugenol and the other alkenylbenzenes (Herrmann et al., 2012). For 
safrole equivocal results have been found in a number of reverse mutation tests 
using bacterial cells (Table 3).
Figure 4. Metabolic pathways of estragole also relevant for the other alkenylbenzenes. Arrows in bold 
indicate the bioactivation to 1’-sulfoxyestragole resulting in DNA-adduct formation. 
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However, it should be noted that cytotoxicity was observed in several of the reverse 
mutation studies performed using safrole (Table 3). It is of importance to note that 
the majority of studies performed for the alkenylbenzenes date from the early to 
mid-1980s (JECFA, 2009). In these studies, relatively high concentrations were used 
that resulted in marked cytotoxic effects in several studies (JECFA, 2009). Moreover, 
during that period extreme culture conditions including hypo- and hyper osmolality 
and a high pH were often used (JECFA, 2009). Reportedly, such conditions can result 
in apoptosis and necrosis leading to DNA fragmentation and this may result in a 
false positive response in clastogenic assays (e.g. chromosomal aberration test and 
micronuclei test) (JECFA, 2009; Meintieres and Marzin, 2004). 
Despite the fact that the alkenylbenzenes have been found to be negative in 
several in vitro and in vivo genotoxicity assays, the formation of DNA adducts has been 
observed in vitro, demonstrating DNA reactivity (Zhou et al., 2007). Moreover, estragole, 
methyleugenol and safrole gave positive results in a variety of in vivo DNA binding 
assays (Boberg et al., 1983; Daimon et al., 1998; Phillips et al., 1981a; Phillips et al., 1981b; 
Randerath et al., 1984; Wiseman et al., 1985) suggesting that the alkenylbenzenes exert 
genotoxic characteristics. The formation of DNA adducts has also been demonstrated 
for the 1’-hydroxymetabolites of estragole and safrole (Wiseman et al., 1985). Moreover, 
Randerath et al. (1984) demonstrated that the binding of safrole to mouse liver DNA 
was inhibited following pre-treatment with pentachlorophenol (PCP), a known SULT 
inhibitor, suggesting that the genotoxic effects are dependent on SULT-mediated 
metabolism. Estragole, methyleugenol and safrole were found to induce unscheduled 
DNA Synthesis (UDS) in several in vitro and in vivo studies (Tables 1-3). In addition, 
Chan and Caldwell (1992) demonstrated that the induction of UDS in rat hepatocytes 
by the 1’-hydroxymetabolites of estragole, methyleugenol and safrole was higher 
than UDS induction by the parent compounds (Chan and Caldwell, 1992). In the UDS 
test, freshly isolated hepatocytes from rat or mouse are generally used to detect DNA 
repair synthesis. These freshly isolated hepatocytes contain enzymes and cofactors 
required for bioactivation of alkenylbenzenes explaining the positive results obtained. 
Overall, UDS tests and DNA-adduct formation in vitro and in vivo suggest 
that the alkenylbenzenes including estragole, methyleugenol and safrole exert 
genotoxic characteristics. The lack of positive results in standard genotoxicity tests 
and the observation that 1’-hydroxyetabolites gave positive results in UDS tests 
emphasize that the genotoxic effects are dependent on metabolism and suggest 
that the sulfonation pathway should be taken into account in standard in vitro tests 
as recently done by Herrmann et al. (2012). 
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Carcinogenicity
In literature several carcinogenicity studies are described for estragole, 
methyleugenol and safrole. A summary of the carcinogenicity studies 
performed using estragole, methyleugenol and safrole is presented below. 
 Estragole and its proximate carcinogenic metabolite, 
1’-hydroxyestragole, have been found to be carcinogenic in CD-1 and B6C3F1 
mice (Drinkwater et al., 1976; Miller et al., 1983; Wiseman et al., 1987). In these 
studies, mice were exposed to estragole or its 1’-hydroxymetabolite by intra 
peritoneal (i.p.) injections (Miller et al., 1983; Wiseman et al., 1987), subcuteneous 
(s.c.) injections (Drinkwater et al., 1967; Miller et al., 1983) or via the diet (Miller 
et al., 1983). Based on the studies performed for estragole, it is suggested 
that male mice are more susceptible for tumor formation than female mice 
(Drinkwater et al., 1976; Miller et al., 1983; Wiseman et al., 1987). In addition 
to hepatic tumors, a few incidences of angiosarcomas and lung adenomas 
were observed (Miller et al., 1983). Wiseman et al. (1976) revealed that the 
induction of liver tumors by estragole was inhibited by PCP suggesting that the 
formation of 1’-sulfoxymetabolites is an important step in the carcinogenicity 
of estragole. Adequate studies in which estragole was tested for carcinogenicity 
in rats are not available in literature. Nevertheless, Miller et al. (1983) showed 
that 1’-hydroxyestragole is carcinogenic in male Fisher rats following the 
subcutaneous injection of 1’-hydroxyestragole. 
Methyleugenol was shown to induce hepatomas in male B6C3F1 
mice following i.p. treatment of methyleugenol twice weekly for a period 
of 12 weeks (Miller et al., 1983). The same effects were seen in mice treated 
with 1’-hydroxymethyleugenol by i.p. injection (Miller et al., 1983). In a 2-year 
gavage study performed by the NTP it was demonstrated that methyleugenol 
is a multisite carcinogen (NTP, 2000). In fact, in male and female F344/N rats 
increased incidences of liver neoplasms and neuroendocrine tumors of the 
glandular stomach were observed (NTP, 2000). In addition, in male rats also 
increased incidences of kidney neoplasms, malignant mesothelioma, mammary 
gland fibro adenoma, and subcutaneous fibroma and fibroma or fibro sarcoma 
were observed (NTP, 2000). In B6C3F1 mice, target organs included the liver and 
glandular stomach (NTP, 2000). 
Safrole was found to be carcinogenic in CD-1 and B6C3F1 mice (Borchert 
et al., 1973; Miller et al., 1983), and Fischer and CD random bred rats (Miller et 
al., 1983; Wislocki et al., 1977). In these studies, mice and rats were exposed 
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to safrole by i.p. injections (Borchert et al., 1973; Miller et al., 1983; Wislocki et 
al., 1977) s.c. injections (Miller et al., 1983; Wislocki et al., 1977) or via the diet 
(Miller et al., 1983; Wislocki et al., 1977). Target organs included liver, lungs, fore 
stomach, kidney and the mammary glands (Wislocki et al., 1977). In addition, 
the induction of hepatomas and lung carcinomas has been demonstrated for 
1’-hydroxysafrole in mice and rats (Miller et al., 1983; Wislocki et al., 1977). 
Overall, estragole, methyleugenol and safrole were found to be multisite 
carcinogens, with the liver being the most important target organ. In addition, 
methyleugenol and safrole were demonstrated to be multispecies carcinogens. 
However, for estragole only mice studies are currently available in literature 
suggesting that estragole is also a multispecies carcinogen as demonstrated 
for its structurally related analogues. In line with these findings, EPA previously 
indicated that mutagenic agents generally show multisite and multispecies 
tumor effects (EPA, 2005). 
Previous risk assessments
Although genotoxic and carcinogenic characteristics have previously been 
indicated for estragole, methyleugenol and safrole, different safety assessments 
of these naturally occurring botanical ingredients present different conclusions. 
Previously, the Flavor and Extracts Manufacturers Association (FEMA) 
suggested that the present human exposure to estragole and methyleugenol 
from herbs and spices does not pose a significant cancer risk at the low levels 
of exposure resulting from flavor use (Smith et al., 2002). Furthermore, the 
European Medicines Agency (EMA, former EMEA) concluded that there is no 
considerable risk for human health resulting from the short-term exposure to 
herbal medicinal products containing alkenylbenzenes by adults at the dosing 
regimen suggested (EMA, 2004, 2005). The conclusions drawn by FEMA and 
EMA, were based on available animal studies on the profiles of metabolism, 
metabolic activation, and covalent binding of estragole and methyleugenol to 
DNA suggesting a dose-response relationship with a non-linear mode of action. 
In fact, it was concluded that the relative importance of the adverse effects will 
be significantly reduced at low exposure levels relevant for the daily human 
exposure to these genotoxic carcinogens (EMA, 2004, 2005; Smith et al., 2002). 
In contrast, the EU Scientific Committee on Food (SCF) previously indicated 
restrictions in the use of these compounds as pure ingredients added to food 
(SCF, 2001a, 2001b, 2002). These restrictions in use were suggested because of 
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the genotoxic and carcinogenic characteristics of these compounds. Because 
of these genotoxic and carcinogenic characteristics, the SCF concluded that the 
presence of a threshold in their mode of action cannot be assumed for these 
compounds thus hampering the determination of a safe exposure limit (SCF, 
2001a, 2001b, 2002). 
Regulatory status
In addition to differences in expert opinions on the safety assessment of the 
alkenylbenzenes, differences can be defined concerning the regulatory actions 
that have been taken at the international level. The alkenylbenzenes estragole, 
methyleugenol and safrole were often directly added to food as a flavoring 
substance in baked goods, candies and other foodstuffs (Smith et al., 2002) in the 
US where these compounds are approved by the Food and Drug Administration 
(FDA) for use in foods for human consumption as a flavoring. However, the use 
of estragole and methyleugenol, as pure substance in food is limited to the US. 
The EU recently decided to prohibit the use of these compounds as flavoring 
agents (Regulation (EC) No 1334/2008 of the European Parliament and of the 
Council 16 December 2008). In addition, maximum levels of estragole and 
methyleugenol, naturally present in food ingredients with flavoring properties, 
have been defined for a number of foodstuffs (Regulation (EC) No 1334/2008 
of the European Parliament and of the Council 16 December 2008). The use of 
safrole, as a flavoring in human nutrition, was already prohibited earlier by the 
Council of the European Communities (Council Directive 88/388/EEC of 22 June 
1988). Safrole is also banned by the FDA (Federal Register of December 3, 1960, 
25 FR 12412). Despite these prohibitions, alkenylbenzenes still occur in the 
regular diet because they occur naturally in herbs and spices and products made 
thereof. Consequently, estragole, methyleugenol and safrole can still be found 
in a variety of products including pesto, tomato sauces, meat-based products, 
such as Bologna and Vienna sausages (Siano et al., 2003), and herbal teas. In 
contrast to the existing regulations for food within the EU, such regulations are 
not in place for the use of alkenylbenzene-containing PFS. 
These existing differences in expert opinions and regulatory actions 
that have been taken at the international level related to the presence of 
alkenylbenzenes in food, underlines the need for uniform and well accepted 
procedures for risk and safety assessment of these genotoxic carcinogens. 
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Outline of the present thesis
The present thesis aimed at testing and validating new concepts that could be of use 
for the risk and safety assessment of PFS focusing on finding adequate ways to judge 
the risk or safety of PFS that may contain compounds that are both genotoxic and 
carcinogenic. The concepts tested include the MOE concept, the use of a mode of action 
based concept for risk assessment, and the matrix effect concept. In addition, safety 
assessment was also performed for botanical preparations in the form of herbal teas. 
Chapter 1, the present chapter, defines the aim of the present thesis and gives 
a general introduction to PFS, an introduction to the concepts tested, an introduction 
to the model compounds tested in the present thesis, and also presents the outline of 
the present thesis. The general framework for safety assessment of PFS is presented 
in Chapter 2. In addition, Chapter 2 provides some examples of types of botanical 
compounds of concern and their major adverse effects. Chapter 3 describes the 
selection and analysis of genotoxic and carcinogenic compounds which can be found in 
PFS and a subsequent risk assessment using the MOE concept. The majority of selected 
compounds were found to belong to the group of alkenylbenzenes (e.g. estragole, 
methyleugenol, safrole and β-asarone) or the group of unsaturated pyrrolizidine alkaloids 
(e.g. riddelliine and monocrotaline). Based on the fact that unsaturated pyrrolizidine 
alkaloids are currently already regulated and not allowed in PFS, in subsequent chapters 
of the thesis studies focused on the group of alkenylbenzenes. In Chapter 4 mode of 
action based PBK models were defined describing the bioactivation and detoxification 
of the alkenylbenzene elemicin in rat and human. The development of PBK models for 
elemicin allowed performing a read across from estragole and methyleugenol for which 
tumor data are available to elemicin for which the toxicological database is limited. 
Based on the results thus obtained a risk assessment could be performed for elemicin. 
In Chapter 5 risk assessment was performed based on an approach that takes the 
matrix-derived combination effects into account. For this purpose, the risk assessment 
described in Chapter 3 for basil-containing PFS was updated taking the matrix-derived 
combination effect for the bioactivation of estragole into account. Chapter 6 presents 
the analysis of estragole in dry fennel preparations and in water infusions prepared from 
them and the evaluation of the potential risk associated to the presence of estragole. 
Finally, Chapter 7 gives a discussion of the results obtained in this thesis and presents 
some suggestions for steps to be taken in the near future for a further improvement of 
the risk and safety assessment of PFS. 
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Abstract
Botanicals and botanical preparations, including plant food supplements (PFS), 
are widely used in Western diets. The growing use of PFS is accompanied by an 
increasing concern because the safety of these PFS is not generally assessed 
before they enter the market. Regulatory bodies have become more aware of 
this and are increasing their efforts to ensure the safety of PFS. The present 
chapter describes an overview of the general framework for safety assessment 
of PFS focusing on different approaches currently in use to assess the safety 
of botanicals and/or botanical compounds including history of safe use, the 
tiered approach proposed by the European Food Safety Authority (EFSA), the 
Threshold of Toxicological Concern (TTC) and the Margin of Exposure (MOE) 
concept. Moreover, some examples of botanical compounds in PFS that may 
be of concern are discussed. Altogether it is clear that 'natural' does not equal 
'safe' and that PFS may contain compounds of concern at levels far above those 
found in the regular diet. In addition, the traditional use of a PFS compound 
as an herb or tea does not guarantee its safety when used as a supplement. 
This points at a need for stricter regulation and control of botanical containing 
products, especially given their expanding market volume.
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General introduction
At present, there is an increasing interest for plant ingredients and their 
use in drugs, for teas, and/or in food supplements. Such use may result in 
intake levels that exceed the normal dietary intake of these botanicals and/
or their ingredients. Although plant food supplements (PFS) are widely 
marketed, the safety of these PFS is not generally assessed before they 
enter the market. Regulatory bodies have become more aware of this and 
are increasing their efforts to ensure the safety of botanical supplements 
(EFSA, 2004a; Taylor, 2004). The Scientific Committee of the European Food 
Safety Authority (EFSA) issued a guidance in which a general framework for 
safety assessment of botanicals and botanical preparations was presented 
(EFSA, 2007). In this opinion it was recommended to test the proposed 
approach for the safety assessment of botanicals and botanical preparations 
with a number of examples, resulting in an advice on the EFSA guidance 
document, based on real case studies by the EFSA Scientific Cooperation 
(ESCO) working group on botanicals and botanical preparations (EFSA, 2009a; 
Speijers et al., 2010) and an updated guidance document (EFSA, 2009b). 
  In spite of this regulatory awareness it cannot be excluded that specific 
developments may still result in health concerns. Such developments include; 
(1) overconsumption by particular groups, sometimes stimulated by companies 
making misleading claims on their websites or in their literature; (2) the fact 
that many consumers equate ‘natural’ with ‘safe’ when considering PFS; (3) the 
availability of potentially harmful PFS through internet sites from countries 
where regulations are not in place; and (4) the fact that often there are no detailed 
requirements on safety and quality of PFS. The latter is especially worrying as 
botanicals are known to be of variable quality with high variation not only in the 
content of the active but also of the toxic principles, and the fact that already 
several cases of replacement of a harmless variety with a toxic alternative have 
occurred. One such example relates to Chinese star anise (Illicium verum) used in 
many cultures, mostly for preparing tea. In September 2001 in The Netherlands, 
more than 60 people showed nausea and vomiting after drinking an herbal tea 
called ‘starmix tea’ containing star anise, and 22 persons were hospitalized due 
to tonic-clonic insults (Johanns et al., 2002; Oudesluys-Murphy and Oudesluys, 
2002). Electroencephalograms (EEGs) showed epileptiform abnormalities 
indicating a diffuse cerebral disease (Biessels et al., 2002). The complaints 
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were ascribed to a toxic star anise species comparable to Japanese star anise 
(Illicium anisatum) containing anisatin which was accidentally exchanged for 
the non-toxic Chinese star anise (Illicium verum) (Johanns et al., 2002). After 
this incident and the detection of Japanese star anise in consignments of 
star anise from third countries, the EU took legislative measures to increase 
control and safeguard public health (Commission Decision 2002/75EC). These 
measures included the requirement of documentary evidence confirming that 
the imported products do not contain any Japanese star anise, and random 
sampling and analysis of these products. Sampling and control was also 
implemented for products already on the market. These measures were of a 
temporal nature as they were lifted one year later given the absence of new 
cases of contamination and poisoning (Commission Decision 2003/602/EC). 
  Another example of replacement of a harmless variety with a toxic 
alternative comes from the use of Chinese medical products. In 1991, a unique 
form of nephropathy was reported in Belgium. Over 100 young women suffered 
from kidney damage, developing into cancer of the kidneys and the urinary 
tract in several patients (Vanhaelen et al., 1994; Vanherweghem et al., 1993). 
This adverse effect was associated with the prolonged intake of a Chinese herb-
based weight loss preparation in which Stephania tetranda was accidentally 
replaced by Aristolochia fanchi, because both plants are used under the same 
name ‘Fangji’ in Chinese folk medicine (Vanherweghem et al., 1993). On the basis 
of this incident, risk management actions have been taken by the authorities 
of most EU Member States to prevent such from happening again.   
  The present chapter focuses on the general framework for safety 
assessment of PFS, presenting also some examples of types of botanical 
compounds of concern and their major adverse effects. Furthermore, some 
emphasis is given to the modulating effect of other PFS ingredients modifying 
the actual risk posed by a specific botanical ingredient. 
General framework for risk/safety assessment of PFS 
At present, a formalized framework for the safety assessment of PFS is 
not in place and safety assessments are performed on a national basis 
or by dedicated bodies like, for example, EMA (former EMEA) (European 
Medicines Agency). EMA, however, judges the safety of medicinal 
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preparations and does not refer to the safety of PFS in the field of food use. 
  In 2009, the Scientific Committee of EFSA published an updated 
guidance on the scientific data needed to carry out a safety assessment of a 
botanical or a botanical preparation (EFSA, 2009b). This guidance proposes 
a two-tiered scientific approach for the safety assessment depending on the 
available knowledge on a given botanical and the substance(s) it contains. The 
tiered approach takes into account the nature of the botanical or botanical 
preparation, its intended uses and levels of use including PFS and whether the 
botanical or botanical preparation has a long term (traditional) history of food 
use, showing that, at proposed exposure levels, no adverse effect on human 
health has been reported (Tier 1). In addition it is indicated that for botanical 
compounds lacking a history of food use, or for botanicals whose intended use 
levels will significantly exceed historical intake levels, an assessment of safety 
based on experimental toxicity data may be required (Tier 2). This further safety 
assessment can focus on a specific compound, if the compound of concern 
in a PFS can be well defined. In that case the safety may be judged based on 
existing safety values for that ingredient such as an Acceptable Daily Intake 
(ADI) or Tolerable Daily Intake (TDI). An example would be evaluating the 
intake of trans-anethole from use of bitter fennel fruits using the temporary 
ADI of 0-2.0 mg/kg bw for trans-anethole (EFSA, 2009a; JECFA, 1998). 
  The EFSA document does not give clear guidance on what to do when 
no health-based guidance values are available, but states that consideration 
of exposure to the substance of concern in relation to the Threshold of 
Toxicological Concern (TTC) values may be helpful. Thus, one may suggest 
that in cases where no health-based guidance values are available, the TTC 
approach could be used. The TTC concept is an approach that aims to establish 
a human exposure threshold value below which there is a very low probability 
of an appreciable risk to human health. This TTC approach compares the 
estimated oral intake with a TTC value derived from chronic oral toxicity 
data for structurally related compounds. The TTC values for the so-called 
Cramer structural classes (Cramer et al., 1976) were established by Munro et 
al. (Munro et al., 1996; Munro et al., 1999) based on an analysis of data from 
chronic toxicity studies on 137, 28 and 448 compounds in the Cramer classes 
I, II and III, respectively. Based on the 5th percentile values for the No Observed 
Adverse Effect Level (NOAEL) distributions for each class of compounds 
and application of a 100-fold uncertainty factor, the corresponding human 
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exposure threshold values were calculated. These analyses gave thresholds of 
toxicological concern of 1800, 540 and 90 µg per person per day for structural 
classes I, II and III, respectively, equivalent to 30, 9 and 1.5 µg/kg bw/day 
for a 60 kg person (Kroes et al., 2007). When the estimated intake of a PFS 
ingredient of concern would be below the TTC of its respective class, this can 
be used to conclude on the safety of its proposed use and use levels.  
  In cases where the botanical ingredient contains substances that are 
both genotoxic and carcinogenic, assessment of the risk for human health is 
complicated and an international scientific agreement concerning the best 
strategy for the risk assessment of genotoxic and carcinogenic compounds is 
lacking (EFSA, 2005). As a result, a variety of approaches is used by different 
regulatory and advisory bodies. While some offer qualitative advice, others 
present quantitative approaches with respect to the risk assessment of 
genotoxic carcinogens (Barlow and Schlatter, 2010). The advice that the intake 
of a particular substance should be as low as reasonably achievable (ALARA) is a 
qualitative approach that is widely used (Barlow et al., 2006; O’Brien et al., 2006). 
Nevertheless, the use of this qualitative approach can be considered to be of 
limited value since it does not define priorities necessary for risk management 
actions (EFSA, 2005; JECFA, 2005). Furthermore, this approach does not include 
data on carcinogenic potency nor data on human exposure (JECFA, 2005; O’Brien 
et al., 2006). As a consequence, this approach might be applied to compounds 
even though their current exposure levels are of no risk to human health. 
  Quantitative approaches often include dose-response data, derived 
from epidemiological studies or rodent carcinogenicity bioassays, and 
exposure data to estimate the risk to human health (O’Brien et al., 2006). 
However, risk estimates for a particular compound may show variable 
outcomes depending more on the selected mathematical model than 
on the experimental data (EFSA, 2005; O’Brien et al., 2006) and the use of 
numerical risk estimates may be interpreted incorrectly (O’Brien et al., 2006). 
  Considering the possible uncertainties and existing disadvantages 
connected to the use of qualitative and quantitative approaches such as ALARA 
and low-dose cancer risk extrapolation, the use of an Margin of Exposure 
(MOE) approach was recommended by expert groups of EFSA, the Joint FAO/
WHO Expert Committee on Food Additives (JECFA) and the International Life 
Sciences Institute (ILSI) (Barlow et al., 2006; EFSA, 2005; JECFA, 2005; O’Brien 
et al., 2006). The MOE is a dimensionless ratio based on a reference point 
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obtained from epidemiologic or experimental data on tumor incidence which 
is divided by the estimated daily intake in humans (EFSA, 2005). Thus, the MOE 
approach compares toxic effect levels with human exposure levels. The MOE 
approach is considered a useful and pragmatic option for risk assessment of 
substances that may be both genotoxic and carcinogenic (Barlow et al., 2006; 
EFSA, 2005). It allows comparison between compounds and prioritization 
of risk management actions, especially if the calculation of the MOE is 
accompanied by an appropriate narrative explaining inherent uncertainties. 
  Alternatively, one may evaluate whether the expected exposure to the 
genotoxic and carcinogenic ingredient is likely to be increased, compared to 
the intake from other sources. We propose that another option would be to 
apply the TTC defined for genotoxic compounds, of 0.15 µg per person per 
day corresponding to 0.0025 µg/kg bw/day for a 60 kg person (Kroes et al., 
2004). This level reflects a low probability of a lifetime cancer risk greater than 
one in a million based on linear extrapolation of the TD50 values from rodent 
carcinogenicity studies on 730 structurally related compounds. Noteworthy, for 
the so-called high potency genotoxic chemicals (i.e. aflatoxin-like compounds, 
N-nitroso-compounds and azoxy-compounds) it is suggested that a TTC 
should not be considered since compound-specific risk assessment is required 
for this group (Kroes et al., 2004). At present, there is an EFSA working group on 
Thresholds of Toxicological Concern (http://www.efsa.europa.eu/en/sc/scwgs.
htm) and this working group may give further guidance on the use of the TTC 
approach.
Prioritization of botanicals of possible concern  
The guidance document published by the Scientific Committee of EFSA (EFSA, 
2009b) provides a set of criteria to help prioritize the safety assessment of bo-
tanical compounds which are in use. The document states that; “Priority should 
be given to botanicals and botanical preparations: (1) known to have an es-
tablished history of food use and that have been identified to contain signifi-
cant levels of substances of concern, (2) that are not allowed/recommended for 
food use in some European countries, but which are still in use in some other 
EU countries, particularly when the intended use levels in food are known or 
expected to be high, (3) for which some adverse health effects have been re-
ported, either anecdotally, or on the basis of case reports of intoxication, epi-
demiological data or any toxicity data from livestock animals or experimental 
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animals, or for botanicals that closely resemble botanicals which are known to 
have caused toxic effects, (4) for which consumption has significantly increased 
during recent years in Member States, (5) for which there are both limited his-
tory of use and toxicity data available, and for which the intended use levels are 
expected to be relatively high (e.g. high interest to the food industry). Botanical 
ingredients that are reported to have a low toxic potential, and for which the 
intended intake/exposure levels are within the range of intake levels resulting 
from the European Member States average diet would be given a low priority.”
EFSA has also compiled the available information on a large number 
of botanicals which have been reported to contain substances that may be 
of health concern when specific parts are used and/or inadequate processing 
procedures are used in making botanical extracts and/or botanical products. 
The resulting compendium can be found on Internet (EFSA, 2009c) and will be 
regularly updated.
Examples of PFS compounds of possible concern because of their genotoxic 
and carcinogenic properties
Botanicals and/or botanical preparations may contain compounds of concern 
because of their genotoxic and carcinogenic properties like, for example, 
compounds belonging to the groups of pyrrolizidine alkaloids, alkenylbenzenes 
or aristolochic acids. 
  Pyrrolizidine alkaloids (Figure 1) are converted by cytochromes 
P450 to pyrrolic dehydro-alkaloid metabolites that alkylate DNA and other 
macromolecules, causing liver cell necrosis and liver cancer (Rietjens et al., 
2005; WHO, 1988). The use of toxic pyrrolizidine alkaloid-containing botanicals 
as food or food products is restricted in several countries around the world. 
Nevertheless, there is no consensus in these regulations. South Africa, the UK, 
Belgium, Australia and New Zealand restricted the internal use of comfrey and 
products derived from this botanical and also completely prohibited the use 
of several other toxic pyrrolizidine alkaloid-containing plants in food such as 
Senecio spp., Symhytym spp., Crotalaria spp., and Heliotropium spp. (Koninklijk 
besluit, 1997; The Medicines, 1994; South African department of Health, 2002; 
Australia New Zealand Food Standards, 2009).
The use of pyrrolizidine alkaloids in PFS is still allowed in The 
Netherlands, as well as in Germany, although limitations have been adopted 
in these countries with regard to the exposure to toxic pyrrolizidine 
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alkaloids resulting from the use of herbal supplements (Bundesrepublik 
Deutschland, 1992; Warenwet Kruidenpreparaten, 2001). Following the Dutch 
‘Warenwetbesluit Kruidenpreparaten’ as adopted in January 2001, the total 
content of pyrrolizidine alkaloids present in botanical supplements may not 
exceed 1 µg/kg. In Germany, the exposure to pyrrolizidine alkaloids may not 
exceed 0.1 µg/day when pyrrolizidine alkaloids containing botanical products 
for oral use are consumed for a period longer than 6 weeks (Bundesrepublik 
Deutschland,1992). When the exposure period does not exceed this limit 
of 6 weeks, an exposure of 1 µg pyrrolizidine alkaloids per day is allowed 
resulting from the use of herbal medicines (Bundesrepublik Deutschland, 
1992). Furthermore, the US Food and Drug Administration (FDA) raised serious 
concerns for human health with regard to the use of pyrrolizidine alkaloids, and 
“the agency strongly recommends that firms marketing a product containing 
comfrey or another source of pyrrolizidine alkaloids remove the product from 
the market and alert its customers to immediately stop using the product” (FDA, 
2001). Within the same line of reasoning, Health Canada advised the Canadian 
population not to use any comfrey containing products (HealthCanada, 2003). 
Figure 1. Structural formulas of several pyrrolizidine alkaloids.
 Alkenylbenzenes including apiol, β-asarone, elemicin, estragole, 
methyleugenol, myristicin and safrole (Figure 2) are converted by cytochromes 
P450 and sulfotransferase (SULT)-mediated biotransformation to genotoxic 
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and carcinogenic 1’-sulfoxymetabolites that bind to DNA and cause liver 
cancer (Jeurissen et al., 2007; Phillips et al., 1981; Smith et al., 2002; Wiseman et 
al., 1985; Wiseman et al., 1987). Although the use of estragole, methyleugenol 
(Regulation (EC) No 1334/2008 of the European Parliament and of the Council 
16 December 2008), safrole and β-asarone (Council Directive 88/388/EEC of 22 
June 1988) as pure compounds in food is prohibited within the EU because 
of their genotoxic and carcinogenic potentials, currently no harmonized 
restrictions have been made in the EU with regard to the use of alkenylbenzene-
containing botanicals in PFS. In countries were no restrictions are applicable, 
PFS containing high levels of alkenylbenzenes may be on the market. 
Figure 2. Structural formulas of important alkenylbenzenes
It is also important to stress that despite prohibitions, products 
containing compounds of concern may still be offered on the market. An 
example of the occurrence of prohibited compounds in botanical preparations 
is the presence of aristolochic acids in Chinese herbal preparations used in 
traditional Chinese medicine. It was previously demonstrated that several 
Chinese herbal preparations that are sold on the Dutch market still contain 
aristolochic acids which are prohibited worldwide (Martena et al., 2007). 
Aristolochic acid I and II (Figure 3) are converted by reductive metabolic 
activation by cytochromes P450 and/or by other enzymes resulting in formation 
of reactive nitrenium ion metabolites which cause Chinese Herb Nephropathy 
and urothelial cancers (Gillerot et al., 2001; Rietjens et al., 2005). In 190 Chinese 
traditional herbal preparations sampled between 2002 and 2006 on the Dutch 
market, aristolochic acid I was found in 25 samples up to a concentration of 
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1676 mg/kg and aristolochic acid II was found in 13 of these samples up to 444 
mg/kg (Martena et al., 2007). 
Figure 3. Structural formulas of aristolochic acid I and II. 
Examples of PFS compounds of possible concern because of neurotoxicity
Another group of PFS compounds may be of concern because of their 
neurotoxicity. These PFS compounds include for example ephedrine analogues, 
anisatin and α-thujone. These compounds appear to interact with one of the 
neurotransmitter systems. 
Ephedrine and ephedrine analogues including pseudo-ephedrine, 
norephedrine, methylephedrine, and norpseudo-ephedrine may act as 
adrenalin agonists. Figure 4 presents the structural formulas of these 
compounds. PFS containing botanicals like Ephedra sinica, Ephedra intermedia, 
and Ephedra equisatine, also known by their Chinese name ‘Ma Huang’, contain 
these compounds and are used for improvement of weight loss and athletic 
performance (Shekelle et al., 2003). As adrenalin agonists, these compounds 
produce a sympathomimetic response, characterized by increased heart rhythm, 
hypertension (elevated blood pressure), and central nervous system stimulation. 
Also p-synephrine (Figure 4) acts as an adrenalin agonist. p-Synephrine is the 
main active principle found in the fruit of several Citrus species including 
Citrus aurantum and Citrus reticulata. In traditional Chinese medicine the fruit 
is also known as ‘Chih-shih’. Evaluations concerning preparations containing 
high amounts of p-synephrine concluded that there may be a possible safety 
concern (Calapai et al., 1999; Jack et al., 2007), and extracts used in many dietary 
supplements and herbal weight-loss formulas as an alternative to Ephedra have 
concentrations of p-synephrine that are much higher than the p-synephrine 
concentrations reported for traditional extracts of the dried fruit or peel (Speijers 
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et al., 2010). This reflects another important issue to be taken into account 
when assessing the safety of PFS, i.e. that some preparations of a botanical may 
be marketed containing significantly higher levels of active (toxic) principles 
than those normally occurring in historical food uses of the same botanical. 
 
 
 
 
Figure 4. Structural formulas of ephedrine and its analogues pseudoephedrine, norephedrine, 
methylephedrine, norpseudo-ephedrine and p-synephrine.
Furthermore, the position isomer of synephrine found in bitter 
orange (Citrus aurantium L. ssp. aurantium L.) peel is p-synephrine, not 
m-synephrine. The presence of any amount of m-synephrine, higher amounts 
of the (+)-p-synephrine stereoisomer or higher amounts of octopamine in PFS 
supposedly containing only extracts of bitter orange should be considered 
undesirable and suspicious of adulteration, thus strongly suggesting 
a requirement for a more efficient quality control (Speijers et al., 2010). 
  Anisatin (Figure 5), the toxic ingredient in Japanese star anise (Illicium 
anisatum) that was accidentally exchanged for the non-toxic Chinese star anise 
(Illicium verum) (Johanns et al., 2002), acts as a non-competitive γ-amino butyric 
acid (GABA)-antagonist that can cause tonic-clonic insults (Kakemoto et al., 1999). 
  The terpenoid α-thujone (Figure 5) occurs in the essential oils and parts of 
the plants of Artemesia absinthum (wormwood), Salvia officinalis (sage), Salvia scarea 
(clary), Tanacetum vulgaris (tansy) and in Juniperus and Cedris spp., which may occur 
in PFS. The mechanism of neurotoxicity of α-thujone has been ascribed to the fact 
that it blocks the receptors for γ-aminobutyric acid (GABA) (Hold et al., 2000). 
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Figure 5. Structural formulas of anisatin, α-thujone and coumarin.
Examples of PFS compounds of possible concern because of other modes 
of action 
PFS compounds of concern because of other modes of action include, for 
example, kavalactones, cyanogenic glycosides and coumarin.
Kavalactones originate from the rootstock of the kava (Piper 
methysticum) plant. The structural formulas of kavain, dihydrokavain, 
methysticin, dihydromethysticin, yangonin and desmethoxy-yangonin, which 
are the main kavalactones found in Piper methysticum, are shown in Figure 
6. Through their action on the nervous system kavalactones exert sedative, 
analgesic, anticonvulsant, and muscle relaxant effects. The mechanism of 
action for this effect may include inhibition of monoamine oxidase (MAO) 
activity, inhibition of noradrenalin reuptake in the presynaptic neuron, and/
or action as a dopamine antagonist (Schelosky et al., 1995; Spollen et al., 1999). 
The major toxic side effects of kava kava are dermopathy and liver toxicity. The 
liver toxicity may be related to glutathione depletion and/or quinone formation 
(Johnson et al., 2003; Rietjens et al., 2005; Whitton et al., 2003). Since 1999, cases 
of severe hepatic toxicity in people using kava-containing herbal products have 
been reported in Europe and the United States (Escher et al., 2001; Centers for 
disease and cancer prevention, 2002), including several cases in which patients 
required liver transplantation following the use of kava-containing products 
(Centers for disease and cancer prevention, 2002). As a result, the use of kava 
kava is now prohibited in PFS and medicinal products in most countries. 
  Cyanogenic glycosides are present in a number of food plants and 
seeds and include compounds like amygdalin, dhurrin, linamarin, linustatin, 
lotaustralin, neolinustatin, prunasin, and taxiphyllin (Figure 7). Products 
containing high levels of amygdalin are sold via Internet as vitamin B17 or 
laetrile, for cancer treatment, although many countries, including the USA, UK, 
Singapore and The Netherlands have banned its sale (The Medicines, 1984; 
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Health Science Authority Singapore, 1985; FDA, 2009). Cyanogenic glycosides 
are a cause of concern because once ingested they are metabolized to cyanide. 
Cyanide is released from the cyanogenic glycosides by plant β-glucosidases 
which come into contact with the cyanogenic glycosides when fresh plant 
material is macerated as in chewing, or by β-glucosidases present in the gut 
flora. Cyanide causes toxic effects by binding to cytochrome oxidase, the 
terminal enzyme in the mitochondrial electron transport chain. By hampering 
the generation of ATP and oxygen utilization, a histotoxic anoxia is produced.
Figure 6. Structural formulas of the main kavalactones found in Piper methysticum. 
 Cinnamon-containing PFS may contain high levels of coumarin 
(Figure 5), which causes liver damage, and at high dose levels, liver tumors by a 
non-genotoxic mechanism. Coumarin induces tumors via a mechanism of 
action that is preceded by toxicity in the target organ, and consequently, a TDI 
of 0.1 mg/kg bw/day has been defined (EFSA, 2004b). This TDI can be used to 
judge the safety of not only coumarin-containing food but also of coumarin-
containing PFS.
Examples of PFS compounds of possible concern because of their 
interactions with prescription drugs
PFS may contain compounds interacting with the pharmacokinetics and/or 
pharmacodynamics of prescription drugs when concomitantly consumed, 
presenting a potential safety issue. The most common botanical-drug 
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interactions that have been described involve botanicals like ginkgo biloba 
(Ginkgo biloba L), kava kava (Piper methysticum), black cohosh (Acteae racemosa), 
ginseng (Panax ginseng) and St. John’s wort (Hypericum perforatum), with the 
latter example being studied most thoroughly. 
Figure 7. Structural formulas of important cyanogenic glycosides.   
St. John’s wort is used to treat a variety of diseases such as anxiety, 
mild to moderate depression, sleeping disorders and obsessive-compulsive 
disorder. The antidepressant effects of St. John’s wort are thought to be caused 
by its ingredient, hyperforin, inhibiting the synaptosomal uptake of serotonin, 
norepinephrine and dopamine (Chatterjee et al., 1998). Several interactions 
with prescribed drugs have been reported for St. John’s wort and a number 
of studies indicated that changes in the activity of specific cytochromes P450 
may underlie these botanical-drug interactions (Gurley et al., 2005; Markowitz 
et al., 2003; Mathijssen et al., 2002; Piscitelli et al., 2000). As a result of the 
potent inhibition of these metabolizing enzymes, plasma levels of prescribed 
drugs including alprazolam, irinotecan and indinavir might be decreased 
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after concurrent use with St. John’s wort (Markowitz et al., 2003; Mathijssen et 
al., 2002; Piscitelli et al., 2000). In 2000, the FDA published a health advisory 
instructing health care professionals to report potential adverse effects related 
to the use of St. John’s wort in combination with prescription drugs (FDA, 2000). 
  Most of the current evidence for botanical-drug interactions is based on 
case reports while experimental data are limited. To date, possible botanical-drug 
interactions are often not indicated on the label of PFS nor the drug, making it 
difficult for consumers to make an informed decision. Moreover, interactions are 
not frequently ascribed to the effects of natural products as these products are 
often regarded as ‘safe’. Therefore, management of botanical-drug interactions 
should take an important position in promoting the safe use of PFS underlining 
awareness for possible interactions between PFS and prescribed drugs. Currently, 
a database is being prepared providing an overview of the existing data, but 
also producing new data, including the interactions between botanicals and 
prescribed drugs (www.plantlibra.eu/web) to assist in monitoring the safety of 
PFS and facilitating information to consumers and health care providers to create 
more awareness on possible botanical-drug interactions. 
Matrix effects modulating toxicity
When evaluating the safety of PFS compounds, it is important to consider that 
the kinetics and/or the toxicity of a PFS ingredient could be modified by the 
matrix in which it is present. This could result in the toxicity being unchanged, 
reduced or even increased.
An example of increased toxicity can be found in the fact that 
epigallocatechin gallate (EGCG) given in a green tea extract to rats appears 
to be eliminated less readily from the body and to have a higher toxicity 
than when given as a pure compound (Chen et al., 1997; Johnson et al., 
1999). An example of decreased toxicity is presented by the reduction 
of the level of DNA binding of the proximate carcinogenic metabolite 
1’-hydroxyestragole by a methanolic basil extract (Alhusainy et al., 2010; 
Jeurissen et al., 2008). This inhibition by the basil extract was shown to 
occur at the level of the SULT-mediated bioactivation of 1’-hydroxyestragole 
to 1’-sulfoxyestragole and to be mediated by the flavonoid nevadensin 
present in basil at a high level (Alhusainy et al., 2010; Jeurissen et al., 2008). 
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  Whenever a matrix effect is advocated to support the safety of 
specific levels of PFS compounds (e.g. that data from a pure compound may 
overestimate effects of the compound in the botanical matrix), data should be 
provided to demonstrate the occurrence of the matrix effect of the preparation 
and its magnitude. It is also important to realize that when a matrix effect is 
demonstrated for an intact botanical, the matrix effect for the PFS may be 
different. Thus, the matrix effect should be taken into account in the safety 
assessment of PFS compounds on a case-by-case basis.
Conclusions
PFS on the market may contain active compounds that are of concern. 
For several compounds regulatory authorities are aware of the problems 
encountered and have taken or are considering appropriate regulatory actions 
to protect the public. These regulatory actions may vary from setting TDIs (such 
as, for example, for coumarin and trans-anethole), setting restrictions in use 
(such as for estragole, methyleugenol, safrole and β-asarone), informing the 
public to be cautious and aware of possible adverse side effects (as for kava 
kava derived kavalactones), or taking specific plant varieties and/or their 
compounds from the market (such as plants containing aristolochic acids, toxic 
pyrrolizidine alkaloids and kavalactones).
However, at present a general framework for the safety assessment of 
PFS is not in place and safety assessments are performed on a national and ad-
hoc basis, often following incidents. Besides, even when regulatory measures are 
in place, PFS containing compounds of concern may still be offered for sale on 
Internet, such as in case of the cyanogenic glycoside amygdalin (vitamin B17) or 
PFS containing high levels of alkenylbenzenes. Altogether it is clear that ‘natural’ 
does not equal ‘safe’ and PFS may contain compounds of concern at levels far 
above those found in the regular diet. In addition, the traditional use of a PFS 
compound as an herb or tea does not guarantee its safety when used as a 
supplement. This points at a need for stricter regulation and control of botanical-
containing products, especially given their expanding market volume. 
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Abstract
The present study describes the selection, analysis and risk assessment 
of genotoxic and carcinogenic compounds of botanicals and botanical 
preparations which can be found in plant food supplements (PFS). First an 
inventory was made of botanical compounds that are of possible concern 
for human health because of their genotoxic and/or carcinogenic properties. 
In total, 30 botanical compounds were selected and subsequently judged 
for their actual genotoxic and/or carcinogenic potential. Among the 30 
compounds considered, 18 compounds were judged to be both genotoxic 
and carcinogenic. Interestingly, the majority of these compounds belong to the 
group of alkenylbenzenes or unsaturated pyrrolizidine alkaloids. Subsequently, 
based on available carcinogenicity data and estimated daily human exposure 
that was determined focusing on the intake from PFS, the Margin of Exposure 
(MOE) was calculated for the alkenylbenzenes estragole, methyleugenol, 
safrole and β-asarone. Calculating the MOE values for intake estimates of these 
alkenylbenzenes from PFS resulted in MOE values that were generally lower 
than 10,000 and often lower than 100. In some cases the MOE was even below 
10 meaning that the estimated daily intake is in the range of dose levels causing 
malignant tumors in experimental animals. This result indicates that the use of 
PFS containing the genotoxic carcinogens estragole, methyleugenol, safrole or 
β-asarone might raise a potential concern for human health and would be of 
high priority for risk management. 
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Introduction 
Herbal products and ingredients such as herbal teas, food flavors and food 
supplements have been, and still are, widely used in Western diets. Currently, 
there is a growing interest in plant food supplements (PFS), which are suggested 
to have the ability to maintain and promote health or reduce the risk factors 
for diseases. In Europe, PFS are easily accessible since they can be bought in 
supermarkets, health-food shops or pharmacies where they are sold over the 
counter at relatively low costs. Moreover, PFS generally have a high acceptance 
by consumers who often consider that ‘natural’ equals ‘safe’. However, this 
reasoning should be considered with care since several botanicals are known 
to contain toxic or even genotoxic and carcinogenic compounds (Rietjens 
et al., 2008). Examples of genotoxic and carcinogenic botanical ingredients 
are the alkenylbenzenes estragole, methyleugenol and safrole, which are 
present in a wide range of botanicals including basil, nutmeg, tarragon and 
fennel (SCF, 2001a, 2001b, 2002a). In the past, the Scientific Committee on 
Food has suggested restrictions in the use of these alkenylbenzenes because 
of their genotoxic and carcinogenic properties (SCF, 2001a, 2001b, 2002a). 
 In 2004, the Scientific Committee of the European Food Safety 
Authority (EFSA) presented a discussion paper describing general concerns 
relating to the quality and safety of botanicals and botanical preparations such 
as PFS and related products (EFSA, 2004a). In line with the existing concerns 
with respect to the use of botanicals, a European collaborative project under 
the Seventh Framework Programme was recently started. This project, 
known as PlantLIBRA (PLANT food supplements: Levels of Intake, Benefits 
and Risk Assessment), aims to encourage the safe use of food supplements 
containing botanicals or botanical ingredients by increasing science-based 
decision making by regulators as well as food chain operators. Within 
PlantLIBRA, different methodologies for risk assessment of botanicals and 
botanical ingredients used as PFS will be defined, validated and disseminated 
in order to enlarge the knowledge on PFS and ensure a safe use of PFS. 
 In general, assessment of the risk for human health from genotoxic 
and carcinogenic compounds occurring in food, the presence of which 
cannot be easily avoided, is accompanied with difficulties (EFSA, 2005). 
Currently, an international scientific agreement is lacking regarding the best 
strategy for the risk assessment of genotoxic and carcinogenic compounds 
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and a variety of approaches is used by different regulatory and advisory 
bodies (EFSA, 2005). While some offer qualitative advice, others present 
quantitative approaches with respect to the risk assessment of genotoxic 
carcinogens (Barlow and Schlatter, 2010; Van den Berg et al., 2011). 
 Amongst the different available qualitative and quantitative 
approaches, the use of a Margin of Exposure (MOE) approach was recommended 
by expert groups of EFSA, the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA) and the International Life Sciences Institute (ILSI) (JECFA, 
2005; Barlow et al., 2006; EFSA, 2005; O’Brien et al., 2006). The MOE is a 
dimensionless ratio based on a reference point obtained from epidemiologic 
or experimental data on tumor incidence which is divided by the estimated 
daily intake in humans (EFSA, 2005). The selected reference point corresponds 
to a dose level causing a low though quantifiable incidence of tumors (EFSA, 
2005). Different approaches have been proposed to select an appropriate 
reference point from the dose-response-curve, of which the use of BenchMark 
Dose (BMD) modeling is the preferred approach (Barlow et al., 2006). The BMD 
approach makes use of different mathematical models for the analysis of the 
observed carcinogenicity data (US EPA, 1995). Making use of this approach, a 
dose can be estimated that causes a predefined cancer response, known as 
the BenchMark Response (BMR) (US EPA, 1995). Generally, a dose that gives 
1%, 5% or 10% extra tumor incidence compared to the background level is 
chosen (US EPA, 1995). However, it is indicated that the use of a dose giving 
10% extra cancer risk above the background level (BMD10) is accompanied 
with the least uncertainties and is therefore preferred (Barlow et al., 2006). The 
BMDL
10
, the 95% lower confidence bound of the BMD
10
, is frequently used as 
a reference point to calculate the MOE. This reference point takes into account 
uncertainties in the experimental data (EFSA, 2005). Moreover, the use of the 
BMDL instead of the BMD will assure with 95% confidence that the value of the 
BMR will not go beyond the predefined value of, for example, 10% (EFSA, 2005). 
 An advantage of the use of the MOE approach is that it sets a basis 
for priority setting that can be used by risk managers. An MOE >10,000 is 
considered as a low priority for risk management actions and would be of low 
concern from a public health point of view (EFSA, 2005). The value of 10,000 
was defined based on considering various factors that cause uncertainties 
in the MOE including (1) a factor 100 for species differences and human 
variability in toxico-kinetics and toxico-dynamics, (2) a factor 10 for inter-
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individual human variability in cell cycle control and DNA repair, and (3) a 
factor 10 for the reason that the BMDL
10
 when used as a reference point is 
not identical to a No Observed Adverse Effect Level (NOAEL) (EFSA, 2005). 
 In the presented chapter, the MOE approach was applied to a series 
of compounds known to be present in botanicals and botanical preparations 
including especially PFS. To this end, first an inventory was made of botanical 
ingredients that are of possible concern for human health because of their 
genotoxic and/or carcinogenic properties. In a next step, cancer data for a 
selected number of these compounds were used to derive a reference point 
preferably a BMDL10. Finally, the MOE values for these ingredients were 
calculated based on the intake estimates resulting from chemical analysis of 
selected PFS as well as their proposed uses. The outcomes generally pointed 
at a high priority for risk management of PFS containing the alkenylbenzenes 
estragole, methyleugenol, safrole and β-asarone. 
Materials and methods 
Selection of botanical ingredients
An inventory was made of botanical ingredients that are of possible concern 
for human health because of their genotoxic and/or carcinogenic properties. 
Selection of these botanical ingredients included three strategies. First, 
compounds indicated to be genotoxic or carcinogenic in the EFSA compendium 
(EFSA, 2009a) were selected as potential candidates for risk assessment using the 
MOE concept. The EFSA compendium summarizes a large number of botanicals 
and botanical ingredients containing substances which might be of possible 
concern for human health. Second, the selection of botanical ingredients 
relevant for risk assessment using the MOE concept was based on data obtained 
from 2-year studies performed by the National Toxicology Program (NTP). To be 
eligible for selection, evidence of genotoxic and/or carcinogenic activities from 
these NTP studies was considered as a requirement. Furthermore, compounds 
tested positive for genotoxicity or carcinogenicity by the NTP were only selected 
if they were listed in the EFSA compendium, because that ascertained their 
occurrence in botanicals or botanical preparations, and they were selected even 
when the EFSA compendium did not list them as genotoxic or carcinogenic. 
Finally, as a third strategy, this list of selected compounds was completed by 
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including compounds of known concerns because of their genotoxic and/or 
carcinogenic characteristics, but not (yet) included in the EFSA compendium or 
not (yet) tested by NTP. These included aristolochic acids as well as a number of 
botanical ingredients classified as alkenylbenzenes or unsaturated pyrrolizidine 
alkaloids. For alkenylbenzenes and unsaturated pyrrolizidine alkaloids, priority 
for risk assessment has been indicated by the partners collaborating within the 
PlantLIBRA project. Moreover, concerns for human health were raised by the EU 
with respect to the occurrence of unsaturated pyrrolizidine alkaloids in plants 
(CCCF, 2010), and the alkenylbenzenes including estragole, methyleugenol, 
safrole, elemicin, myristicin, and apiol have been given priority by JECFA for 
evaluation of their risks resulting from consumption of botanicals and botanical 
preparations (JECFA, 2009). 
Selection of carcinogenicity data relevant for benchmark modeling 
In general, the calculation of BMD(L)
10
 values was based on rodent carcinogenicity 
bioassays preferably accomplished under current guidelines. For this purpose, 
several studies implemented by the NTP were used for modeling. These studies 
often included three exposure concentrations administered to rats and mice of 
both sexes (50 animals per group) during a lifetime (i.e. 2 years). However, not 
for all selected botanical compounds such studies were available. Therefore, 
studies were included that were not performed according to current standards. 
Selection of studies suitable for BMDL
10
 modeling included the requirement that 
studies were conducted using a control group and two or more exposure levels. 
When studies were completed in a period shorter than the standard lifespan of 
2 years, an adjustment for the length of treatment and the observation period 
was made. This was done following the method reported by the European 
Chemical Agency (ECHA, 2008) and previously applied in the MOE approach 
as performed by an Expert Panel of ILSI (Benford et al., 2010). This adjustment 
allows a correction for the underestimation in tumor incidence that would occur 
when an experiment is discontinued before the standard lifespan (Benford et al., 
2010). For this purpose, a correction of (w1/104) x (w2/104) was applied to the 
dose in which w1 represents the duration of dosing in weeks and w2 reflects the 
period of observation in weeks. For example, if rodents were treated for 52 weeks 
in an experiment proceeding for 80 weeks, the dose (d) was corrected following 
(52/104) x (80/104) x d. In addition, the dose levels were also corrected for the 
number of doses per week by adjusting the dose to equal a daily administration 
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of the test compound keeping the total weekly dose constant. Thus, if the test 
compound was administered for 5 times a week, a correction factor of 5/7 was 
applied to the dose. When studies reported the dose administered in mg/kg 
diet, a daily food consumption of 130 g diet/kg bw/day, 120 g diet/kg bw/day 
and 40 g/kg bw/day for female and male mice and male rats, respectively, was 
used to calculate the dose in mg/kg bw/day (Gold et al., 1984). Only organ-
specific carcinogenicity data were included for modeling with the emphasis 
on malignant neoplasms. Data on benign tumors were precluded since these 
neoplastic lesions do not express the same characteristics as malignant 
tumors that are capable of spreading by invading surrounding tissues or by 
metastasizing. Although malignant tumors are able of metastasizing, only 
primary tumors were taken into consideration for modeling. When different 
malignant tumors were observed in a cancer bioassay, the tumor-site with 
the highest incidence at comparable dose levels was chosen. Data for males 
and females were not combined. Other criteria for selecting carcinogenicity 
data were: the occurrence of a treatment-related dose-response relationship, 
oral administration of the compound (i.e. through the diet, drinking water or 
by gavage) and a tumor type that is of relevance for humans. The number of 
animals in a group is also needed for adequate BMD modeling and equaled the 
number of animals that were examined microscopically. 
Benchmark dose modeling 
BMD(L)
10
 values were obtained by fitting the carcinogenicity data to a number 
of different mathematical models using EPA BMDS software, version 2.1.2. The 
following models were used: Gamma, Logistic, LogLogistic Probit, LogProbit, 
Multistage, Weibull and the Quantal-linear model. BMDS software was applied 
using default settings for model restrictions, risk type (extra), confidence level 
(95%), and BMR (10%). The BMD(L)
10
 values derived from the different fitted 
models were only accepted if the fit of the selected model was not of poorer 
quality than that of the so-called full model representing a perfect fit to the 
dose-response data. For this purpose, the log-likelihood ratio test was applied 
in order to measure the goodness-of-fit of the chosen models. The acceptance 
of a model was based on comparing the critical differences in the log-likelihood 
values between the full and the fitted model as reported by Slob (2002). The 
evaluation of these critical differences was based on the discrepancy in the 
amount of parameters used by the full and the selected model (i.e. the degrees 
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of freedom) (Slob, 2002). Exceeding the critical difference implied that the 
model with the highest number of parameters (i.e. the full model) had the best 
fit (Slob, 2002) and consequently the selected model was not accepted for 
BMD(L) calculation. Moreover, the p-value representing the goodness-of-fit of 
the selected dose was taken into account with a value below 0.05 resulting in 
model rejection. 
Method for determination of intake levels
Theoretical estimations 
Intake estimates resulting from use of PFS were not available in the literature 
and were made in the present study. PFS were selected that are offered for sale 
on the market via Internet and/or health shops and that consist of botanicals 
known to contain different quantities of one or more of the compounds of 
interest. Exposure estimates were made taking into consideration the content 
of the compound of interest in the plant as reported in literature. When such 
data were not available, the amount of essential oil that is reported to be present 
in the plant and the amount of the compound in the essential oil were used to 
estimate the ingredient level in the plant. When the amount of compound (in 
mg) present in a particular botanical was determined, the daily exposure to the 
compound of interest (in mg/kg bw/day) was calculated based on the daily intake 
of that botanical resulting from the use of PFS at the dose recommended by the 
respective manufacturer. In general, data of PFS prepared from one botanical 
were used. When a PFS consisted of two or more botanicals, the relative amount 
of the botanical of interest present in the PFS as indicated by the manufacturer 
was used to correct the daily dose of the PFS. Since manufacturing methods for 
preparing the PFS from the original plant were not available, it was assumed 
that the PFS equals the botanical as such. 
Quantitative detection of alkenylbenzenes in PFS
To determine if the theoretical levels represent the actual levels of the genotoxic 
carcinogens of interest in commercially available PFS, a quantitative analysis 
was performed. To this end, the content of the alkenylbenzenes of interest in 28 
different PFS containing basil, cinnamon, sassafras, nutmeg, fennel or calamus 
was measured. Exposure estimates were made based on the content of the 
compound of interest in the PFS as measured together with the weight of the 
capsules and the recommended daily dose as indicated on the label. 
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PFS and chemicals 
PFS were selected that are widely offered for sale on the market via Internet and/
or health shops and consist of botanicals known to contain different quantities 
of one or more of the compounds of interest. 28 PFS were purchased via Internet, 
local Dutch and Italian health shops and a Dutch pharmacy. Methyleugenol 
(purity 99%), safrole (purity >97%), β-asarone (purity 70%), methanol (HPLC 
supra gradient) and acetonitrile (ULC/MS gradient) were supplied by Sigma-
Aldrich (Steinheim, Germany). Estragole (purity 98%) was purchased from Acros 
Organics (Geel, Belgium). Nanopure water was obtained from a Barnstead 
Nanopure Type I ultrapure water system. 
Sample preparation 
All 28 alkenylbenzene-containing PFS were extracted using methanol based 
on the method described by Gursale et al. (2010) with minor modifications. 
To prepare these methanolic extracts, 1 g of powdered PFS material was 
suspended in 25 mL methanol followed by ultrasonic extraction for 15 min at 
room temperature. An aliquot of each extract solution was filtered through a 
0.45 µm cellulose acetate membrane filter (VWR International) and stored at 
-20˚C until Ultra Performance Liquid Chromatography (UPLC)-analysis. 
UPLC analysis 
Before UPLC analysis, aliquots of the extract solutions were diluted in 
nanopure water (1:100 v/v). However, when the level of the analyte was 
found to be outside the acceptable level for quantification, the final dilution 
factor was adjusted. Accordingly, extract solutions were diluted in a range 
of 2 to 1000 fold depending on the quantity of estragole, methyleugenol, 
safrole or β-asarone present in the sample. After centrifugation at 16,000g 
for 5 min, 3.5 µL of each sample was subjected to UPLC analysis (n=3). 
 UPLC analysis was performed on a Waters ACQUITY UPLC H-Class system 
connected to an ACQUITY UPLC photodiode array detector and a quaternary 
solvent manager. Chromatographic separation was achieved using an ACQUITY 
UPLC BEH C18 1.7 µm column, 2.1 x 50 mm. The column was thermostated at 30˚C 
and the sample manager was set at 10˚C. The gradient was made with nanopure 
water and acetonitrile. The mobile phase started with 23% acetonitrile for 10 min 
after which the acetonitrile percentage was increased to 58% in 3 min and further 
increased to 80% in 1 min at which it was kept for 30 seconds. Starting conditions 
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were reached within the next 30 seconds and retained for another 30 seconds. 
During the whole run, the flow rate was set at 0.6 mL/min. Under these conditions, 
the retention times for methyleugenol, β-asarone, safrole and estragole were 
9.0, 9.6, 12.3, and 12.7 min, respectively. The levels of the alkenylbenzenes 
of interest were quantified by comparing the peak areas to the calibration 
curves of these compounds derived from commercially available standards. 
 For nutmeg-containing PFS, a different method was used to separate 
the structurally related alkenylbenzenes elemicin and methyleugenol which 
both occur in nutmeg (EFSA, 2009a). The gradient was made with nanopure 
water and acetonitrile. The acetonitrile percentage was increased from 32% to 
35% in 3.5 min and further increased to 60% in 1.5 min and to 80% in 30 seconds 
at which it was kept for 30 seconds. Starting conditions were obtained in 30 
seconds and the system was equilibrated for another 30 seconds. Elution was at 
a flow rate of 0.6 mL/min and the column temperature and sample temperature 
were set at 22˚C and 10˚C respectively. Under these conditions, the retention 
times were 2.9, 3.1 and 4.8 min for elemicin, methyleugenol and safrole in the 
order given. 
Accuracy 
The accuracy of the developed method was assessed by means of a recovery 
study. Pure standards of commercially available estragole, methyleugenol, 
safrole or β-asarone were added in different quantities (final concentrations 
of 250 µM, 500 µM and 750 µM) to 1 g powdered PFS consisting of fennel, 
nutmeg or calamus dissolved in a final volume of 25 mL methanol. Samples 
were prepared and analyzed by UPLC as described above (n=6). The average 
percentage recoveries were found to equal 87.6 ± 4.9% for estragole, 89.7 ± 
8.1% for methyleugenol, 98.9 ± 15.0% for safrole and for β-asarone this was 81.1 
± 7.7%. Based on these outcomes the levels of the alkenylbenzenes detected in 
the different PFS were corrected for sample recovery. 
Calculation of the Margin of Exposure 
The full range of BMDL
10
 values (i.e. lowest to highest BMDL
10
 value) was 
compared with the estimated daily intakes of the alkenylbenzenes of interest 
resulting from the use of PFS to derive an MOE range. MOE values are rounded 
to a single significant figure. 
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Results
Selection of compounds 
First an inventory was made of botanical ingredients that are of possible 
concern for human health because of their genotoxic and/or carcinogenic 
properties. As described in the Materials and Method section, the selection of 
these botanical ingredients was performed based on (1) the EFSA compendium, 
(2) the available NTP studies on botanical ingredients and (3) knowledge from 
partners within the PlantLIBRA consortium. Table 1 provides an overview of 
the 30 compounds thus selected that might be of concern because of their 
genotoxic and/or carcinogenic potentials. Most of these compounds occur in a 
variety of botanicals several of which, such as fennel, are commonly used in PFS. 
Table 1 also lists the overall judgment on the genotoxicity and carcinogenicity of 
the selected compounds as based on available literature data. This reveals that 
not all 30 selected compounds appear to be both genotoxic and carcinogenic. 
For the majority of the selected botanical ingredients carcinogenicity has been 
reported or suspected. However, for several compounds, such as for coumarin 
and trans-anethole, a genotoxic mode of action is not indicated. 18 Of the 
30 selected compounds, appeared to be both genotoxic and carcinogenic. 
These compounds include apiol, aristolochic acid (I and II), elemicin, estragole, 
heliotrine, lasiocarpine, lucidin, methyleugenol, monocrotaline, myristicin, 
ptaquiloside, reserpine, riddelliine, safrole, senecionine and symphytine. 
Although for β-asarone the genotoxicity data are equivocal, EFSA previously 
concluded that when the carcinogenic mode of action of a certain compound is 
not identified, a genotoxic mode of action will usually be assumed (EFSA, 2005). 
However, EFSA mentioned that this presumption of genotoxicity is based on a 
lack of other information and should not be interpreted as the actual mode of 
action. Interestingly, most of the selected botanical ingredients that are both 
genotoxic and carcinogenic belong to the groups of the alkenylbenzenes or 
the unsaturated pyrrolizidine alkaloids, with the exception of aristolochic acid 
(I and II), lucidin, reserpine and ptaquiloside. For 8 of the 18 compounds that 
appeared to be both genotoxic and carcinogenic, data on carcinogenicity are 
available from which a reference point (e.g. BMDL10 or T25) could be obtained, 
allowing the use of the MOE concept. These compounds included reserpine, 
the alkenylbenzenes estragole, methyleugenol, safrole and β-asarone and the 
unsaturated pyrrolizidine alkaloids riddelliine, lasiocarpine and monocrotaline. 
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Given that the use of unsaturated pyrrolizidine alkaloids in food, including PFS, 
is already regulated and not allowed, in the present study further emphasis was 
placed on the risk assessment of PFS containing the alkenylbenzenes estragole, 
methyleugenol, safrole and/or β-asarone.
Carcinogenicity data and BMDL
10
Table 2 gives an overview of the carcinogenicity data describing the incidences 
of hepatocellular carcinomas in rodents exposed to estragole, methyleugenol 
or safrole. In the same table, the results of an unpublished study referred to 
by JECFA (1981) is given on the incidences of leiomyosarcomas of the small 
intestines of male rats exposed to increasing concentrations of β-asarone. Table 
3 presents the results of BMD analysis of these data (for details see the Supple-
mentary Materials Tables S1-S4). For estragole, the BMDL
10
 value varies between 
3.3 and 6.5 mg/kg bw/day. For methyleugenol, BMDL
10
 values ranging between 
15.3 and 34.0 mg/kg bw/day were found for male rats whereas BMDL
10
 values 
of 48.8-73.6 mg/kg bw/day were found for female rats. The BMDL
10
 values range 
between 1.9 and 5.1 mg/kg bw/day for safrole and between 9.6 and 21.5 mg/
kg bw/day for β-asarone. 
 
Exposure data 
Intake estimates of alkenylbenzenes from consumption of PFS 
Characteristics of the PFS for which intake estimates were made are presented in 
Table 4. Table 5 presents estimated daily exposure to estragole, methyleugenol, 
safrole or β-asarone from the use of PFS. These estimates were based on PFS 
available on the market and known to contain different quantities of botanicals that 
contain one or more of the alkenylbenzenes of interest. Using the suggested dose 
of PFS intake as recommended by the manufacturer of the PFS and the estimated 
alkenylbenzene level in the PFS, daily intake estimates of the alkenylbenzenes 
resulting from use of the various PFS were obtained. The alkenylbenzene level in 
the PFS was calculated based on the percentage of the alkenylbenzene present 
in the essential oil, the percentage of the essential oil in the plant and the amount 
of the plant in the PFS. Thus, assuming a dose of 230-690 mg basil supplement, 
0.11-85% of estragole present in the essential oil of sweet basil (EFSA, 2009a; 
Zheljazkov et al., 2008) and 0.11-1.9% of essential oil in this plant (Zheljazkov et 
al., 2008), the estimated daily intake of estragole would amount to 0.005-186 µg/
kg bw/day for a 60 kg person considering the full range of data.
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For methyleugenol, the daily intake resulting from the use of the same PFS 
amounts to 0.02-200 µg/kg bw/day taking into account that the essential oil 
contains 0.46-91.1% methyleugenol (Zheljazkov et al., 2008). In general, intake 
estimates for estragole, methyleugenol, safrole and β-asarone, resulting from 
the use of PFS, range between 0.004 to 2.96 mg/kg bw/day, depending on the 
botanical of interest, the variable amounts of the genotoxic carcinogens within 
the plants, and the different recommended daily intakes for the PFS under 
consideration. When interpreting these intake estimates, it should be kept in 
mind that all calculations were performed under the assumption that PFS 
contained the botanical as such and corrections for the manufacturing 
procedure were not applied. However, when PFS consist of powdered herb 
material prepared by freeze drying for example, the actual level of the compound 
of interest may be higher compared to the intake estimates that have been 
made for the use of the botanical as such leading to lower MOE values. On the 
contrary, levels may be lower when the PFS is prepared by decoction. Therefore, 
in a next step the levels of these alkenylbenzenes in commercial available PFS 
and the resulting estimated human intakes were quantified based on chemical 
analysis. 
Table 3. Results of a BMD analysis of the carcinogenicity data on the incidence of malignant tumors in 
rodents exposed to estragole, methyleugenol, safrole, or β-asarone. The data used as input for the BMD 
analysis are presented in Table 2.
Compound Species and sex Tumors BMDL
10
(mg/kg bw/day)
Estragole Female mice hepatocellular carcinomas 3.3-6.5
Methyleugenol Male rats hepatocellular carcinomas 15.3-34.0
Methyleugenol Female rats hepatocellular carcinomas 48.8-73.6
Safrole Female mice hepatocellular carcinomas 1.9-5.1
β-asarone Male rats leiomyosarcomas of the small intestine 9.6-21.5
Intake estimates of alkenylbenzenes from consumption of PFS based on analytical 
quantification 
Table 6 shows the results of the quantitative measurement of estragole, 
methyleugenol, safrole and β-asarone present in different commercially available 
PFS for which also theoretical estimations were made. Among the different PFS, 
estragole was found in a range of 0.07-241.56 mg/g PFS corresponding to an 
estimated daily intake of 0.001-4.78 mg/kg bw/day based on the recommended 
daily intake of the PFS as indicated on the label of the respective supplements. 
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The levels of methyleugenol were equal to 0.34-1.04 mg/g PFS in the tested 
nutmeg-containing PFS. Based on the recommended daily intake of the 
corresponding nutmeg PFS, the daily methyleugenol intake would equal 0.005-
0.065 mg/kg bw/day. For calamus-containing PFS, the amount of β-asarone was 
found to be in the range of 0.12-44.28 mg/g PFS, resulting in a daily intake 
of β-asarone equal to 0.003-0.635 mg/kg bw/day. These daily intake estimates 
based on chemical analysis of the alkenylbenzene levels in the different PFS 
are in line with the estimated intake levels of the alkenylbenzenes obtained on 
the basis of the theoretical estimates for the levels of the alkenylbenzenes in 
these PFS. 
Margins of Exposure for alkenylbenzenes 
The MOE values obtained by comparison of the BMDL
10
 values with the estimated 
daily intake of estragole, methyleugenol, safrole or β-asarone resulting from the 
use of different PFS, appear to be relatively low (Table 5). For example, upon 
use of a particular basil-containing PFS consisting of the essential oil, the MOE 
amounts to 1-2,000 for estragole and a value ranging between 5 and 5,000 
was found for methyleugenol. For fennel-containing PFS, the MOE values range 
between 3 and 20,000 for estragole. Taking into account the consumption of 
a β-asarone-containing calamus PFS, the MOE was found equal to 60-7,000. 
Also when considering the actual levels of these compounds in commercially 
available PFS as quantitatively determined, relatively low MOE values were 
derived (Table 6). In some cases the MOE was even found to be below 10 which 
means that the daily intake of the compounds of interest are within the range 
of the dose levels causing tumors in experimental animals. 
Discussion 
In the presented chapter, the MOE approach was used for the risk assessment 
of a series of compounds that are both genotoxic and carcinogenic 
and known to be present in botanicals and PFS. In total, 30 botanical 
ingredients were identified as a possible risk for human health based on 
their genotoxic and/or carcinogenic characteristics. Out of these selected 
botanical ingredients 18 compounds appeared to be both genotoxic and 
carcinogenic. Interestingly, most of these compounds are a member of the 
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group of alkenylbenzenes or unsaturated pyrrolizidine alkaloids. Based on 
this thorough selection of genotoxic and carcinogenic botanical compounds 
of interest and the availability of carcinogenicity data allowing the use of the 
MOE concept, this concept was applied to the alkenylbenzenes estragole, 
methyleugenol, safrole and β-asarone. The results presented show that 
the consumption of PFS containing estragole, methyleugenol, safrole 
or β-asarone may represent a high priority for risk management actions. 
 Performing the exposure assessment, intake estimates were made 
based on available literature data. However, the prediction of the content of the 
botanical compounds of interest in PFS was hampered by uncertainties in the 
processing techniques used to prepare the respective PFS and varying amounts 
of these compounds found in plants belonging to the same species depending 
on the plant maturity at harvest and climatic conditions among others (Smith 
et al., 2002). To determine if the estimates of human dietary exposure represent 
the actual levels of the genotoxic carcinogens of interest in commercially 
available PFS, the content of alkenylbenzenes in different PFS was analyzed. The 
theoretical estimates made for the levels of estragole, methyleugenol, safrole 
and β-asarone in the different PFS were generally in agreement with the levels 
of these compounds actually detected in chemical analysis. In general, a wide 
range of estimated intake levels was obtained for each PFS of interest because 
of the different amounts of the respective compounds in the plants and their 
corresponding PFS, resulting in a wide range of MOE values. Moreover, making use 
of the levels of the alkenylbenzenes of interest in a particular PFS, as determined 
by chemical analysis, resulted also in a wide range of MOE values. It was seen that 
the wide variations in MOE values for a specific PFS is not due to a large variation 
in the BMDL10 values, because these values vary only 2 to 3 fold. On the contrary, 
intake estimates may vary greatly. For example, for a basil-containing PFS, the 
recommended daily intake equals 1-4 tablets (i.e. 270-1080 mg/day) and while 
the daily methyleugenol exposure resulting from the daily use of 1 tablet does 
not indicate a potential risk for human health, the daily intake of 4 tablets does. 
As a consequence, it is difficult to express these relatively wide ranging MOE 
values in terms of concern for human health and this involves an increased risk 
of misinterpretation, demonstrating the importance of a narrative describing 
the context of uncertainties in the exposure assessment. The importance of an 
explanatory narrative was previously indicated (Barlow et al., 2006; Benford et al., 
2010) and will allow a better interpretation of the potential risk for human health. 
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 Based on the analytical measurements, it was shown that also between 
the PFS consisting of the same botanical species, differences occur in the levels 
of the alkenylbenzenes of interest. The variability in these alkenylbenzene 
concentrations in the different products can have several causes. The 
theoretical approach presented in this chapter and tested towards a number 
of PFS available on the market, made heavily clear some points of concern. 
Alkenylbenzenes are present in the essential oil of the plant. The quantity of 
the essential oil and the amount of alkenylbenzenes is dependent on genetic 
factors and geographical influences in cultivation. Further compositional 
changes are seen depending on the moment of harvesting, the way of drying, 
processing and manufacturing conditions. Therefore, when manufacturing PFS 
a strict analytical procedure is necessary in order to determine and follow up the 
amount of the alkenylbenzenes. In herbal trade, the use of the binomial plant 
name including the author, the chemotype, variety, hybrid or cultivar should 
be used and when possible, the geographical origin. In case of using botanicals 
known to contain genotoxic and carcinogenic compounds, this should be a 
legal requirement and in fact also be a requirement for all botanicals used in 
food and food supplements. Basil is an example. ‘Basil’ is an undefined vernacular 
name. The sweet basil is Ocimum basilicum L. containing often less than 0.2% 
methyleugenol. However, when cultivated in Egypt the amount increases 
to an average of 5.6%. O. basilicum var. basilicum contains on average 1.6% 
methyleugenol and O. basilicum L. var. minimum up to 55% methyleugenol. 
Both are sold as ‘basil’ or also as Ocimum basilicum L. Even for a morphological 
well defined species, also different chemotypes exist: ‘linalool’ type, ‘linalool 
and estragole’ and ‘linalool and eugenol’ all having huge differences in the 
amount of the alkenylbenzenes. The amount of methyleugenol and estragole 
also depends on the size of the herb with small plants having a higher amount 
of methyleugenol and less estragole whereas taller plants showing a higher 
amount of estragole and lower methyleugenol levels. The moment of harvesting 
is therefore important as well as the drying methods which heavily influence 
the content of the volatile compounds of basil (di Cesare et al., 2003; Miele et 
al., 2001). 
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 The potential risks resulting from the use of alkenylbenzene-containing 
PFS are especially of concern because multiple supplements might be consumed 
in addition to the regular daily diet. Previous studies already performed a risk 
assessment based on the MOE concept for the botanical ingredients estragole 
(Rietjens et al., 2010) and methyleugenol (Benford et al., 2010; Rietjens et al., 2008) 
indicating that the use of a regular diet containing estragole or methyleugenol 
is associated with concerns from the human health point of view since low 
MOE values ranging between 129 and 3300 were found for estragole taking 
into account the total estimated daily intake (Rietjens et al., 2010). Also for 
methyleugenol low MOE values were obtained amounting to 42-416 (Rietjens 
et al., 2008) and 100-800 (Benford et al., 2010). Moreover, it is important to 
recognize that often various structurally related compounds, causing the same 
adverse effects, occur together in one botanical such as the alkenylbenzenes 
estragole and methyleugenol which can be found in sweet basil. However, one 
should keep in mind that whenever basil (Ocimum basilicum L.) expresses for 
example high levels of estragole, methyleugenol levels are often low and vice 
versa (Zheljazkov et al., 2008). Although the addition of estragole, methyleugenol 
(Regulation (EC) No 1334/2008 of the European Parliament and of the Council 
16 December 2008), safrole and β-asarone (Council Directive 88/388/EEC of 22 
June 1988) as pure compounds in food is prohibited within the EU because 
of their genotoxic and carcinogenic potentials, currently no restrictions 
have been made with regard to the use of alkenylbenzene-containing PFS. 
 Methyleugenol and structurally related alkenylbenzenes are not 
carcinogenic by nature but metabolic conversion into a biological active form 
is required to give expression to the carcinogenic capacities in rodent bioassays. 
It is reported that the metabolic pathway responsible for the formation of a DNA 
reactive carbonium ion occurs at relatively high intake levels when metabolic 
conversion through a standard metabolic pathway is saturated (Smith et al., 
2002). Accordingly, Benford et al. (2010) stated that “derivation of a BMD/BMDL 
based on modeling of high-dose animal study data does not allow threshold 
effects in metabolism to be accounted for and thus alters the interpretation of 
the calculated MOE”. However, a recent study showed only a minor increase 
(<1-fold) in the relative formation of the ultimate carcinogenic metabolite of 
methyleugenol at high dose levels as compared to low dose levels (Al-Subeihi 
et al., 2011). Using a physiologically based kinetic (PBK) model, it was predicted 
that the formation of the ultimate carcinogen (i.e. 1’-sulfoxymethyleugenol) in 
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rats would correspond to 0.043% of the initial dose at 0.05 mg/kg bw followed 
by an increase to 0.06% of the dose at a dose of 300 mg/kg bw (Al-Subeihi et 
al., 2011). These data are also available for the bioactivation of estragole and 
safrole. For estragole, the formation of the ultimate carcinogenic metabolite 
was predicted to show a 2-fold relative increase when comparing a low dose 
(0.05 mg/kg bw) with a high dose (300 mg/kg bw) of estragole (Punt et al., 2008). 
Whereas for safrole, the PBK model predicted that the increase in the formation 
of the ultimate carcinogen with the dose is negligible (Martati et al., 2011). 
Conclusion  
In conclusion, a number of genotoxic and/or carcinogenic compounds can 
be found in botanicals and botanical preparations. Especially compounds 
belonging to the group of alkenylbenzenes and unsaturated pyrrolizidine 
alkaloids are of possible concern for human health resulting from their genotoxic 
and carcinogenic potentials. In fact, PFS that are on the market may contain 
alkenylbenzenes at levels that, at the recommended daily dose of the supplement, 
may result in a daily intake that is in the range of dose levels causing malignant 
tumors in experimental animals. While in several countries the use of the 
alkenylbenzenes estragole, methyleugenol, safrole and β-asarone as flavorings 
in food products is regulated and prohibited, the use of PFS containing these 
ingredients in high levels is not regulated. This is remarkable since the use of PFS 
might result in high exposures to these compounds and consequently low MOE 
values suggesting a high priority for risk management. It must be emphasized 
that in the present chapter the MOE values are calculated based on BMDL10 
values obtained in studies administering high doses of the pure alkenylbenzene 
compounds to rodents, instead of dosing the botanical as such or in a form of 
a multicomponent extract. Ideally the studies in rodents should be performed 
with the botanical or the standardized traditional extract(s) of that botanical. 
This because studies are already available suggesting that results obtained with 
the botanical or its extract, containing the genotoxic compound in its food 
matrix, may be different from those obtained when using the purified genotoxic 
carcinogenic compounds (de Paula et al., 2007; Jeurissen et al., 2008; Smith et 
al., 2002). Such differences may occur for example when additional compounds 
present in the botanical or its extract may modulate the bioactivation and/or 
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detoxification pathways of the genotoxic carcinogen of interest. For example, 
Jeurissen et al. (2008) demonstrated that a methanolic basil extract was able 
to adequately inhibit the sulfotransferase catalyzed bioactivation and DNA-
adduct formation in HepG2 human hepatoma cells exposed to the proximate 
carcinogen of estragole. The basil compound responsible for the inhibition was 
subsequently identified as nevadensin (Alhusainy et al., 2010). These results 
indicate that the bioactivation of estragole is likely to be lower when estragole 
is consumed in the presence of other herbal ingredients compared to the 
exposure of estragole as a pure compound. If such a matrix effect would occur 
also upon intake of the alkenylbenzenes from PFS, the use of the BMDL10 data 
obtained in studies with pure estragole, methyleugenol, safrole and β-asarone 
to calculate the MOE values, would be a worst-case approach and may result in 
an overestimation of the potential risk for human health. In spite of this, it is still 
concluded that the use of PFS containing the genotoxic carcinogens estragole, 
methyleugenol, safrole or β-asarone might raise a potential concern for human 
health and would be of high priority for risk management.
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Supplementary Materials Chapter 3
Table S1. Results from a BMD analysis for induction of hepatocellular carcinomas in mice administered 
0, 2300 or 4600 mg/kg diet estragole 3 days a week for 12 months (Miller et al., 1983) using BMDS 
software version 2.1.2, a BMD of 10% and default settings. The data used as input for the BMD analysis 
are presented in Table 2.
Model No. of parameters Log Likelihood p-value Accepted BMD
10
 
(mg/kg 
bw/day)
BMDL
10
 
(mg/kg  
bw/day) 
Null 1 -100.09     
Full 3 -62.21     
Gamma 1 -62.71 0.61 Yes 8.0 6.5
Logistic 2 -70.84 0.00 No
LogLogistic 1 -62.21 1.00 Yes 4.7 3.3
Probit 2 -70.14 0.00 No
LogProbit 2 -62.21 1.00 Yes 4.9 ND*
Multistage 1 -62.71 0.61 Yes 8.0 6.5
Weibull 1 -62.71 0.61 Yes 8.0 6.5
Quantal-linear 1 -62.71 0.61 Yes 8.0 6.5
* Not determined. Benchmark dose computation failed. Lower limit includes zero.
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Table S2. Overview of BMD analysis for hepatocellular carcinomas in male and female rats administered 
0, 37, 75 or 150 mg/kg bw methyleugenol 5 days per week for 105 weeks (NTP, 2000). BMDS software 
version 2.1.2 was used for BMD analysis using a BMD of 10% and default settings. The data used as input 
for the BMD analysis are presented in Table 2.
Gender Model No. of pa-
rameters
Log Likelihood p-value Accepted BMD
10 
(mg/kg 
bw/day)
BMDL
10 
(mg/kg 
bw/day) 
Male Null 1 -105.38     
Full 4 -84.05     
Gamma 3 -84.77 0.23 Yes 35.2 21.1
Logistic 2 -85.67 0.20 Yes 40.8 34.0
LogLogistic 3 -84.70 0.25 Yes 35.0 21.9
Probit 2 -85.38 0.26 Yes 37.8 31.6
LogProbit 3 -84.50 0.35 Yes 35.7 23.3
Multistage 3 -85.06 0.16 Yes 35.3 19.3
Weibull 3 -84.91 0.19 Yes 34.3 20.3
Quantal-lin-
ear 2 -86.54 0.08 Yes 20.1 15.3
Female Null 1 -45.27     
Full 4 -35.67     
Logistic 2 -37.81 0.12 Yes 87.6 73.6
LogLogistic 2 -36.70 0.35 Yes 76.2 55.6
Probit 2 -37.51 0.16 Yes 84.4 69.9
LogProbit 2 -36.50 0.43 Yes 74.2 54.9
Multistage 1 -36.75 0.53 Yes 77.5 57.3
Weibull 2 -36.74 0.34 Yes 76.9 56.0
Quantal-lin-
ear 1 -37.62 0.27 Yes 75.9 48.8
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Table S3. Results from a BMD analysis for induction of hepatocellular carcinomas in mice administered 
0, 2500 or 5000 mg/kg diet safrole 3 days a week for 12 months (Miller et al., 1983) using BMDS software 
version 2.1.2, a BMD of 10% and default settings. The data used as input for the BMD analysis are 
presented in Table 2.
Model No. of parameters Log Likelihood p-value Accepted BMD
10
 
(mg/kg 
bw/day)
BMDL
10
 
(mg/kg 
bw/day) 
Null 1 -101.20    
Full 3 -52.51    
Gamma 1 -54.32 0.16 Yes 6.2 5.1
Logistic 2 -65.17 0.00 No
LogLogistic 1 -52.71 0.82 Yes 2.8 1.9
Probit 2 -65.11 0.00 No
LogProbit 2 -52.51 1.00 Yes 0.2 ND*
Multistage 1 -54.32 0.16 Yes 6.2 5.1
Weibull 1 -54.32 0.16 Yes 6.2 5.1
Quantal-linear 1 -54.32 0.16 Yes 6.2 5.1
 
* Not determined. Benchmark dose computation failed. Lower limit includes zero.
Table S4. Overview of BMD analysis performed using BMDS software version 2.1.2, a BMD of 10% and 
default settings. BMD10 and BMDL10 values are derived from the incidence of leiomyosarcomas of the 
small intestine in male rats following a 2 year period of treatment with 0, 400, 800, or 2000 mg/kg diet 
β-asarone (JECFA, 1981). The data used as input for the BMD analysis are presented in Table 2.
Model No. of parameters Log Likelihood p-value Accepted BMD
10 
(mg/kg 
bw/day)
BMDL
10
 
(mg/kg 
bw/day) 
Null 1 -43.97     
Full 4 -34.31     
Gamma 2 -34.60 0.75 Yes 21.6 10.7
Logistic 2 -35.68 0.25 Yes 27.6 21.5
LogLogistic 2 -34.59 0.76 Yes 21.5 10.1
Probit 2 -35.36 0.35 Yes 26.2 20.2
LogProbit 2 -34.50 0.83 Yes 21.6 10.4
Multistage 2 -34.70 0.68 Yes 22.0 10.5
Weibull 2 -34.65 0.71 Yes 21.4 10.6
Quantal-linear 1 -35.30 0.58 Yes 14.1 9.6
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Abstract 
The present study describes physiologically based kinetic (PBK) models for 
the alkenylbenzene elemicin (3,4,5-trimethoxyallylbenzene) in rat and human, 
based on the PBK models previously developed for the structurally related 
alkenylbenzenes estragole, methyleugenol, and safrole. Using the newly 
developed models, the level of metabolic activation of elemicin in rat and human 
was predicted to obtain insight in species differences in the bioactivation of 
elemicin and read across to the other methoxy allylbenzenes, estragole and 
methyleugenol. Results reveal that the differences between rat and human in 
the formation of the proximate carcinogenic metabolite 1’-hydroxyelemicin 
and the ultimate carcinogenic metabolite 1’-sulfoxyelemicin are limited (<3.8-
fold). In addition, a comparison was made between the relative importance 
of bioactivation for elemicin and that of estragole and methyleugenol. Model 
predictions indicate that compound differences in the formation of the 
1’-sulfoxymetabolites are limited (<11-fold) in rat and human liver. The insights 
thus obtained were used to perform a risk assessment for elemicin using the 
Margin of Exposure (MOE) approach and read across to the other methoxy 
allylbenzene derivatives for which in vivo animal tumor data are available. This 
reveals that elemicin poses a lower priority for risk management as compared 
to its structurally related analogues estragole and methyleugenol. Altogether, 
the results obtained indicate that PBK modeling provides an important insight 
in the occurrence of species differences in the metabolic activation of elemicin. 
Moreover, they provide an example of how PBK modeling can facilitate a read 
across in risk assessment from compounds for which in vivo toxicity studies 
are available to a compound for which only limited toxicity data have been 
described, thus contributing to the development of alternatives for animal 
testing. 
27938 Berg, Suzanne vd.indd   106 24-04-14   12:57
4Physiologically based kinetic models for the alkenylbenzene elemicin 
in rat and human and possible implications for risk assessment
107
Introduction 
Elemicin (3,4,5-trimethoxyallylbenzene) is an aromatic compound that naturally 
occurs in a variety of herbs and spices such as nutmeg (Myristica fragrans 
Houtt.), parsley [Petroselinum crispum (Mill.) A. W. Hill], sassafras [Sassafras 
albidum (Nutt.) Nees.] (EFSA, 2009) and products made thereof including 
plant food supplements (PFS). Belonging to the group of alkenylbenzenes, 
elemicin is structurally related to estragole, methyleugenol, safrole, apiol, and 
myristicin (Figure 1). A number of rodent carcinogenicity studies revealed 
hepatocarcinogenic effects of estragole, methyleugenol, and safrole, and 
a genotoxic mode of action has been suggested for these compounds (SCF 
2001a, 2001b, 2002). However, elemicin is less well studied as compared to its 
structurally related analogues and only limited toxicological data are available. 
Figure 1. The structural formulas of estragole, methyleugenol, elemicin, safrole, myristicin and apiol.
On the basis of the studies available, elemicin is indicated to be 
DNA reactive; however, evidence for hepatocarcinogenic activity in rodents 
is equivocal (Hasheminejad and Caldwell, 1994; Miller et al., 1983; Phillips et 
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al., 1984; Randerath et al., 1984; Wiseman et al., 1987). Elemicin gave positive 
results in several genotoxicity assays, that is, an unscheduled DNA synthesis 
(UDS) assay in adult rat hepatocytes and two in vivo DNA-binding assays 
using mice, indicating DNA reactivity (Hasheminejad and Caldwell, 1994; 
Phillips et al., 1984; Randerath et al., 1984). Nevertheless, DNA binding was up 
to 27-fold lower at comparable experimental conditions as compared to that 
of structurally related compounds including estragole, methyleugenol, and 
safrole (Phillips et al., 1984; Randerath et al., 1984). Miller et al. (1983) revealed 
that there was no significant hepatocarcinogenic response in mice exposed to 
elemicin or its metabolite 1’-hydroxyelemicin via i.p. injections with a total dose 
corresponding to 4.75 µmol/animal calculated to be equivalent to 49.5 mg/kg 
bw elemicin or 53.3 mg/kg bw 1’-hydroxyelemicin assuming a bw of 20 g. In 
line with these results, Wiseman et al. (1987) showed that 1’-hydroxyelemicin 
had no hepatocarcinogenic activities in male mice after i.p. injections of a single 
dose of 0.1 or 0.25 µmol/g bw 1’-hydroxyelemicin corresponding to 22.4 or 56.3 
mg/kg bw 1’-hydroxyelemicin. However, a significant increased incidence in the 
formation of treatment-related liver tumors was observed upon administration 
of 1’-hydroxyelemicin to male mice at the highest dose tested (i.e. four injections 
with a total dose of 9.5 µmol which equals 106.5 mg/kg bw) (Wiseman et al., 1987). 
 The DNA reactive and carcinogenic activities of estragole, 
methyleugenol, and safrole have been ascribed to their metabolic activation 
to an unstable DNA reactive 1’-sulfoxymetabolite (Boberg et al., 1983; Phillips 
et al., 1981; Randerath et al., 1984; Wiseman et al., 1985). On the basis of 
the related structural characteristics of estragole, methyleugenol, safrole, 
elemicin, myristicin, and apiol (i.e. all containing alkylated and no free hydroxyl 
substituents and an allyl side chain with a C2=C3 double bond), similar 
metabolic pathways can be expected for these six alkenylbenzenes. Figure 2 
gives an overview of the different metabolic pathways of elemicin based on the 
metabolites formed from the related alkenylbenzenes and also the metabolites 
identified in rat and human urine after elemicin exposure (Beyer et al., 2006). 
O-demethylation, 1’-hydroxylation, 3’-hydroxylation and epoxidation are the 
most important cytochrome P450-catalyzed conversions. O-demethylation of 
the alkoxy ring substituents represents a metabolic detoxification because the 
resulting (di)phenolic derivate can be conjugated and excreted in the urine as 
the sulfate or glucuronic acid metabolite (Anthony et al., 1987; Benedetti et al., 
1977; Beyer et al., 2006; Lee et al., 1998; Solheim and Scheline, 1973). Another 
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detoxification route is the formation of a 2’,3’-epoxide arising after epoxidation 
of the alkene side chain. Although epoxides of related alkenylbenzenes have 
been shown to be able to form DNA adducts in vitro, these epoxides when 
formed in vivo are rapidly detoxified by glutathione S-transferases and 
epoxide hydrolases (Luo and Guenthner, 1996; Luo et al., 1992). In addition, the 
formation of 3’-hydroxymetabolites is considered to be an important metabolic 
pathway. Although it is stated in the literature that 1’-hydroxymetabolites can 
be isomerized yielding 3’-hydroxymetabolites (Borchert et al., 1973b; Solheim 
and Scheline, 1976, 1980; Stillwell et al., 1974), others pointed toward a direct 
formation of 3’-hydroxymetabolites from the parent alkenylbenzene (Boberg 
et al., 1986; Martati et al., 2011; Punt et al., 2008). 3’-Hydroxymetabolites can 
be oxidized to cinnamic acid derivatives and can ultimately be excreted as 
glycine conjugates (Anthony et al., 1987; Boberg et al., 1986; Solheim and 
Scheline, 1973, 1976, 1980). 1’-Hydroxylation of the alkene side chain yields 
the proximate carcinogenic metabolite and is considered as the primary 
bioactivation pathway (Borchert et al., 1973a; Borchert et al., 1973b; Gardner 
et al., 1997; Zangouras et al., 1981). It is reported in the literature that a notable 
increase in the formation of the 1’-hydroxymetabolite occurs after an increase 
in dose of the parent compound which is accompanied by a shift in metabolic 
pathways (Anthony et al., 1987; Benedetti et al., 1977; Zangouras et al., 1981). 
1’-Hydroxylation of the alkene side chain appears to be more prominent at 
relatively high exposure levels when enzymes involved in the O-demethylation 
pathway become saturated (Zangouras et al., 1981). However, going from 
dose levels at which for different alkenylbenzenes tumor incidence is already 
observed (3-50 mg/kg bw/day) down to dose levels representing realistic 
human exposure the metabolic shift and changes in the relative amount of 
bioactivation to the 1’-hydroxymetabolites might be limited. Sulfonation of 
the 1’-hydroxymetabolite results in the formation of the ultimate carcinogenic 
1’-sulfoxymetabolite. Because of the unstable nature of this metabolite in an 
aqueous environment, a reactive electrophilic metabolite is formed that can 
bind covalently to proteins, RNA, and DNA (Boberg et al., 1983; Phillips et al., 
1981; Randerath et al., 1984; Wiseman et al., 1985). In addition to being converted 
in the sulfonation pathway, the 1’-hydroxymetabolite can be converted and 
detoxified by glucuronidation or oxidation, the latter possibly followed by 
glutathione (GSH) conjugation (Fennell et al., 1984; Punt et al., 2009). 
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In 2008, the Joint FAO/WHO Expert Committee on Food Additives (JECFA) 
concluded that for the alkenylbenzenes estragole, methyleugenol, safrole, 
elemicin, myristicin, and apiol “further research is needed to assess the potential 
risk to human health from low-level dietary exposure to alkoxy-substituted 
allylbenzenes present in foods and essential oils and used as flavoring agents” 
(JECFA, 2008). However, for an assessment of the potential risk to human 
health at low-level dietary exposure scenarios, it is of importance to take non-
linear effects as well as species differences in kinetics into consideration when 
extrapolating data obtained in animal experiments performed with high dose 
levels to low dose levels corresponding to relevant dietary human exposures. 
On the basis of the mode of action, physiologically based kinetic (PBK) models 
for rat and human for estragole (Punt et al., 2008, 2009), methyleugenol (Al-
Subeihi et al., 2011, 2012), and safrole (Martati et al., 2011, 2012) were recently 
developed. Mode of action based PBK modeling enables quantification of the 
relative importance of detoxification and bioactivation, taking non-linear effects 
in kinetics into account, allowing a read across from one compound to another 
and between species, such as from rat to human. The aim of the present study 
was to extend the rat and human PBK models of estragole, methyleugenol, and 
safrole to rat and human PBK models for elemicin, to predict the bioactivation 
and detoxification of elemicin in rat and human at realistic low exposure levels. 
This will facilitate read across from data on the two structurally related methoxy 
allylbenzenes estragole and methyleugenol for which in vivo toxicity studies are 
available, to elemicin for which the toxicological database is far more limited. 
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Figure 2. Proposed metabolic pathways of the alkenylbenzene elemicin.   
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Materials and methods 
Caution: elemicin and 1’-hydroxyelemicin are possible carcinogens and should be 
handled with care. 
Chemicals and reagents
Elemicin was purchased from Synchem OHG (Felsberg, Germany). 
Tris(hydroxymethyl)aminomethane, uridine 5'-diphosphoglucuronic acid 
(UDPGA), reduced L-glutathione (GSH), alamethicin (from Trichoderma 
viride), 3'-phosphoadenosine 5'-phosphosulfate (PAPS), L-cysteine, N-acetyl-
L-cysteine and 4-allyl-2,6-dimethoxyphenol (also known as 4-hydroxy-3,5-
dimethoxyallylbenzene) were purchased from Sigma-Aldrich (Steinheim, 
Germany). β-Nicotinamide adenine dinucleotide (NAD+), reduced 
β-nicotinamide adenine dinucleotide phosphate (NADPH), β-nicotinamide 
adenine dinucleotide phosphate (NADP+) and reduced β-nicotinamide adenine 
dinucleotide (NADH) were from Roche Diagnostics (Mannheim, Germany). 
β-glucuronidase (from Escherichia Coli) was purchased from Boehringer 
(Mannheim, Germany) and dimethylsulfoxide (DMSO) was obtained from 
Acros Organics (Geel, Belgium).Potassium dihydrogen phosphate, dipotassium 
hydrogen phosphate trihydrate, acetic acid and magnesium chloride were 
supplied by VWR International (Darmstadt, Germany). Acetonitrile (ULC/MS 
grade) was purchased from Biosolve BV (Valkenswaard, The Netherlands). 
Pooled male rat liver microsomes and S9 from Sprague Dawley and mixed 
gender pooled human liver microsomes and S9 were from BD Gentest (Woburn, 
USA). Pooled male Sprague Dawley rat lung, kidney and small intestinal 
microsomes and pooled gender human lung, kidney and intestinal microsomes 
were purchased from BioPredic International (Rennes, France). 
Synthesis of metabolites 
A synthetic standard of 1’-hydroxyelemicin was prepared as described 
previously for 1’-hydroxysafrole using 1,2,3-trimethoxybenzaldehyde as 
starting material (Jeurissen et al., 2004). GC-MS analysis was performed as 
described by Jeurissen et al. (2004) for the analysis of 1’-hydroxysafrole. Based 
on GC-MS and HPLC analyses, the purity of 1’-hydroxyelemicin was found to be 
more than 95%. Synthesis of 3’-hydroxyisoelemicin was based on the method 
described previously using 1’-hydroxyelemicin as starting material (Borchert 
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et al., 1973b; Solheim and Scheline, 1980). Based on HPLC analysis, the purity 
of 3’-hydroxyisoelemicin was found to be more than 65%. The synthesis of 
1’-oxoelemicin from 1’-hydroxyelemicin was carried out as described previously 
for the synthesis of 1’-oxosafrole from 1’-hydroxysafrole (Wislocki et al., 1976). 
HPLC analysis revealed that the purity of 1’-oxoelemicin was more than 95%. 
Elemicin-2’,3’-oxide was prepared based on the procedure reported by Luo et al. 
(1992) using elemicin as starting material. Based on HPLC analysis the purity was 
found to equal 10% with the remaining 90% consisting of the starting material 
elemicin, but this was sufficient for identification. 
The identities of elemicin, 1’-hydroxyelemicin, 3’-hydroxyisoelemicin, 
1’-oxoelemicin and elemicin-2’,3’-oxide were confirmed by NMR analysis. 
Characteristic NMR chemical shifts are presented in Table S1 of the 
Supplementary Materials of Chapter 4. 
In vitro Incubations 
Microsomal metabolism of elemicin by relevant rat and human tissue fractions
In a first step, it was determined which organs are involved in the 
biotransformation of elemicin in rat and human. For this purpose, liver, kidney, 
lung and small intestine microsomes from male Sprague Dawley rat and human 
were used. Incubations were performed by adding 1 mg/mL of the microsomal 
protein preparations to an incubation mixture containing (final concentrations) 
3 mM NADPH in 0.2 M Tris-HCl (pH 7.4). After a 1 min pre-incubation at 37°C, 
elemicin (final concentration 100 µM) was added from a 100 times concentrated 
stock solution in DMSO so that the final DMSO content was 1% (v/v). Incubations 
were carried out for 30 min after which the reactions were terminated by 
adding 25 µL ice-cold acetonitrile. All samples were centrifuged for 5 min at 
16,000g and the supernatant was stored at -20˚C until High Performance Liquid 
Chromatography (HPLC) analysis. 
For male rats, metabolism of elemicin was observed in incubations 
with liver and lung microsomes and hence kinetic constants for the formation 
of microsomal metabolites were determined in the respective tissue fractions 
(see result section). For humans these constants were determined for elemicin 
microsomal metabolism occurring in incubations with liver microsomes only 
since microsomal samples from no other human organs investigated were found 
capable of metabolizing this alkenylbenzene (see results section). Incubations 
to determine kinetic constants were performed following the conditions 
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described above using final concentrations of elemicin from 25 to 1000 µM for 
rat and human liver, and from 50 to 2000 µM for rat lung. In all incubations, the 
final concentration of DMSO, in which elemicin was dissolved, was kept at a final 
concentration of 1% (v/v). Formation of different microsomal metabolites was 
linear with time and microsomal protein concentrations under the conditions 
described. Blank incubations were performed in the absence of the cofactor 
NADPH. All incubations were performed in duplicate. 
Stereochemistry of 1’-hydroxyelemicin 
1’-Hydroxyelemicin is a chiral molecule. To determine if the synthetic and 
metabolically formed 1’-hydroxyelemicin existed of two enantiomers, 
the chirality of both the synthetized 1’-hydroxyelemicin as well as of the 
1’-hydroxyelemicin formed in microsomal incubations was analyzed using the 
chiral HPLC method described by Punt et al. (2007) to quantify the enantiomers 
of 1’-hydroxyestragole with minor modifications. In short, an isocratic elution 
using 10 mM sodium acetate (pH 4.5) was applied at a flow rate of 0.4 mL/min 
to separate both enantiomers. 
Glucuronidation of 1’-hydroxyelemicin 
The kinetic constants for the metabolic conversion of 1’-hydroxyelemicin to 
1’-hydroxyelemicin glucuronide in both male rat and human liver fractions were 
determined as described previously for related 1’-hydroxyalkenylbenzenes (Al-
Subeihi et al., 2011 and 2012; Martati et al., 2011 and 2012; Punt et al., 2008 
and 2009) with minor modifications. In short, incubations were performed 
using (final concentrations) 10 mM UDPGA and 0.5 mg/mL male Sprague 
Dawley S9 protein in 0.2 M Tris-HCl (pH 7.4) with 10 mM MgCl2. To overcome 
enzyme latency and to obtain maximal glucuronidation activity, incubations 
containing S9 were pre-treated on ice with 0.025 mg/mL alamethicin added 
from a 200 times concentrated stock dissolved in methanol (Fisher et al., 2000; 
Lin and Wong, 2002). After 15 min of alamethicin treatment, samples were pre-
incubated at 37˚C for 1 min, and reactions were subsequently started by adding 
1’-hydroxyelemicin in final concentrations of 50 to 4000 µM. 1’-Hydroxyelemicin 
was added from a 200 times concentrated stock dissolved in DMSO. The 
reaction was incubated for 30 min and terminated by adding 25 µL of ice-cold 
acetonitrile. Blank incubations were carried out in the absence of the cofactor 
UDPGA. Experiments were performed in duplicate. Similar incubations were 
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performed using mixed gender human pooled liver S9 proteins. However, 
because of a lower rate of glucuronidation by human S9 proteins, samples were 
incubated for a longer time, that is, 120 min. The formation of 1’-hydroxyelemicin 
glucuronide was linear with time and S9 protein concentration under the 
experimental conditions described. 
The formation of 1’-hydroxyelemicin glucuronide was verified by 
incubating a sample made as described above, for which the reaction was 
not terminated using acetonitrile, with β-glucuronidase. For this purpose, 90 
µL sample was added to 10 µL of 1 M potassium phosphate (pH 6.2) and 2 
µL of β-glucuronidase solution (final concentration 0.3 U) and subsequently 
incubated for 1 h at 37˚C. All samples were centrifuged for 5 min at 16,000g and 
the supernatant was stored at -20˚C until HPLC analysis. 
Oxidation of 1’-hydroxyelemicin 
The kinetic constants for the enzymatic conversion of 1’-hydroxyelemicin to 
1’-oxoelemicin were determined using incubation mixtures containing (final 
concentrations) 3 mM NAD+, 2 mM GSH and 1 mg/mL rat liver microsomes or 
human liver S9 in 0.2 M Tris-HCl (pH 7.4). GSH was added to the incubation 
mixtures to trap the reactive 1’-oxometabolite formed after oxidation of 
1’-hydroxyelemicin (Punt et al., 2009). Although the formation of the GSH 
adduct of 1’-oxoelemicin was also observed in incubations using human liver 
homogenates with NADP+ as a cofactor, NADP is mainly present in reduced 
form with a NADP+/NADPH ratio of about 0.005 in human liver. Incubations 
using different ratios of NADP+/NADPH (i.e. 0.005, 0.01, 0.05, 0.1, 0.5, and 1) 
revealed that the rate of conversion of 1’-hydroxyelemicin to 1’-oxoelemicin 
was not significant when in addition to NADP+ also NADPH was present at a 
physiologically relevant ratio (data not shown). Therefore, kinetic constants for 
this reaction in rat and human liver were derived by performing incubations with 
NAD+ as a cofactor, given that in rat and human liver, NAD is mainly present in an 
oxidized form with levels of NAD+ being much higher than that of NADH. Prior 
to the addition of 1’-hydroxyelemicin at final concentrations ranging between 
40 and 4000 µM to the incubation mixture, samples were pre-incubated for 
1 min at 37˚C. Reactions were terminated after 5 min by adding 25 µL of ice-
cold acetonitrile. The formation of the GSH conjugate of 1’-oxoelemicin, GS-1’-
oxoelemicin, was linear with time and microsomal or S9 protein concentrations 
under the experimental conditions used. Blank incubations were performed 
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without the cofactor NAD+. Incubations were performed in duplicate. All 
samples were centrifuged for 5 min at 16,000g, and the supernatant was stored 
at -20˚C until HPLC analysis. 
Sulfonation of 1’-hydroxyelemicin
The formation of 1’-sulfoxyelemicin was determined using incubations 
containing male rat liver Sprague Dawley S9 or mixed gender pooled human liver 
S9 proteins, PAPS as a cofactor and GSH, which acts as a scavenger of the reactive 
carbocation formed due to the unstable nature of the 1’-sulfoxymetabolite in an 
aqueous environment (Al-Subeihi et al., 2011; Martati et al., 2011). Incubation 
mixtures containing (final concentrations) 10 mM GSH, 0.2 mM PAPS and 4 mg/
mL male rat liver S9 or mixed gender pooled human liver S9 proteins in 0.1 
M potassium phosphate (pH 8.2) were pre-incubated for 1 min at 37˚C. After 
this pre-incubation, 1’-hydroxyelemicin dissolved in DMSO was added in final 
concentrations ranging between 0.5 and 4000 µM, keeping the final percentage 
of DMSO at 1%. The reaction was terminated after 180 min by adding 25 µL of 
ice-cold acetonitrile. The formation of the GSH conjugate of 1’-sulfoxyelemicin 
was linear with time and S9 protein concentrations under the experimental 
conditions used. The scavenging may be either chemically or catalyzed by 
the glutathione S-transferases present in the S9 incubations in which the 
sulfonation of 1’-hydroxyelemicin was measured. The mechanism underlying 
the scavenging of 1’-sulfoxyelemicin by GSH was investigated to a further extent 
performing additional incubations with cysteine or N-acetylcysteine as trapping 
agent using incubation conditions as described above. Blank incubations were 
performed in the absence of PAPS. Incubations were performed in duplicate. All 
samples were centrifuged for 5 min at 16,000g and the supernatant was stored 
at -20˚C until Ultra Performance Liquid Chromatography (UPLC) analysis. 
Identification and quantification of elemicin metabolites 
For identification and quantification of microsomal elemicin metabolites, 
aliquots of 50 µL of each sample were subjected to HPLC analysis as described 
by Punt et al. (2008). Identification was achieved by comparing the retention 
times and UV spectra of the formed metabolites to the retention times and 
UV spectra of the commercially available or synthesized reference standards. 
Quantification of the formed metabolites was done by comparing the peak 
areas to those of calibration curves of the corresponding reference compounds 
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at a wavelength of 208 nm. The synthetized elemicin-2’,3’-oxide still contained a 
substantial amount of the starting compound elemicin and could thus be used for 
identification but not for quantification. Therefore quantification of elemicin-2’,3’-
oxide and 2’,3’-dihydroxyelemicin, reflecting the formation of elemicin-2’,3’-oxide, 
was achieved using the calibration curve for 1’-hydroxyelemicin which was shown to 
have the same UV spectrum. Quantification of 3’-hydroxyisoelemicin was done at a 
wavelength of 265 nm. 
Chromatographic analysis of 1’-hydroxyelemicin glucuronide and 
1’-oxoelemicin in both male rat and human liver incubations was performed 
as described previously by Punt et al. (2008) and Punt et al. (2009), respectively. 
Because a synthetic reference compound was not available for 1’-hydroxyelemicin 
glucuronide, quantification was based on comparison of the peak area of the 
formed metabolite to the calibration curve of 1’-hydroxyelemicin. This could be done 
because 1’-hydroxyelemicin glucuronide was found to have the same UV spectrum as 
1’-hydroxyelemicin. Quantification of GS-1’-oxoelemicin was based on a calibration 
curve for GS-1’-oxoelemicin made as previously described (Al-Subeihi et al., 2011; 
Martati et al., 2011; Punt et al., 2009). In short, 60 µM of the synthetic standard of 
1’-oxoelemicin, dissolved in acetonitrile, was incubated with different concentrations 
of GSH (i.e. 0 to 20 µM) in 0.2 M Tris-HCl (pH 7.4) for 6 h at 37˚C resulting in full conversion 
of the GSH to GS-1’-oxoelemicin. Quantification was done comparing the peak areas 
of the formed GS-1’-oxometabolite in the incubation mixtures with peak areas of the 
GS-1’-oxoelemicin calibration curve thus obtained at a wavelength of 283 nm. 
Quantification of 1’-sulfoxyelemicin was done using UPLC analysis as described 
for the quantification of 1’-sulfoxysafrole (Martati et al., 2011). The UV spectrum of 
the GSH adduct of 1’-sulfoxyelemicin was found to be similar to the UV spectrum of 
3’-hydroxyisoelemicin and quantification of the GSH adduct of 1’-sulfoxyelemicin was 
thus accomplished by comparing the peak area of this metabolite to the calibration 
curve of 3’-hydroxyisoelemicin.
Determination of kinetic constants 
Kinetic constants for the metabolic conversions of elemicin and 1’-hydroxyelemicin 
were derived by fitting the data to a standard Michaelis-Menten equation; v = Vmax x [S]/
K
m
 + [S], in which [S] represents the substrate concentration, V
max
 the maximum velocity 
and K
m
 the Michaelis-Menten constant for the formation of the different metabolites 
of elemicin or 1’-hydroxyelemicin. Data analysis was accomplished using GraphPad 
Prism, version 5.04 (GraphPad Software, San Diego, California, USA). 
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PBK models
Two PBK models were developed describing the relative importance of 
bioactivation and detoxifi cation of elemicin in, respectively, rat and human at 
diff erent oral dose levels. The models developed in this study were essentially 
based on the PBK models previously defi ned for the metabolism of estragole 
(Punt et al., 2008 and 2009), methyleugenol (Al-Subeihi et al., 2011 and 2012), and 
safrole (Martati et al., 2011 and 2012) in rat and human. A schematic overview of 
the developed PBK models for elemicin metabolism in rat and human is shown 
in Figure 3. The models consist of several compartments representing diff erent 
organs and tissues (i.e. liver, lungs, fat tissue, richly perfused tissues and slowly 
perfused tissues) that are mutually connected through the systemic circulation. 
First order kinetics was used to describe the uptake of elemicin from the 
gastrointestinal tract assuming a direct uptake by the liver with an absorption 
rate constant (ka) of 1.0 h
-1 which is based on the fast and complete absorption 
of the structurally related alkenylbenzene estragole from the gastrointestinal 
tract (Punt et al., 2008). 
Figure 3. Schematic overview of the physiologically based biokinetic (PBK) model for elemicin in rat and 
human. Metabolites marked with an asterisk (*) were only found in rat tissue fractions. 
For rat, the liver and lungs were able to convert elemicin to diff erent 
microsomal metabolites (see result section). 2’,3’-Dihydroxyelemicin, 
1’-hydroxyelemicin, 3’-hydroxyisoelemicin, an unidentifi ed minor metabolite 
referred to as M4, elemicin-2’,3’-oxide, 4-hydroxy-3,5-dimethoxyallylbenzene 
and 3-hydroxy-4,5-dimethoxyallylbenzene were formed in rat liver whereas 
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in rat lung minor amounts of 2’,3’-dihydroxyelemicin, elemicin-2’,3’-oxide, 
1’-hydroxyelemicin and 3-hydroxy-4,5-dimethoxyallylbenzene were formed (see result 
section). Since 2’,3’-dihydroxyelemicin is formed after hydrolysis of elemicin-2’,3’-oxide, 
data for both metabolites that result from epoxidation of elemicin were combined 
and referred to as elemicin-2’,3’-oxide. 4-Hydroxy-3,5-dimethoxyallylbenzene was 
only formed in minor quantities at the highest concentrations tested and therefore 
excluded from further analysis. Accordingly, mass balance equations for elemicin in 
rat liver and lung were as follows: 
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where uptake
E
 (μmol) is the amount of elemicin taken up from the gastrointestinal 
tract, AGI
E
 (μmol) is the amount of elemicin remaining in the gastrointestinal tract, ATi
E
 
(μmol) is the amount of elemicin in a tissue (Ti = L (liver) or Lu (lung)). CTi
E
 is the elemicin 
concentration in a tissue (μmol/L). CA
E
 and CV
E
 are the elemicin concentrations in the 
arterial and venous blood (both in μmol/L), QTi is the blood flow rate to a tissue (L/h), 
QC is the cardiac output (L/h), VTi is the volume of a tissue (L), PTi
E
 is the tissue/blood 
partition coefficient of elemicin, and V
max,Ti_M
 and K
m,Ti_M
 are the values representing 
the maximum rate of formation and Michaelis-Menten constant, respectively, for 
the formation of 1’-hydroxyelemicin (HE), 3’-hydroxyisoelemicin (3HE), elemicin-2’,3’-
oxide (EO), M4 (M4), and 3-hydroxy-4,5-dimethoxyallylbenzene (3HDMA). 
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In contrast to rat lung tissue fractions, elemicin was not converted in 
incubations with human lung tissue fractions and metabolism was only observed 
in incubations with human liver fractions (see results section). Moreover, M4 
was not formed in a significant quantity in incubations with human liver tissue 
and was therefore not included in the human PBK model. As a result, the mass 
balance equation for elemicin metabolism in human liver tissue is as follows: 
Liver: dAL
E
/dt = dUptake
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In both models, the conversion of elemicin to 3’-hydroxyisoelemicin, elemicin-
2’,3’-oxide, and 3-hydroxy-4,5-dimethoxyallylbenzene are described, but further 
reactions with these metabolites were not included in the model. For the rat 
model, also no further conversion of M4 was included. It was assumed that 
these metabolites and/or their possible conjugates were completely excreted 
into the urine. Since the liver is the major target organ for alkenylbenzene-
induced carcinogenicity in rats and mice, the present study focused primarily on 
metabolic conversion of 1’-hydroxyelemicin by glucuronidation, oxidation and 
sulfonation in the liver only. The mass balance equation for 1’-hydroxyelemicin 
in rat and human liver is as follows: 
Liver: dAL1HE/dt = Vmax, L_HE*CLE/PLE/(Km, L_HE + CLE/PLE)
V
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*CL
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where AL
HE
 is the amount of 1’-hydroxyelemicin in the liver (μmol), CL
HE
 is 
the 1’-hydroxyelemicin concentration in the liver (μmol/L), PL
HE
 is the liver/
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blood partition coefficient of 1’-hydroxyelemicin, and V
max,L_M
 and K
m,L_M
 are 
the maximum rate of formation and Michaelis-Menten constant, respectively, 
for the formation of the different 1’-hydroxyelemicin metabolites in the liver, 
including 1’-hydroxyelemicin glucuronide (HEG), 1’-oxoelemicin (HEO), and 
1’-sulfoxyelemicin (HES).
V
max
 and K
m 
values for the different metabolic pathways of elemicin 
and 1’-hydroxyelemicin were derived in vitro in the present study. V
max
 values 
that were derived in vitro expressed as nmol min-1 (mg liver microsomal or S9 
protein)-1 were scaled to values representing the V
max
 per µmol h-1 (g liver)-1 
using microsomal and S9 protein yields of 35 and 143 mg/g liver respectively 
as defined by Punt et al. (2008, 2009) based on Medinsky et al. (1994). For lung 
V
max
 values expressed as nmol min-1 (mg lung microsomal protein)-1 were scaled 
using a microsomal protein yield of 20 mg/g lung (Punt et al., 2009).
Tables 1 and 2 summarize the physiological parameters (i.e. tissue 
volumes, cardiac output and tissue blood flows) for rat and human, respectively, 
which were derived from literature (Brown et al., 1997). Partition coefficients 
were derived in sillico based on a method described by DeJongh et al. (1997) 
using the log K
ow
. Log K
ow
 values for elemicin (ClogP 2.51) and 1’-hydroxyelemicin 
(ClogP 0.958) were estimated using ChemBio3D 2010 (CambrigeSoft, USA). 
Mass balance equations were coded and numerically integrated in Berkely 
Madonna 8.3.18 (Macey and Oster, UC Berkeley, CA, USA) using the Rosenbrock’s 
algorithm for stiff systems. 
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Table 1. Parameters used in the physiologically based biokinetic model for elemicin in male rat.
Physiological parameters
(Brown et al., 1997)
Tissue: blood partition coefficients
(DeJongh et al., 1997)
Body weight (kg) 0.25
Percentage of body weight Elemicin
liver 3.4 liver 1.68
lung 0.5 lung 1.68
fat 7.0 fat 37.73
rapidly perfused 5.1 rapidly perfused 1.68
slowly perfused 60.2 slowly perfused 0.67
arterial blood 1.85
venous blood 5.55 1’-hydroxyelemicin
Cardiac output (L/h) 5.4 liver 0.94
Percentage of cardiac output
liver 25.0
fat 7.0
rapidly perfused 51.0
slowly perfused 17.0
 
 
Table 2. Parameters used in the physiologically based biokinetic model for elemicin in human.
Physiological parameters
(Brown et al., 1997)
Tissue: blood partition coefficients
(DeJongh et al., 1997)
Body weight (kg) 60
Percentage of body weight Elemicin
liver 2.6 liver 4.22
fat 21.4 fat 83.45
rapidly perfused 5.0 rapidly perfused 4.22
slowly perfused 51.7 slowly perfused 2.81
blood 7.9
1’-hydroxyelemicin
Cardiac output (L/h) 310 liver 0.93
Percentage of cardiac output
liver 22.7
fat 5.2
rapidly perfused 47.3
slowly perfused 24.8
Sensitivity analysis
To determine which parameters have the greatest influence on model 
predictions, a sensitivity analysis was performed as described previously (Al-
Subeihi et al., 2011 and 2012; Martati et al., 2011 and 2012; Punt et al., 2008 and 
2009). For this purpose normalized sensitivity coefficients (SC) were determined 
using the following equation: SC = (C’ – C)/(P’ – P) * (P/C), with C being the initial 
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value of model output, C’ the modified value of the model output resulting 
from an increase in parameter value, P is the initial parameter value and P’ 
represents the modified parameter value. An increase of 5% in parameter values 
was used to analyze the effect of a change in parameter on the formation of 
1’-hydroxyelemicin and 1’-sulfoxyelemicin (expressed as a percentage of the 
dose over 24 h). Each parameter was analyzed individually while the other 
parameters were kept at their initial value. 
Comparison of the PBK model based prediction of bioactivation of elemicin by 
rat and human to the PBK model predictions for bioactivation of the structurally 
related compounds estragole and methyleugenol 
The predicted model outcomes for the formation of 1’-hydroxyelemicin 
and 1’-sulfoxyelemicin were compared with the predicted dose-dependent 
formation of the 1’-hydroxy and 1’-sulfoxymetabolites of the structurally 
related alkenylbenzenes. For this purpose the previously defined PBK models 
for estragole (Punt et al., 2008 and 2009), and methyleugenol (Al-Subeihi et al., 
2011 and 2012) were run as described by Martati et al. (2011) and Martati et al. 
(2012) for rat and human models, respectively, with minor modifications. The 
models describing the metabolism of elemicin, estragole and methyleugenol 
were run for a period of 24 h. 
Important to note is that in spite of the fact that safrole shares structural 
characteristics with elemicin (i.e. alkylated and no free hydroxyl substituents 
and an allyl side chain with a C2=C3 double bond), it contains a methylenedioxy 
substituent of the allylbenzene nucleus while elemicin contains methoxy 
substituents similar to estragole and methyleugenol. Hence, the read across 
from data of estragole and methyleugenol, for which in vivo data are available, 
may provide a better representation of the carcinogenic potency of elemicin 
for which the toxicological database is far more limited and gives a better 
basis for the risk assessment of elemicin. For this reason, a comparison of the 
PBK model based prediction of bioactivation of elemicin by rat and human 
to the PBK model prediction for bioactivation of safrole was not made. 
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Results
Stereochemistry of 1’-hydroxyelemicin 
Chiral HPLC analysis of synthetic 1’-hydroxyelemicin and metabolically formed 
1’-hydroxyelemicin in male rat and human microsomal liver fractions showed 
two enantiomers eluting at 14.8 and 16.2 min. Chromatographic analysis 
revealed that synthetic 1’-hydroxyelemicin consisted of both enantiomers in a 
ratio of approximately 45:55 and for metabolically formed 1’-hydroxyelemicin 
ratios of 70:30 and 55:45 were found for rat and human microsomal liver fractions 
respectively. Since the 1’-hydroxyelemicin formed by rat and human microsomal 
liver fractions and the one used for the studies on its glucuronidation, oxidation, 
and sulfonation were shown to consist of a racemic mixture, the synthetic 
1’-hydroxyelemicin could be used as a substrate for determining kinetic 
constants of the respective metabolic conversions of 1’-hydroxyelemicin. 
Microsomal conversion of elemicin
To identify which organs are involved in the metabolism of elemicin in both 
male rat and human, incubations were performed using microsomal protein 
preparations from liver, kidney, lung and small intestine. Chromatographic 
analysis of these incubations revealed that for rat no metabolism occurred 
in incubations with small intestine microsomes or kidney microsomes, while 
elemicin metabolism was observed in incubations with rat liver and lung tissue 
fractions at varying rates. For human, microsomal conversion of elemicin to 
different metabolites was observed in incubations with mixed gender pooled 
human liver microsomes only, whereas human lung, kidney, and small intestine 
microsomes were incapable of converting elemicin (data not shown). 
Figure 4 shows an example of a chromatogram of an incubation of 
elemicin with male rat liver microsomes and NADPH as a cofactor. In 
incubations with rat liver microsomes 2’,3’-dihydroxyelemicin (RT = 7.5 min), 
1’-hydroxyelemicin (RT = 13.2 min), 3’-hydroxyisoelemicin (RT = 13.9 min), a 
minor unidentified metabolite referred to as M4 (RT = 14.8 min), elemicin-2’,3’-
oxide (RT = 19.6 min), 4-hydroxy-3,5-dimethoxyallylbenzene (RT = 35.5 min) 
and 3-hydroxy-4,5-dimethoxyallylbenzene (RT = 36.7 min) were formed. In 
incubations with human liver microsomes the same seven metabolites were found 
(for details see Supplementary Materials Figure S1A). In incubations with rat lung 
microsomes 2’,3’-dihydroxyelemicin, elemicin-2’,3’-oxide, 1’-hydroxyelemicin 
and 3-hydroxy-4,5-dimethoxyallylbenzene were identified (for details see 
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Supplementary Materials Figure S1B). Identification was done based on 
comparison of the UV spectra and retention times of the formed metabolites 
with those of the specific synthesized or commercially available reference 
compounds. However, tentative identification of 2’,3’-dihydroxyelemicin was 
done based on analogy of HPLC chromatograms of metabolic conversions of 
estragole, methyleugenol and safrole and the fact that elemicin-2’,3’-oxide, 
isolated following incubation with liver microsomes, NADPH and elemicin, was 
found to be hydrolyzed by epoxide hydrolase to 2’,3’-dihydroxyelemicin as was 
previously also demonstrated for the structurally related alkenylbenzenes (Al-
Subeihi et al., 2011; Guenthner and Luo, 2001; Luo and Guenthner, 1996; Luo 
et al., 1992; Martati et al., 2011; Punt et al., 2008). Furthermore, no reference 
compound for the metabolite eluting at 36.7 min was available. Therefore, 
tentative identification was based on the metabolism of elemicin proposed 
by Beyer et al. (2006) describing the formation of two O-demethylated 
products, that is, 4-hydroxy-3,5-dimethoxyallylbenzene and 3-hydroxy-4,5-
dimethoxyallylbenzene. Moreover, comparison to chromatographic details 
obtained for microsomal metabolites of methyleugenol was used for tentative 
identification (Al-Subeihi et al., 2011). Al-Subeihi et al. (2011) demonstrated the 
formation of two O-demethylated metabolites of methyleugenol comprising 
highly similar structures to those formed after metabolism of elemicin namely 
4-hydroxy-3-methoxyallylbenzene and 3-hydroxy-4-methoxyallylbenzene. The 
difference between these metabolites of methyleugenol and the ones formed 
upon elemicin metabolism is that the latter ones have an extra methoxy moiety 
attached to their allylbenzene nucleus. In the study of Al-Subeihi et al. (2011) it 
was shown that both compounds eluted closely before the parent compound 
methyleugenol with 4-hydroxy-3-methoxyallylbenzene eluting first followed 
by 3-hydroxy-4-methoxyallylbenzene. These results are in line with what was 
found for the chromatographic profile of elemicin microsomal incubations 
with two metabolites eluting closely before elemicin of which the metabolite 
eluting at 35.5 min was identified as 4-hydroxy-3,5-dimethoxyallylbenzene 
based on the UV spectrum and retention time of its commercially available 
reference compound. Based on these considerations, the metabolite eluting 
at 36.7 min was tentatively identified as 3-hydroxy-4,5-dimethoxyallylbenzene. 
The metabolite indicated as M4 was only formed to a small extent and hence 
its identification was not deemed necessary. However, it should be noted that 
in rat liver, the kinetic constants and the formation of M4 are in the same range 
27938 Berg, Suzanne vd.indd   125 24-04-14   12:57
Chapter 4
126
as the formation of 3-hydroxy-4,5-dimethoxyphenol (see Table 4, Figure 7). 
Data revealed that 3’-hydroxyisoelemicin was formed directly from elemicin 
rather than from isomerization of 1’-hydroxyelemicin since the formation of 
3’-hydroxyelemicin was not observed in incubations of 1’-hydroxyelemicin with 
liver microsomes and NADPH (data not shown). 
Figure 4. Chromatogram showing the diff erent metabolites of elemicin formed in incubations with 
male rat liver microsomes. Incubations were performed using a fi nal concentration of 100 µM elemicin 
and NADPH as a cofactor for 30 min at 37 ˚C. The peaks marked with an asterisk (*) were also present in 
blank incubations performed in the absence of the cofactor NADPH. 
Figure S2 in the Supplementary Materials of Chapter 4 presents  the 
rates of formation of diff erent microsomal metabolites in incubations with 
male rat liver microsomes (A), male rat lung microsomes (B), and human liver 
microsomes (C) with increasing elemicin concentrations ranging from 25 to 
2000 μM. Table 3 shows the kinetics constants (i.e. V
max
 and K
m
) derived from 
these plots and the catalytic effi  ciencies, calculated as V
max
/K
m
. Analysis of 
incubations that were performed with male rat liver microsomal preparations 
revealed that the metabolite arising from epoxidation of elemicin, namely 
elemicin-2’,3’-oxide, had the highest V
max
 value. Moreover, 1’-hydroxyelemicin 
and 3’-hydroxyisoelemicin were abundantly formed in incubations with male 
rat microsomal liver preparations with a high affi  nity. In incubations performed 
with male rat liver microsomes, 3-hydroxy-4,5-dimethoxyallylbenzene and M4 
were the least important metabolites formed upon conversion of elemicin. In 
general, the catalytic effi  ciency for the formation of 1’-hydroxyelemicin by male 
rat liver microsomes had the highest value, followed by the catalytic effi  ciently 
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for formation of 3’-hydroxyisoelemicin, elemicin-2’,3’-oxide, 3-hydroxy-4,5-
dimethoxyallylbenzene and M4. The catalytic efficiency for the formation of 
1’-hydroxyelemicin was found to be approximately 30-fold higher compared 
to that for formation of M4. In male rat lung microsomes, elemicin-2’,3’-oxide, 
1’-hydroxyelemicin and 3-hydroxy-4,5-dimethoxyallylbenzene were formed 
with relatively low in vitro catalytic efficiencies indicating that the formation 
of microsomal elemicin metabolites is more efficient when using rat liver 
microsomes compared to rat lung microsomes, demonstrating that extra 
hepatic metabolism of elemicin in rat contributes to only a minor extent to 
the overall microsomal metabolism as was previously also shown for safrole 
(Martati et al., 2011). 
In incubations with human liver fractions, 1’-hydroxyelemicin was found 
to be the most abundant metabolite formed followed by 3’-hydroxyisoelemicin 
and elemicin-2’,3’-oxide. Analysis of the catalytic efficiencies for the formation 
of different microsomal metabolites of elemicin, obtained with pooled 
human liver microsomes, showed that the formation of 3-hydroxy-4,5-
dimethoxyallylbenzene, 3’-hydroxyisoelemicin and 1’-hydroxyelemicin were 
the least important routes of elemicin metabolism, whereas the formation 
of elemicin-2’,3’-oxide represents the major pathway for the conversion of 
elemicin. M4 and 4-hydroxy-3,5-dimethoxyallylbenzene were only detected 
in incubations performed with the highest substrate concentrations tested in 
minor quantities and were therefore not included in further analysis. 
Glucuronidation of 1’-hydroxyelemicin 
Chromatographic analysis of incubations with male rat liver S9 and mixed 
gender pooled human liver S9, UDPGA as cofactor and 1’-hydroxyelemicin as 
substrate revealed a peak at 17.2 min (chromatogram not shown) tentatively 
identified as 1’-hydroxyelemicin glucuronide since treatment of the sample 
with β-glucuronidase resulted in full elimination of the respective peak 
accompanied by a concomitant increase of the peak of 1’-hydroxyelemicin. 
Moreover, chromatographic analysis of incubations performed in the absence 
of the cofactor UDPGA did not show a peak at a retention time of 17.2 min. 
Together these data indicate that the compound eluting at 17.2 min corresponds 
to 1’-hydroxyelemicin glucuronide. 
 The rate of the metabolic conversion of 1’-hydroxyelemicin to 
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1’-hydroxyelemicin glucuronide in incubations with both male rat and human 
liver fractions with increasing concentrations of 1’-hydroxyelemicin is presented 
in Figure 5A. Table 3 presents the kinetic constants derived from these plots. 
Oxidation of 1’-hydroxyelemicin 
Figure 5B shows the rate of oxidation of 1’-hydroxyelemicin in incubations 
with male rat liver microsomes and pooled human liver S9 with increasing 
concentrations of 1’-hydroxyelemicin. The kinetic constants derived from these 
plots are presented in Table 3. 
Table 3. Kinetic constants for metabolism of elemicin and 1’-hydroxyelemicin in incubations with 
Sprague Dawley male rat liver and lung microsomes and mixed gender pooled human liver microsomes. 
 Metabolite Organ Rat   Human   
V
max
a,b K
m
a,c in vitro
catalytic 
efficiencyd
V
max
a,b K
m
a,c in vitro
catalytic 
efficiencyd
Conversion of elemicin
1’-hydroxyelemicin Liver 0.5 19 26.3 1.1 415 2.7
Lung 0.06 189 0.3 ND ND -
3’-hydroxyisoelemicin Liver 0.4 16 25.0 0.6 83 7.27
M4 Liver 0.2 213 0.9 ND ND -
elemicin-2’,3’-oxide Liver 1.8 139 12.9 0.5 27 18.5
Lung 0.02 37 0.5 ND ND -
3-hydroxy-4,5- 
dimethoxyallylbenzene
Liver 0.1 34 2.9 0.1 54 1.9
 Lung 0.02 194 0.1 ND ND -
Conversion of 1’-hydroxyelemicin
1'-hydroxyelemicin 
glucuronide
Liver 2.4e 1543e 1.6 0.2e 337e 0.6
1'-oxoelemicin Liver 26.3 15232 1.7 2.1e 6895e 0.3
1'-sulfoxyelemicin Liver 7*10-4 e 120e 0.006 1*10-4 e 39e 0.003
 
a Mean values of two independent measurements 
b nmol min-1 (mg microsomal or S9 protein)-1
c µM 
d µL min-1 (mg microsomal or S9 protein)-1, (V
max
/K
m
 x 1000 µL/mL)
e experiments performed with S9 tissue fractions
ND not detected
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Figure 5. Concentration dependent rate of A) glucuronidation of 1’-hydroxyelemicin in pooled male rat 
liver S9 (•) or pooled human mixed gender liver S9 ( ), B) oxidation of 1’-hydroxyelemicin in pooled male 
rat liver microsomes (•) or pooled human mixed gender liver S9 ( ) and C) sulfonation of 
1’-hydroxyelemicin in pooled male rat liver S9 (•) or pooled human mixed gender liver S9 ( ). Data points 
represent mean values of two individual experiments. 
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Sulfonation of 1’-hydroxyelemicin
In the present study, GSH was used to trap the reactive 1’-sulfoxyelemicin 
formed upon sulfonation of the proximate carcinogenic metabolite of elemicin. 
The scavenging may be either chemically or catalyzed by the glutathione 
S-transferases present in the S9 incubations in which the sulfonation of 
1’-hydroxyelemicin was measured. However, the level of 1’-sulfoxyelemicin 
conjugates formed in incubations using cysteine or N-acetylcysteine, 
representing enzymatic-independent trapping methods, was comparable to 
the 1’-sulfoxyelemicin adduct formation detected using GSH as a trapping agent, 
indicating that the mechanism underlying the scavenging of 1’-sulfoxyelemicin 
by GSH is mainly chemical (data not shown). In addition, it was found that the 
amount of the GSH conjugate of 1’-sulfoxyelemicin detected was not increased 
when the concentration of GSH was doubled from 10 to 20 mM (data not shown). 
Together these data indicate that under the conditions applied, the scavenging 
of 1’-sulfoxyelemicin by GSH proceeds by an efficient chemical reaction and is 
not enzyme mediated. 
Chromatographic analysis of incubations with male rat liver S9 and 
mixed gender pooled human liver S9, 1’-hydroxyelemicin, PAPS and GSH 
revealed a peak at 1.1 min (chromatogram not shown), which was tentatively 
identified as the GSH-adduct of the carbocation of 1’-sulfoxyelemicin. 
Tentative identification was achieved based on the chromatographic analysis 
of incubations performed in the absence of GSH and the presence of PAPS and 
liver S9 proteins since in these incubations no peak was found at 1.1 min. Figure 
5C presents the rate of formation of 1’-sulfoxyelemicin in incubations with male 
rat liver S9 and mixed gender pooled human liver S9. The kinetic constants for 
the conversion of 1’-hydroxyelemicin to 1’-sulfoxyelemicin in rat and human 
liver are presented in Table 3. 
Comparison of the kinetic constants for conversion of elemicin and 
1’-hydroxyelemicin by male rat and mixed gender pooled human tissue fractions 
To allow a comparison between the kinetic constants for metabolism of 
elemicin and 1’-hydroxyelemicin by male rat and mixed gender pooled human 
tissue fractions, Vmax values that were derived in vitro expressed as nmol min
-1 
(mg microsomal or S9 protein)-1 were scaled to values representing the V
max
 
per µmol h-1 (g tissue)-1 using microsomal and S9 protein yields as described 
in literature (Medinsky et al., 1994) and previously used by Punt et al. (2008, 
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2009), Al-Subeihi et al. (2011, 2012), and Martati et al. (2011, 2012). Making use 
of the in vivo V
max
 values derived accordingly, a scaled catalytic efficiency (scaled 
V
max
 in vivo/K
m
) for the formation of elemicin metabolites could be calculated 
(Table 4). These values show that the catalytic efficiency for formation of the 
proximate carcinogenic metabolite of elemicin, 1’-hydroxyelemicin, was found 
to be 10-fold higher in male rat liver compared to human liver. This difference 
in catalytic efficiency for the formation of 1’-hydroxyelemicin is predominantly 
caused by the high affinity (expressed as K
m
) for its formation from elemicin in 
male rat liver since the K
m
 value in rat liver incubations was 22-fold lower than 
that in human liver incubations. 
 The detoxification of 1’-hydroxyelemicin by formation of 
1’-hydroxyelemicin glucuronide was found to be the main metabolic reaction 
with 1’-hydroxyelemicin in rat and human liver. However, this pathway was 
more efficient in rat than in human liver fractions. Although glucuronidation 
of 1’-hydroxyelemicin occurs in male rat with a relative low affinity (i.e. K
m
 1.5 
mM whereas in human this was 337 µM), analysis of the data revealed a high 
V
max
 value resulting in a catalytic efficiency that was 2.6-fold higher in male rats 
compared to human. 
Oxidation of 1’-hydroxyelemicin was found to be 1.4 times more efficient 
in male rat liver compared to human liver resulting from a 3.1-fold higher V
max
 
and a 2.2-fold higher K
m
. 
Sulfonation was found to be the least efficient metabolic pathway for 
1’-hydroxyelemicin in both rats and human. For rat, the in vivo scaled catalytic 
efficiency was 0.05 mL h-1 (g S9 protein)-1 and for human this was 0.03 mL h-1 (g 
S9 protein)-1, indicating that sulfonation of 1’-hydroxyelemicin is more efficient 
in male rat liver than human liver. 
Altogether, it can be concluded that glucuronidation of 
1’-hydroxyelemicin, representing a detoxification pathway, is the most 
important pathway in rat and in human. Moreover, based on the kinetic data 
obtained, bioactivation of 1’-hydroxyelemicin following sulfonation was found 
to represent only a minor pathway in both rat and human. 
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Evaluation of PBK model performance
The performance of the newly developed PBK models for elemicin could not 
be evaluated against in vivo data because quantitative data on the excretion of 
the different metabolites formed after elemicin metabolism in rat or humans 
exposed to elemicin are not available. However, Beyer et al. (2006) identified 
different metabolites of elemicin excreted in rat urine in a qualitative manner. 
It was demonstrated that the formation of 2’,3’-dihydroxyelemicin, formed after 
hydrolysis of elemicin-2’,3’-oxide, was the most abundant metabolite found in 
rat urine samples collected over a 24 h period after administration of a single oral 
dose of 100 mg/kg bw elemicin (Beyer et al., 2006). In line with these results, the 
developed PBK model predicted elemicin-2’,3’-oxide to be the major metabolite 
formed at a dose of 100 mg/kg bw elemicin in rat after 24 h. 
Important to note is, however, that the PBK models for elemicin were 
based on the PBK models for estragole, methyleugenol and safrole, for which 
more data allowing evaluation of the models were available. Punt et al. (2008), 
Al-Subeihi et al. (2011) and Martati et al. (2011) described the performance of 
the rat PBK models developed for, respectively, estragole, methyleugenol, and 
safrole. Evaluation was done by comparing the predicted levels of a variety of 
metabolites in plasma or excreted in the urine of rats. Data revealed that the 
predicted PBK model values and the levels of these metabolites derived from 
in vivo studies adequately matched (Al-Subeihi et al., 2011; Martati et al., 2011; 
Punt et al., 2008). Furthermore, also for the developed human PBK models for 
estragole (Punt et al., 2009), methyleugenol (Al-Subeihi et al., 2012), and safrole 
(Martati et al., 2012) a comparison could be made between model predictions 
and the reported in vivo data for blood concentrations or the urinary excretion of 
some of the metabolites, thereby further supporting the validity of the models. 
Considering these data, it was concluded that the developed PBK models 
for elemicin would also adequately describe the in vivo levels of metabolites 
formed in rat and human after conversion of elemicin and 1’-hydroxyelemicin 
at different oral dose levels of elemicin. 
PBK model predictions 
Following an exposure to 0.05 mg/kg bw elemicin, both elemicin and its 
proximate carcinogenic metabolite 1’-hydroxyelemicin were predicted to be 
almost completely metabolized within a 10 h period in rat and human (data 
not shown). At a higher oral dose level of 300 mg/kg bw elemicin, both elemicin 
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and 1’-hydroxyelemicin are predicted to be metabolized within 24 h (data not 
shown). Dose levels of 0.05 and 300 mg/kg bw were chosen to allow comparison 
with the PBK model outcomes previously reported for estragole (Punt et al., 
2008 and 2009), and methyleugenol (Al-Subeihi et al., 2011 and 2012). Figure 6A 
shows the PBK model based predictions for the dose-dependent formation of 
the different microsomal metabolites of elemicin in rat 24 h after exposure. The 
percentage of the dose converted to 1’-hydroxyelemicin is predicted to decrease 
in a dose-dependent manner. Concurrent with the decreased percentage 
of the dose that undergoes 1’-hydroxylation of the alkene side chain, a 2.4-
fold dose-dependent increase in the percentage of the dose that underwent 
epoxidation was observed. A less than 2-fold decrease in the formation of 
3’-hydroxyisoelemicin was observed. The relative formation of M4 changed 
from 1.4% to 4.1% when the dose increased. The formation of 3-hydroxy-
4,5-dimethoxyphenol did not change with increasing dose-levels and was 
equal to 4.3% of the administered dose. Figure 6B shows the dose-dependent 
decrease in the formation of the metabolites of 1’-hydroxyelemicin. This reveals 
a relative decrease in the percentage of the dose ultimately converted into 
1’-hydroxyelemicin glucuronide, 1’-sulfoxyelemicin and 1’-oxoelemicin which 
can be explained by the decrease of the formation of 1’-hydroxyelemicin with 
increasing dose levels.
 Figure 7A reveals that in human the percentage of the dose converted to 
1’-hydroxyelemicin equaled 7.9% at a dose of 0.05 mg/kg bw/day and increased 
to 15.6% at a dose of 300 mg/kg bw/day. Concomitant with the increase in 
the formation of 1’-hydroxyelemicin, a relative decrease in the formation 
of 3’-hydroxyisoelemicin and elemicin-2’,3’-oxide is predicted. 3-Hydroxy-
4,5-dimethoxyphenol was predicted to change only to a small extent with 
increasing dose. Figure 7B shows the dose-dependent increase in the formation 
of 1’-hydroxyelemicin glucuronide and 1’-oxoelemicin and the dose-dependent 
decrease of 1’-sulfoxyelemicin in human liver 24 h after elemicin exposure. 
 Comparison of the relative extent of bioactivation of elemicin by 
rat and human liver revealed that species differences in the formation of 
1’-hydroxyelemicin and 1’-sulfoxyelemicin (expressed as nmol/g liver) are 
limited (<3.8-fold) from a relatively low dose of 10-6 mg/kg bw up to dose levels 
of 100 mg/kg bw (Figure 8). 
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Figure 6. PBK predicted dose-dependent changes in overall formation of A) microsomal metabolites of 
elemicin in male rat lung and liver and B) metabolites of 1’-hydroxyelemicin in male rat liver. The lines 
correspond to A) 1’-hydroxyelemicin (-·-), 3’-hydroxyisoelemicin (- - -), elemicin-2’,3’-oxide (—), M4 (— 
—) and 3-hydroxy-4,5-dimethoxyallylbenzene (···) and B) 1’-hydroxyelemicin glucuronide (—), 
1’-oxoelemicin (- - -) and 1’-sulfoxyelemicin (insert), 24 h after elemicin exposure. 
Figure 7. PBK predicted dose-dependent changes in overall formation of A) microsomal metabolites of 
elemicin and B) metabolites of 1’-hydroxyelemicin in human liver. The lines correspond to A) 
1’-hydroxyelemicin (-·-), 3’-hydroxyisoelemicin (- - -), elemicin-2’,3’-oxide (—) and 3-hydroxy-4,5-
dimethoxyallylbenzene (···) and B) 1’-hydroxyelemicin glucuronide (—), 1’-oxoelemicin (- - -) and 
1’-sulfoxyelemicin (insert), 24 h after elemicin exposure. 
 
Figure 8. PBK predicted dose-dependent formation of A) 1’-hydroxyelemicin and B) 1’-sulfoxyelemicin 
in rat (—) and human (- - -) liver 24 h after elemicin exposure. 
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Sensitivity analysis
A sensitivity analysis was performed to define model parameters that are capable 
of influencing the formation of 1’-hydroxyelemicin and 1’-sulfoxyelemicin in 
rat and human liver. For this purpose, normalized sensitivity coefficients were 
calculated for all parameters at a dose of 0.05 mg/kg bw elemicin. Figure 9 
presents the parameters affecting the formation of 1’-hydroxyelemicin (A) and 
1’-sulfoxyelemicin (B) that have a normalized sensitivity coefficient higher than 
|0.1|. 
 In rat and human liver, formation of 1’-hydroxyelemicin is primarily 
influenced by the kinetic constants for its formation from elemicin (V
max
,
L_HE
, K
m,L_HE
) 
(Figure 9A). Figure 9B reveals that the formation of the ultimate carcinogenic 
metabolite 1’-sulfoxyelemicin is mainly influenced by the kinetic constants for 
its formation from 1’-hydroxyelemicin (V
max,L_HES
, K
m,L_HES
). The kinetic constants 
for the formation of 1’-hydroxyelemicin glucuronide (V
max,L_HEG
, K
m,L_HEG
) were also 
found to highly influence the formation of 1’-sulfoxyelemicin in rat and human 
liver. The kinetic constants for formation of 1’-oxoelemicin were predicted to 
affect the formation of 1’-sulfoxyelemicin in rat and human liver to a smaller 
extent. These results suggest that glucuronidation of 1’-hydroxyelemicin 
can be considered as the most important competitive metabolic pathway to 
sulfonation in rat and human due to its high catalytic efficiency. 
Comparison of the PBK model based prediction of bioactivation of elemicin by 
rat and human to the PBK model predictions for bioactivation of the structurally 
related compounds estragole and methyleugenol 
By defining mode of action based PBK models for elemicin metabolism in rat and 
human, a read across to data from estragole and methyleugenol was facilitated. 
On the basis of the PBK models for these structurally related alkenylbenzenes 
(Al-Subeihi et al., 2011 and 2012; Punt et al., 2008 and 2009), comparisons 
were made for the dose-dependent formation of the 1’-hydroxymetabolites of 
these compounds and the formation of their 1’-sulfoxymetabolites. Figure 10 
shows the dose-dependent formation of these metabolites in rat as predicted 
by the respective PBK models. The PBK model based predicted formation of 
the proximate carcinogenic 1’-hydroxymetabolites was found to be very 
similar for all three alkenylbenzenes. Up to dose levels of 100 mg/kg bw, the 
predicted formation of 1’-hydroxyelemicin increased linearly with the dose 
and was found to be approximately 2-fold higher compared to the formation 
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of 1’-hydroxyestragole and 1’-hydroxymethyleugenol (Figure 10A). Figure 
10B shows the predicted model outcomes for the formation of the ultimate 
carcinogenic metabolites of estragole, methyleugenol and elemicin. In rat liver, 
the formation of the 1’-sulfoxymetabolites is expected to be highest for elemicin 
followed by methyleugenol and estragole in decreasing order. 
Figure 9. Sensitivity analysis of the predicted formation of A) 1’-hydroxyelemicin and B) 1’-sulfoxyelemicin 
in rat (black bars) and human (white bars). S9PL = S9 protein yield of the liver, MPL = microsomal protein 
yield of the liver, Vmax and Km are respectively the maximum rate of formation and the Michaelis-
Menten constant for formation of different metabolites in the liver (L) including 1’-hydroxyelemicin (HE), 
elemicin-2’,3’-oxide (EO), 3’-hydroxyisoelemicin (3HE), 1’-hydroxyelemicin glucuronide (HEG), 
1’-oxoelemicin (HEO), and 1’-sulfoxyelemicin (HES).   
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However, the differences between the formation of these metabolites varies 
within one order of magnitude for all alkenylbenzenes as it was seen that 
the formation of 1’-sulfoxyelemicin is 2-fold higher than that of 
1’-sulfoxymethyleugenol whereas it is approximately 8-fold higher as compared 
to the predicted formation of 1’-sulfoxyestragole. For all alkenylbenzenes, the 
formation of their 1’-sulfoxymetabolite increases linearly up to a dose of 100 
mg/kg bw.   
 Figure 11 shows the predicted dose-dependent formation of the 
1’-hydroxymetabolites and 1’-sulfoxymetabolites of elemicin, estragole, and 
methyleugenol in human liver. The predicted formation of 1’-hydroxyelemicin 
is similar to the formation of 1’-hydroxymethyleugenol, 11-fold lower than the 
formation of 1’-hydroxyestragole. Thus, compound differences in the formation 
of 1’-hydroxymetabolites are limited. Moreover, data reveal that in human at 
dose levels around the BMDL10 (i.e. the lower confidence limit of the BenchMark 
Dose resulting in a 10% extra cancer incidence) down to realistic exposure 
levels, the formation of the DNA reactive 1’-sulfoxymetabolite is relatively low 
after elemicin exposure, being 11- and 2-fold lower as compared to the 
formation of the 1’-sulfoxymetabolites of estragole and methyleugenol, 
respectively. The formation of 1’-sulfoxymetabolites was found to increase in a 
linear manner up to dose levels of 10 mg/kg bw. 
Figure 10. PBK predicted dose-dependent formation of A) 1’-hydroxymetabolites and B) 
1’-sulfoxymetabolites of estragole (—), methyleugenol (—) and elemicin (- - -) in male rat liver after 24 h. 
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Figure 11. PBK predicted dose-dependent formation of A) 1’-hydroxymetabolites and B) 
1’-sulfoxymetabolites of estragole (—), methyleugenol (—) and elemicin (- - -) in human liver after 24 h.
Implications for risk assessment 
The Margin of Exposure (MOE) concept was applied to assess the possible risks for 
human health resulting from the daily exposure to elemicin (EFSA, 2005; JECFA, 
2005; Barlow et al., 2006; O’Brien et al., 2006). The MOE is a dimensionless ratio 
based on a reference point representing a dose causing a low but measurable 
cancer incidence in experimental animals (e.g. a BMDL
10
) which is divided by 
the estimated daily intake in humans (EFSA, 2005). When the MOE is lower 
than 10,000, the compound of interest is considered to be of priority for risk 
management actions and a concern for human health (EFSA, 2005). This value 
of 10,000 is based on several factors that may cause uncertainty in the MOE 
including species differences and human variability in kinetics and dynamics 
among others (EFSA, 2005). 
 To date, tumor data for elemicin, from which a BMDL
10
 can be derived, 
are absent in the available literature, hampering the application of the MOE 
approach in the risk assessment of elemicin. Nevertheless, PBK model predictions 
indicate that at dose levels in the range of the BMDL
10
 values, the formation 
of 1’-sulfoxymetabolites of elemicin in human liver is lower as compared to 
that of the structurally related methoxy allylbenzene derivatives estragole and 
methyleugenol, facilitating read across from carcinogenicity data on the two 
alkenylbenzenes to elemicin assuming, as a worst case approximation, that 
formation of the ultimate carcinogenic metabolite would be linearly related to 
the tumor incidence. On the basis of these considerations, the specific BMDL
10
 
values of estragole and methyleugenol (Table 5) were used to estimate possible 
BMDL
10
 values for elemicin using the results of the present study showing the 
formation of the 1’-sulfoxymetabolite of elemicin to be 11- and 2-fold lower 
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in human liver and, therefore, multiplying the BMDL
10
 values of estragole and 
methyleugenol by these factors. In a next step, MOE values for elemicin were 
calculated based on the estimated daily intake (Table 6). For comparison Table 
5 presents the MOE values for the other two related methoxy allylbenzenes. The 
intake estimates used to calculate the MOE values were based on exposure from 
the use of herbs and spices and products made thereof (SCF 2001a, 2001b). MOE 
values for estragole and methyleugenol (Table 5) were found to be generally 
lower than the MOE default of 10,000 and even lower than 1,000 indicating 
a priority for risk management actions. Table 6 illustrates the results from the 
read across from BMDL10 values of estragole and methyleugenol to elemicin. 
The results obtained indicate that the daily exposure to elemicin resulting from 
the use of spices, food, and essential oils is generally of lower priority for risk 
management than the exposure to the two related alkenylbenzenes resulting 
from these sources. The intake of elemicin resulting from the use of essential oils 
is only limited, and specific data are lacking. Assuming that the total intake from 
nutmeg and mace as spices exceeds the intake from essential oils by a factor 
10 at least (WHO, 2009), MOE values equal to 40,000 – 100,000 were found for 
intake from elemicin from essential oils (Table 6). In addition, MOE values were 
calculated based on the intake estimates of elemicin resulting from the use of 
nutmeg-containing PFS based on chemical analysis of these products as well as 
their proposed uses as described previously (van den Berg et al., 2011). On the 
basis of the daily intake estimates thus derived, MOE values of 80 – 40,000 were 
found (Table 6). 
Table 5. BMDL
10
 values for estragole and methyleugenol derived from long-term carcinogenicity studies 
(Miller et al., 1983; NTP, 2000) as calculated previously (van den Berg et al., 2011), corresponding daily 
exposures from all food sources (SCF 2001a and 2001b) and MOE values.
Compound Species and 
sex
Tumors BMDL
10
(mg/kg bw/day)
Estimated daily 
intake
(mg/kg bw/day)
MOEa
Estragole Female mice hepatocellular 
carcinomas
3.3 - 6.5
(Miller et al., 1983; van 
den Berg et al., 2011)
0.07
(SCF, 2001b)
50-90
Methyl-
eugenol
Male rats hepatocellular 
carcinomas
15.3 - 34.0
(NTP, 2000; van den Berg 
et al., 2011)
0.19
(SCF, 2001a)
80-200
Female rats hepatocellular 
carcinomas
48.8 - 73.6
(NTP, 2000; van den Berg 
et al., 2011)
0.19
(SCF, 2001a)
300-400
a MOE values are rounded to a single significant value 
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Table 6. Read across of BMDL
10
 values for estragole and methyleugenol to estimated BMDL
10
 values for 
elemicin based on the lower relative extent of formation of 1’-sulfoxymetabolites compared to its 
structurally related analogues as demonstrated in the present study, corresponding daily exposures 
from spices, foods and essential oils (SFE) (WHO, 2009), essential oils only (EO) or plant food supplements 
(PFS) and resulting MOE values a. 
Compound
for read 
across
BMDL
10
(mg/kg  
bw/day)
Fold dif-
ference
Corrected 
BMDL
10
(mg/kg 
bw/day)
Estimated daily 
intakeb
(mg/kg bw/day)
MOEd
Estragole 3.3 - 6.5
(Miller et al., 
1983; van den 
Berg et al., 
2011)
11 36.5 – 71.5 SFE: 0.017
(WHO, 2009)
SFE: 2,000 – 4,000
EO: 0.00071
(WHO, 2009)
EO: 50,000 – 100,000
PFS: 0.002 – 0.40c PFS: 90 – 40,000
Methyl-
eugenol
15.3 - 34.0
(NTP, 2000; van 
den Berg et al., 
2011)
2 30.6-68.0 SFE: 0.017
(WHO, 2009)
SFE: 2,000 – 4,000
EO: 0.00071
(WHO, 2009)
EO: 40,000 – 100,000
PFS: 0.002 – 0.40c PFS: 80 – 30,000
 
a To make a worst-case estimate only the lowest BMDL
10
 values for methyleugenol were used and data 
from female rats were discarded from further analysis.
b Estimated daily intake from spices, food and essential oils (SFE) and from nutmeg-containing plant 
food supplements (PFS). Intake data from essential oils only (EO) are based on the mean per capita daily 
intake of nutmeg, mace and their essential oils within the EU assuming that the intake from spice sources 
exceeds the intakes from essential oils by a factor 10 at least (WHO, 2009). 
c Intake estimates were made using the levels of elemicin in commercial available PFS based on chemical 
analysis and the use of PFS at the dose recommended by the respective manufacturer as described 
previously (van den Berg et al., 2011). 
d MOE values are rounded to a single significant value. 
Discussion
In the presented chapter, the recently developed mode of action based PBK models 
for detoxification and bioactivation of the structurally related alkenylbenzenes 
estragole (Punt et al., 2008, 2009), methyleugenol (Al-Subeihi et al., 2011, 2012), and 
safrole (Martati et al., 2011, 2012) in male rat and human were extended to elemicin. 
The newly developed PBK models combine biochemical and physicochemical 
information of elemicin and physiology of the organism of interest (i.e. rat and 
human), enabling the quantification of detoxification and bioactivation in rat and 
human at realistic low exposure levels. The development of these models facilitates 
a read across from data on estragole and methyleugenol, for which in vivo toxicity 
studies are available, to elemicin a compound for which toxicity data are limited. 
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Although the PBK models for elemicin defined in the present chapter 
were able to predict the overall formation of the reactive 1’-sulfoxyelemicin 
metabolite in the liver of rat and human and compare this overall formation 
to the overall formation of the 1’-sulfoxymetabolites of the corresponding 
alkenylbenzenes facilitating a relative comparison, the models did not include 
further metabolic reactions of the 1’-sulfoxymetabolite such as conjugation 
with GSH, RNA, DNA, and other cellular macromolecules. Such subsequent 
steps (as well as DNA repair and reversibility of DNA-adduct formation) should 
be included in the model when the ultimate aim would be to predict DNA-
adduct formation (see, for an example, Paini et al., 2010) but this was beyond 
the scope of the present study. Comparison of the rat and human PBK model 
predictions indicated a species-dependent difference in the bioactivation of 
elemicin. However, the influence of species-differences on the overall metabolic 
activation of elemicin was limited and comparable to the species-differences in 
metabolic activation of estragole (Punt et al., 2008; 2009) and methyleugenol 
(Al-Subeihi et al., 2011, 2012) to the respective 1’-sulfoxymetabolites and also 
in line with the default factor of 4 which is generally used to describe kinetic 
differences between species (IPCS, 2010). 
 In addition to species differences in the relative extent of bioactivation 
and detoxification, the newly developed PBK models for elemicin were used to 
compare the levels of metabolic activation of elemicin, to those for estragole 
(Punt et al., 2008; 2009) and methyleugenol (Al-Subeihi et al., 2011, 2012) in 
male rat and human liver. Results reveal that the formation of the proximate 
and ultimate carcinogenic metabolites of the three alkenylbenzenes of interest 
in rat is predicted to be comparable within an order of magnitude. In line with 
these findings, previous studies demonstrated the ability of elemicin, estragole, 
and methyleugenol to all induce unscheduled DNA synthesis (UDS) in rat 
hepatocytes (Chan and Caldwell, 1992; Hasheminejad and Caldwell, 1994; Howes 
et al., 1990). In fact, the UDS responses of all alkenylbenzenes of interest were 
found to be in close agreement, revealing a dose-dependent increase in UDS 
from 2.0- up to 2.7-fold as compared to the control at comparable experimental 
conditions (Chan and Caldwell, 1992; Hasheminejad and Caldwell, 1994; Howes 
et al., 1990). 
In humans the formation of especially the 1’-sulfoxymetabolites of 
the three alkenylbenzenes are predicted to be lower for elemicin as compared 
to what was predicted for the 1’-sulfoxy formation for the structurally related 
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analogues. This difference can be ascribed to the fact that sulfonation of the 
1’-hydroxymetabolites of estragole and methyleugenol is up to 3 times more 
efficient by human liver than that of 1’-hydroxyelemicin. Moreover, metabolic 
conversion of 1’-hydroxyelemicin toward 1’-hydroxyelemicin glucuronide was 
found to be 5-10 times more efficient as compared to the glucuronidation of 
1’-hydroxymetabolites of estragole (Punt et al., 2009) and methyleugenol (Al-
Subeihi et al., 2012) affecting the amount of 1’-hydroxyelemicin in human liver 
available for sulfonation. Interestingly, glucuronidation of 1’-hydroxymetabolites 
is more important than the oxidation pathway for elemicin metabolism but not 
for the structurally related analogues for which the oxidation of the proximate 
carcinogenic metabolites represents the major detoxification pathway. It is 
important to note that the oxidation of 1’-hydroxyelemicin to 1’-oxoelemicin 
might be reversible. However, given the rapid scavenging of 1’-oxoelemicin by 
GSH as observed in the present study, the ultimate effect may still represent 
an important detoxification pathway also considering that 1’-oxometabolites 
of alkenylbenzenes have not been observed to be carcinogenic in vivo in mice 
(Wiseman et al., 1987; Wislocki et al., 1977). Thus, in the model, it was implicitly 
assumed that scavenging of the 1’-oxometabolite by GSH would dominate over 
reduction back to 1’-hydroxyelemicin, allowing as a first approximation to not 
include these steps explicitly in the model.
Making use of the human PBK model outcomes obtained for the 
formation of reactive 1’-sulfoxymetabolites of elemicin, estragole, and 
methyleugenol, a comparison can be made to the relative potency of these 
compounds to bind to DNA. However, the ability of elemicin to form DNA 
adducts in cultured human cells has not been studied yet. Punt et al. (2007) 
concluded that sulfonation of 1’-hydroxyestragole is equally efficient in male 
mice S9 as in human S9 indicating that data derived from mice studies may 
accurately represent the level of bioactivation by sulfotransferases in human. 
Thus, in vivo data of DNA adducts formed in mice liver following elemicin, 
estragole, or methyleugenol exposure can provide an insight in the relative 
extent of metabolic activation of the three alkenylbenzenes in human. Previous 
studies demonstrated that the covalent binding of elemicin to female CD-1 
mouse liver DNA and B6C3F1 male mice liver DNA was up to 27-fold lower as 
compared to that of structurally related compounds including estragole and 
methyleugenol (Phillips et al., 1984; Randerath et al., 1984). Moreover, tumor 
induction in male B6C3F
1
 mice given i.p. injections of 1’-hydroxyelemicin prior 
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to weaning was found to be 30-fold lower, on a molar basis, as compared to the 
results found for its structurally related analogue 1’-hydroxyestragole (Wiseman 
et al., 1987). Consistent with these results, the PBK model outcomes revealed 
that in human liver the lowest levels of the ultimate carcinogenic metabolite 
would be formed after elemicin exposure as compared to its structurally 
related analogues. In line with these results, it was seen that despite the fact 
that estragole and methyleugenol were capable of inducing hepatic tumors 
in male mice, no detectable hepatocarcinogenic activities were observed in 
mice after administration of elemicin at comparable experimental conditions 
(Miller et al., 1983). These differences in DNA binding activities and subsequent 
tumor formation between the different alkenylbenzenes might be explained 
by the fact that increasing the number of methoxy substituents will decrease 
the electrophilicity of their 1’-sulfoxymetabolites and/or the corresponding 
carbocations, which is in line with the fact that it was previously shown that 
mono- and di-substituted alkenylbenzenes were bound more rapidly to mouse 
liver DNA and showed higher levels of hepatocarcinogenic activity compared 
to structurally related analogues exerting multiple methylenedioxy and/or 
methoxy groups (Miller et al., 1983; Randerath et al., 1984). 
On the basis of the results now available for the different 
alkenylbenzenes, the present study also presents a risk assessment performed 
for elemicin using the MOE approach. To be able to apply the MOE in the risk 
assessment of elemicin, for which data on tumor formation are currently not 
available, BMDL10 values of related alkenylbenzenes were corrected, reflecting 
the lower relative extent of elemicin bioactivation in human liver predicted by the 
newly developed PBK models. Extrapolation of the BMDL
10
 values for estragole 
and methyleugenol to a possible BMDL
10
 for elemicin, based on the differences in 
formation of the related ultimate carcinogenic 1’-sulfoxymetabolites, results in 
a BMDL
10
 value for elemicin that is at least 30.6 mg/kg bw/day (Table 6) and thus 
significantly higher than the BMDL
10
 values for the other two alkenylbenzenes 
(Table 5). This is in line with the fact that Miller et al. (1983) and Wiseman et al. 
(1987) showed that elemicin and 1’-hydroxyelemicin had no hepatocarcinogenic 
activities in mice after i.p. injections of up to approximately 60 mg/kg bw while 
a significant increased incidence in the formation of treatment-related liver 
tumors was observed upon administration of 1’-hydroxyelemicin at the highest 
dose tested (i.e. 4 injections with a total dose of 106.5 mg/kg bw). The daily 
intake of estragole and methyleugenol resulted in relatively lower MOE values 
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as compared to the daily intake of elemicin, indicating the intake of these related 
methoxy allylbenzenes to be of higher priority for risk management actions. Data 
also indicated that the use of elemicin-containing PFS is generally considered to 
be of lower risk for human health as compared to the use of some PFS containing 
estragole or methyleugenol that were previously shown to present a possible 
priority for risk management (van den Berg et al., 2011). 
Finally, it is of importance to note that the developed PBK models, as 
other models, are based on assumptions needed to considerably reduce the 
number of parameters. As a result, some factors are not taken into account, 
including for example further metabolic reactions of 1’-sulfoxyelemicin, the 
possible reversibility of oxidation of 1’-oxoelemicin, and extrahepatic metabolic 
activation of 1’-hydroxyelemicin. Rationales for these assumptions were provided 
and as a result the outcomes of the developed PBK models for elemicin could be 
compared to those of the previous developed PBK models for estragole (Punt et 
al., 2008, 2009), methyleugenol (Al-Subeihi et al., 2011, 2012) which were found 
to adequately describe the in vivo situation. In view of model simplification and 
associated uncertainties, conclusions obtained from the developed models should 
preferably be based on a relative comparison of the relative extent of bioactivation 
and detoxification as was done in the present study.
Altogether, the results obtained indicate that PBK modeling provides an 
important insight in the occurrence of species differences in the metabolic activation 
of elemicin. Moreover, they provide an example of how PBK modeling can facilitate a 
read across in risk assessment from compounds for which in vivo toxicity studies are 
available to a compound for which only limited toxicity data have been described, 
thus contributing to development of alternatives for animal testing. 
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Table S1. Characteristic NMR chemical shifts.
Compound Position Chemical shift (ppm)
elemicina 
H4/H6 6.49
H1’ 3.33
H2’ 5.97
H3’a
H3’b
5.10
5.05
1-OCH
3
, 3-OCH
3
3.82
2-OCH
3
3.75
1’-oxoelemicina
H4/H6 7.34
H2’ 7.38
H3’a
H3’b
6.43
5.97
1-OCH
3
, 3-OCH
3
3.93
2-OCH
3
3.87
elemicin-2’,3’-oxidea, b 
H4/H6 6.58
H1’a
H1’b
2.84
2.73
H2’ 3.14
H3’a
H3’b
2.79 
2.59
1-OCH
3
, 3-OCH
3
3.84
2-OCH
3
3.75
1’-hydroxyelemicinc
H4/H6 6.59
H1’ 5.12
H2’ 6.02
H3’a 5.36
H3’b 5.20
1-OCH
3
, 3-OCH
3
3.85
2-OCH
3
3.82
3’-hydroxyisoelemicind H2/H6 6.64
H1’ 6.55
H2’ 6.31
H3’ 4.35
OCH
3
3.89
a Measurements were performed at 300K using a 1D NOESY pulse sequence at a Bruker Avance III 600 
MHz NMR spectrometer equipped with a 5 mm cryoprobe using CD
3
OD. The methanol peak was set at 
3.33 ppm. 
b Elemicin-2’,3’-epoxide was, because of the additional presence of elemicin, checked by means of 2D 
NMR spectroscopy (1H-1H COSY, 1H-1H TOCSY, 1H-13C HSQC, 1H-13C HMBC). 
c NMR analysis was performed on a Bruker AV-500 NMR spectrometer using CDCl
3
.  
d NMR analysis was performed on a Bruker AV-400 MHz spectrometer using CDCl
3
.   
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Figure S1. Chromatograms showing the diff erent metabolites of elemicin formed in incubations with A) 
pooled human mixed gender liver microsomes and B) male rat lung. Incubations were performed using 
a fi nal concentration of 100 µM elemicin and NADPH as a cofactor for 30 min at 37 ˚C. The peaks marked 
with an asterisk (*) were also present in blank incubations performed in the absence of the cofactor 
NADPH.
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Figure S2. Elemicin concentration dependent rate of formation of different elemicin metabolites in 
incubations with A) male rat liver and B) lung microsomes and C) mixed gender pooled human liver 
microsomes and NADPH as a cofactor. Each point represents the mean formation 1’-hydroxyelemicin 
(), 3’-hydroxyisoelemicin (), M4 () elemicin-2’,3’-oxide (•), 3-hydroxy-4,5-dimethoxyallylbenzene (•) 
obtained from two individual experiments. 
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Abstract
Basil-containing plant food supplements (PFS) can contain estragole which 
can be metabolized into a genotoxic and carcinogenic 1’-sulfoxymetabolite. 
This chapter describes the inhibition of sulfotransferase (SULT)-mediated 
bioactivation of estragole by compounds present in basil-containing PFS. Results 
reveal that PFS consisting of powdered basil material contain other compounds 
with considerable in vitro SULT-inhibiting activity, whereas the presence of such 
compounds in PFS consisting of basil essential oil was limited. The inhibitor in 
powdered basil PFS was identified as nevadensin. Physiologically based kinetic 
(PBK) modeling was performed to elucidate if the observed inhibitory effects can 
occur in vivo. Subsequently, risk assessment was performed using the Margin 
of Exposure (MOE) approach. Results suggest that the consequences of the in 
vivo matrix-derived combination effect are significant when estragole would be 
tested in rodent bioassays with nevadensin at ratios detected in PFS, thereby 
increasing MOE values. However, matrix-derived combination effects may be 
limited at lower dose levels, indicating that the importance of matrix-derived 
combination effects for risk assessment of individual compounds should be 
done on a case-by-case basis considering dose-dependent effects. Furthermore, 
this study illustrates how PBK modeling can be used in risk assessment of PFS, 
contributing to further reduction in the use of experimental animals. 
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Introduction
Plant food supplements (PFS) are widely marketed throughout Europe where 
they are sold in pharmacies, drug stores, health-food shops, supermarkets and 
via Internet. Despite the fact that the use of botanical products is suggested to 
be beneficial for overall health, the use of some PFS that are available on the 
market might raise concerns as several botanicals are known to contain toxic 
compounds (EFSA, 2012). Examples of naturally present botanical compounds 
of concern include the group of alkenylbenzenes (EFSA, 2012; van den Berg 
et al., 2011a, 2011b). In fact, it was recently demonstrated that some -though 
not all- PFS derived from basil, fennel, nutmeg, sassafras or calamus contain 
relatively high levels of the alkenylbenzenes estragole, methyleugenol, safrole 
and/or β-asarone (van den Berg et al., 2011b). Based on the Margin of Exposure 
(MOE) approach it was even concluded that the use of such products, at dose 
levels recommended by the respective manufacturers, may lead to a daily intake 
of these genotoxic carcinogens comparable to dose levels causing malignant 
tumors in rodents, indicating a priority for risk management and a potential 
risk for human health (van den Berg et al., 2011b). It is important to note that 
the available tumor data for these food-borne alkenylbenzenes, which were 
used to estimate the MOE values, were obtained from long-term rodent studies 
performed with pure compounds dosed in the absence of a botanical matrix 
(Miller et al., 1983). It can be argued whether such data represent an adequate 
basis for the risk assessment for these botanical products (Rietjens et al., 2008). 
 The genotoxic and carcinogenic activity of alkenylbenzenes has 
been ascribed to their bioactivation by cytochromes P450, leading to the 
formation of 1’-hydroxymetabolites, and the subsequent sulfonation of these 
1’-hydroxymetabolites by sulfotransferases (SULTs), generating unstable DNA 
reactive 1’-sulfoxymetabolites (Figure 1) (Anthony et al., 1987; Drinkwater et 
al., 1976; Miller et al., 1983; Sangster et al., 1987; Solheim and Scheline, 1973; 
Wiseman et al., 1987). Interestingly, a previous study (Jeurissen et al., 2008) 
showed that a methanolic basil extract caused a reduction in the level of 
DNA-adduct formation in incubations with DNA and rat or human liver S9 
as well as in human hepatoma HepG2 cells exposed to 1’-hydroxyestragole, 
demonstrating the importance of the botanical matrix. The major compound in 
the methanolic basil extract responsible for this in vitro inhibition of the SULT-
mediated bioactivation of estragole was found to be the flavonoid nevadensin 
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(Alhusainy et al., 2010). Recently, it was demonstrated that nevadensin is also 
able to significantly inhibit the SULT-mediated bioactivation of estragole in vivo, 
resulting in reduced levels of estragole DNA-adducts in the livers of rats exposed 
simultaneously to estragole and nevadensin as compared to the estragole DNA-
adduct levels in the livers of rats exposed to estragole alone (Alhusainy et al., 
2013). 
 
Figure 1. Metabolic pathways of estragole. Arrows in bold indicate the bioactivation to 1’-sulfoxyestragole 
and the formation of DNA-adducts.
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Although a methanolic basil extract could thus markedly inhibit the 
metabolic bioactivation of estragole, compositional changes might occur when 
processing and manufacturing PFS. As a result, the level of SULT-inhibition can 
be different for botanicals used as herbs and spices compared to processed 
PFS prepared from the same botanical. Therefore, the aims of the present study 
were (1) to examine the effect on the bioactivation of estragole by compounds 
present in PFS consisting of powdered basil material or its essential oils for 
which we previously demonstrated a potential risk for human health (van den 
Berg et al., 2011b), (2) to identify the most potent SULT inhibitor(s) in these PFS, 
(3) to perform physiologically based kinetic (PBK) modeling to elucidate if the 
observed inhibitory effects can occur in vivo and (4) to perform an updated risk 
assessment for the basil-containing PFS based on the MOE approach taking this 
matrix-derived combination effect into account. 
Materials and methods
PFS and chemicals
Five basil-containing PFS were selected for which a risk assessment was previously 
made based on the MOE approach, indicating that use of all these basil-containing 
PFS results in MOE values in the range of 1-1,000 pointing at a high priority for risk 
management actions and a potential risk for human health (van den Berg et al., 
2011b). Two of the selected PFS consisted of powdered basil material and three 
of the selected PFS were prepared from the essential oil of basil. Characteristics of 
the selected PFS are presented in Table 1. Basil-containing PFS were purchased via 
Internet. 
Apigenin, 7-hydroxycoumarin (7HC), 7-hydroxycoumarin sulfate (7HCS), 
tris-(hydroxymethyl)aminomethane, 3’-phosphoadenosine-5’-phosphosulfate 
(PAPS) and pentachlorophenol (PCP) were purchased from Sigma-Aldrich 
(Steinheim, Germany). Nevadensin was from Sinova Inc. (Bethesda, USA). Pooled 
liver S9 from male Sprague-Dawley rats and mixed gender pooled human liver S9 
were supplied by BD Gentest (Woburn, United States). Acetic acid was obtained from 
VWR International (Darmstadt, Germany) and dimethyl sulfoxide (DMSO) was from 
Acros Organics (Geel, Belgium). Methanol (ULC/MS grade) and acetonitrile (ULC/MS 
grade) were purchased from Biosolve (Valkenswaard, The Netherlands). Ultrapure 
water was obtained from a Barnstead Nanopure Type I ultrapure water system. 
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Preparation of methanolic PFS extracts
The selected PFS consisting of powdered basil material were extracted as 
described previously (Alhusainy et al., 2010; Jeurissen et al., 2008). In short, 5 
g of powdered PFS material was extracted with a mixture of methanol, water 
and acetic acid (ratio 80:19:1) by stirring the powdered PFS material twice for 2 
h at room temperature, each time using 100 mL of the extraction mixture. After 
filtration of the extract solution through a folded filter (Schleicher & Schuell), 
the filtrates of each PFS were pooled and evaporated to dryness using a rotary 
evaporator (Heidolph LABOROTA 4000 efficient, Metrohm USA). The extraction 
yields were found to range between 21.6% and 23.8%. The dried extracts were 
subsequently dissolved in methanol to obtain concentrations of 2, 5, and 20 
mg/mL. PFS consisting of basil essential oil were directly dissolved in methanol 
to obtain a concentration of 20 mg/mL followed by sonication (Bandelin 
Sonorex RK 100) for 10 min at room temperature. Thereafter, dilution series 
were prepared in methanol to make aliquots of 2 and 5 mg/mL. All stocks were 
filtered using a 0.2 µM cellulose acetate filter membrane (VWR international) 
and stored at -20˚C until use in the SULT assay. 
SULT assay
The inhibition of SULT activity by the different methanolic basil-containing PFS 
extracts was measured as described by Alhusainy et al. (2010). Since the sulfonated 
1’-hydroxymetabolite of estragole is unstable in an aqueous environment, 
hampering its direct detection by means of HPLC analysis, 7-hydroxycoumarin 
(7HC) was used as a substrate as previously described (Alhusainy et al., 2010, 
2012). Incubations were performed in a total volume of 100 µL with 0.1 M Tris-
HCl (pH 7.4) containing (final concentrations) 0.4 mg/mL commercially obtained 
pooled liver S9 from male Sprague-Dawley rats or mixed gender pooled human 
liver S9 to 0.1 mM 3’-phosphoadenosine-5’-phosphosulfate (PAPS) and 10, 25 or 
100 µg/mL of a methanolic PFS extract (added from a 200 times concentrated 
stock in methanol). Prior to the addition of 25 µM 7HC (added from a 200 
times concentrated stock solution in DMSO), samples were pre-incubated for 
1 minute at 37 ºC. Reaction mixtures were incubated for 10 min at 37 ºC and 
terminated by adding 25 μl ice-cold acetonitrile. Incubations performed in the 
absence of PFS extract or in the presence of 25 µM of the known SULT inhibitor 
pentachlorophenol (PCP) (added from a 200 times concentrated stock solution 
in DMSO) were used as controls. In addition, blank incubations were performed 
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in the absence of the cofactor PAPS or S9 liver homogenates. In all incubations, 
the total amount of methanol and/or DMSO was kept below 1% (v/v). All 
samples were centrifuged at 5 ºC for 5 min at 16,000g and the supernatant was 
stored at -20˚C until HPLC analysis. Experiments were performed in triplicate. 
HPLC analysis and quantification of 7HCS
For quantification of 7HCS, 50 µL of each sample obtained in the SULT assay 
was subjected to HPLC analysis as described previously (Alhusainy et al., 2010, 
2012). Chromatographic analysis was performed using a Waters 2695 separation 
module liquid chromatography system, connected to a 2996 photodiode array 
detector and an Alltima C18 5 µm column, 150 mm x 4.6 mm (Grace Alltech, Breda, 
The Netherlands). The gradient was made with ultrapure water containing 0.1% 
(v/v) acetic acid and acetonitrile. The flow rate was 1 mL/min and a gradient 
was applied from 0% acetonitrile to 20% acetonitrile in 2 min, increased to 21% 
acetonitrile over 10 min and further increased to 100% acetonitrile in 2 min at 
which it was kept for 1 minute. Starting conditions were reached in the next 2 
min and retained for another 10 min. Under the conditions applied, 7HCS eluted 
at 6.2 min. 
Fractionation of methanolic basil-containing PFS extracts 
All methanolic basil-containing PFS extracts were subjected to fractionation 
based on the method described previously (Alhusainy et al., 2010). In short, 50 
µL of a concentrated PFS extract (i.e. 150 mg/mL) dissolved in methanol were 
injected into a Waters 600 controller liquid chromatography system connected 
to a Waters 996 photodiode array detector. Chromatographic separation 
was performed using an Alltima C18 5 µm column 150 mm x 4.6 mm (Grace 
Alltech, Breda, The Netherlands). The gradient was made with ultrapure water 
containing 0.1% (v/v) acetic acid and methanol. The flow rate was 1 mL/min. The 
mobile phase started with 0% methanol and was increased to 100% methanol 
within 60 min at which it was kept for 10 min. Starting conditions were reached 
in 10 min and retained in the next 10 min. In total, 60 fractions with a one minute 
interval were collected into Eppendorf tubes. Subsequently, the methanolic 
solvent present in the collected fractions was evaporated under a stream of 
gaseous nitrogen and the residual water was removed by freeze drying using 
a Christ Alpha RVC freeze dryer at 0.8-1.2 mbar. For each basil-containing PFS, 
fractionation was repeated five times and the dried fractions obtained of each 
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replicate were pooled by reconstituting them in 50 µL methanol. All fractions 
were tested in the SULT activity assay for their SULT-inhibitory potential. 
Identification and quantification of the compounds present in the most 
potent fractions were accomplished by comparison of their retention times and 
UV spectra to the retention times and UV spectra of commercially available 
reference compounds. 
UPLC analysis and quantitative detection of nevadensin in PFS consisting of basil 
For quantification of nevadensin, the major SULT-inhibiting constituent in the 
methanolic basil-containing PFS extracts prepared in this study (see results 
section), 3.5 µL of each methanolic extract was subjected to UPLC analysis 
(n=3). UPLC analysis was performed on a Waters ACQUITY UPLC H-Class system 
connected to an ACQUITY UPLC photodiode array detector and a quaternary 
solvent manager. Chromatographic separation was achieved using an ACQUITY 
UPLC BEH C18 1.7 μm column, 2.1 × 50 mm. The column was kept at 30°C and 
the sample manager was set at 10°C. The gradient was made with nanopure 
water containing 0.1% (v/v) TFA and acetonitrile. The flow rate was 0.6 mL/
min and a gradient was applied from 0% acetonitrile to 20% acetonitrile in 
0.2 min, increased to 79% acetonitrile over 1.8 min and further increased to 
100% acetonitrile in 0.2 min at which it was kept for 0.6 min. Starting conditions 
were reached in the next 0.2 min and retained for another 1.2 min. The levels 
of nevadensin were quantified by comparing the peak areas to those in the 
calibration curve of nevadensin derived using a commercially available 
reference compound.
PBK modeling, BMDL10 analysis and updated risk assessment using the MOE 
approach
An updated risk assessment of basil-containing PFS was made including the 
matrix-derived combination effect of nevadensin on the bioactivation of 
estragole. The reduction in the formation of estragole DNA-adducts (N2-(trans-
isoestragol-3'-y1)-2'-deoxyguanosine (E-3'-N2-dGuo)) in the liver of rat following 
the combined exposure to estragole and nevadensin was predicted based on 
the PBK models previously developed for the bioactivation and detoxification 
of estragole (Punt et al., 2009) including a sub-model describing the absorption, 
distribution, metabolism and excretion of nevadensin (Alhusainy et al., 2013). 
The binary estragole-nevadensin PBK model used in this study was previously 
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validated based on an in vivo study in which rats were exposed to estragole and 
nevadensin showing that the PBK model based predictions adequately match the 
measured DNA-adduct levels in the liver of rats (Alhusainy et al., 2013). In the present 
study, the estragole-nevadensin model (Alhusainy et al., 2013) was run for a period 
of 24 h using the estragole dose levels administered to mice (Miller et al., 1983) 
and a relative ratio of estragole and the SULT inhibitor nevadensin reflecting their 
occurrence in the specific PFS. 
Based on the outcomes of the PBK model, the incidence of hepatomas as 
reported by Miller et al. (1983) was refined assuming a linear relationship between 
the reduced formation of E-3’-N2-dGuo DNA-adducts and the reduction in the 
hepatoma incidence. In a next step, refined BMDL
10
 (i.e. the lower confidence limit 
of the benchmark dose resulting in a 10% extra cancer incidence) values were 
calculated by performing a BMD (BenchMark Dose) analysis of the newly refined 
hepatoma incidences using EPA BMD software (version 2.1.2) as previously described 
(van den Berg et al., 2011b). MOE values were calculated by dividing the refined 
BMDL
10
 values by the estimated daily intake of estragole resulting from the use of 
each specific basil-containing PFS of interest (Table 1) (van den Berg et al., 2011b). 
Results
Inhibition of SULT activity in rat and human liver S9 homogenates by methanolic extracts 
of basil-containing PFS
The inhibition of SULT activity by several methanolic basil-containing PFS extracts in 
incubations with rat and human liver S9 is shown in Figure 2. All tested methanolic 
extracts were found to inhibit the metabolic conversion of 7HC to 7HCS in a dose-
dependent manner. The extracts prepared from PFS consisting of powdered basil 
material (i.e. PFS1 and PFS2) were found to exert the most potent SULT-inhibiting 
effects. In fact, in human liver S9 homogenates, PFS2 completely blocked the 
formation of 7HCS at all concentrations tested (i.e. final concentrations of 10, 25 and 
100 µg/mL) comparable to the effect observed when incubations were performed 
using 25 µM of the known SULT inhibitor PCP. In contrast, extracts that were prepared 
from PFS consisting of the essential oil of basil (i.e. PFS3, PFS4 and PFS5) resulted 
in only a moderate level of SULT-inhibition (Figure 2). Chromatographic analysis of 
incubations performed in the absence of the cofactor PAPS or S9 liver homogenates 
demonstrated that under these conditions 7HCS was not formed. 
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Figure 2. Inhibition of the SULT-mediated conversion of 7HC to 7HCS by methanolic extracts of several 
basil-containing PFS. Incubations were performed using pooled rat (black bars) or human liver (grey 
bars) S9 homogenates, 7HC as a substrate and PAPS as a cofactor in the presence or absence of final 
concentrations of 10, 25 or 100 µg/mL of methanolic basil-containing PFS extracts or 25 µM PCP 
(positive control). Data are presented as a percentage of the amount of 7HCS formed in incubations 
without a methanolic PFS extract (i.e. control MeOH). An asterix (*) indicates a significant decrease in the 
formation of 7HCS compared to incubations without SULT inhibitor (p<0.05). 
Fractionation of methanolic extracts of basil-containing PFS
The methanolic extracts of basil-containing PFS were subjected to fractionation 
using HPLC. Figure 3 displays the inhibition of the SULT-catalyzed conversion of 
7HC to 7HCS by all fractions obtained upon fractionation of methanolic extracts 
of the powdered basil-containing PFS (i.e. PFS1 and PFS2) (Figure 3A and 3B) or 
from PFS containing basil-derived essential oil (i.e. PFS3, PFS4 and PFS5) (Figure 
3C-E). A potent SULT-inhibiting effect was shown for several fractions of the 
methanolic extracts prepared from PFS consisting of powdered basil material 
(Figure 3A and 3B). Fraction 51 was found to exert the highest level of SULT-
inhibiting activity for PFS1 and PFS2 (Figure 3A and 3B). In fact, the formation of 
7HCS was completely blocked in the presence of fraction 51. Fraction 50 of PFS1 
also resulted in complete inhibition of SULT activity, whereas for PFS2 this fraction 
resulted in an almost complete SULT-inhibition of 92.9%. In addition, for both 
methanolic PFS extracts from powdered basil material, fraction 45 and 46 were 
found to contain potent SULT inhibitors resulting in a level of SULT-inhibition of 
92.9-96.1%. Chromatographic analysis of fraction 50 and 51 demonstrated the 
presence of only one major compound in both fractions which was identified 
as nevadensin based on comparison of the retention time and UV spectra of 
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these fractions to those of a commercially available standard of nevadensin. 
Apigenin was identified in fraction 46 of both PFS consisting of powdered basil 
material (i.e. PFS1 and PFS2), although chromatographic analysis of this fraction 
also revealed the presence of other minor constituents. 
In comparison to the methanolic extracts prepared from PFS 
consisting of powdered basil material, the level of SULT-inhibition by fractions 
of methanolic extracts from PFS consisting of basil essential oil was found to 
be limited amounting to 39.4% or less (Figure 3C-E). Moreover, there was no 
analogy between the three fractionation patterns with regard to the fractions 
showing the most potent SULT-inhibiting effect. 
PBK prediction of the effect of nevadensin on in vivo estragole DNA-adduct 
formation 
PBK modeling was performed to predict the in vivo effect of the combined exposure to 
estragole and nevadensin on E-3’-N2-dGuo formation in rat liver. The binary estragole-
nevadensin PBK model used for these analyses was previously validated based on an 
in vivo study in which DNA-adducts were quantified in the liver of rats simultaneously 
exposed to estragole and nevadensin (Alhusainy et al., 2013). DNA-adduct formation 
was modeled using the binary estragole-nevadensin PBK model (Alhusainy et al., 2013) 
at estragole dose levels used in the estragole rodent bioassay (Miller et al., 1983) on 
which our previous risk assessment of the basil-containing PFS was based (van den 
Berg et al., 2011b). Table 2 shows that the level of estragole DNA-adduct formation in 
rat liver at dose levels of 54 and 107 mg/kg bw/day estragole are predicted by the PBK 
model to equal 1983 adducts in 108 nt and 4114 adducts in 108 nt in the absence of 
nevadensin. In the presence of nevadensin, at a ratio between estragole and nevadensin 
reflecting their levels in PFS1, a reduction in the formation of estragole DNA-adducts by 
65% (i.e. 688 adducts in 108 nt) and 66% (i.e. 1385 adducts in 108 nt) was predicted for 
estragole dose levels of 54 and 107 mg/kg bw/day respectively. Table 2 also shows the 
predicted PBK model outcomes for the formation of estragole DNA-adducts following 
an exposure to 54 and 107 mg/kg bw/day estragole in the presence of nevadensin at 
levels reflecting the ratio between estragole and nevadensin in PSF2. 
 Results reveal that, at 54 and 107 mg/kg bw/day estragole, the reduction of 
E-3’-N2-dGuo DNA-adduct formation is predicted by the PBK model to equal 89% and 
88% following the co-administration of estragole and nevadensin at a ratio relevant for 
their occurrence in PFS2.  
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Figure 3. Inhibition of the SULT-mediated conversion of 7HC to 7HCS by several basil-containing PFS 
fractions collected by HPLC. Incubations were performed using pooled rat liver S9 homogenates, 7HC 
as a substrate and PAPS as a cofactor in the presence of fractions of A) basil-containing PFS1, B) basil-
containing PFS2, C) basil-containing PFS3, D) basil-containing PFS4 or E) basil-containing PFS5. Data are 
presented as a percentage of the amount of 7HCS formed in incubations without SULT inhibitor (i.e. 
control MeOH).  
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Extracts of PFS consisting of basil essential oils were able to inhibit SULT activity 
only to a moderate extent and the effect of this SULT-inhibition was not further 
investigated. It should be noted that the rodent bioassay by Miller et al. (1983) 
was performed using dose levels of estragole that considerably exceed the 
levels of exposure to estragole resulting from the use of basil-containing PFS. 
The levels of DNA-adduct formation at levels of 4.6 and 13.9 µg/kg bw/day 
estragole, the estimated daily intake of estragole resulting from the use of PFS1 
at the recommended daily intake of 1 or 3 capsules, respectively, were predicted 
by the PBK model to equal 0.1 adducts per 108 nt or 0.3 adducts per 108 nt. Co-
administration of estragole and nevadensin, at a dose reflecting their actual 
levels in PFS1, was predicted to result in a decrease of estragole DNA-adduct 
formation by 0.02% and 0.07% following exposure to 4.6 or 13.9 µg/kg bw/day 
estragole respectively. For PFS2, DNA-adduct formation was predicted by the 
PBK model to amount to 0.1 adducts in 108 nt or 0.2 adducts in 108 nt following 
exposure to 5.4 or 8.1 µg/kg bw/day estragole, respectively, the estimated daily 
intake of estragole resulting from the use of PFS2 at the recommended daily 
intake of 4 and 6 capsules, respectively. The formation of estragole DNA-
adducts was predicted to decrease by 0.22% and 0.33% at estragole intake 
levels of 5.4 and 8.1 µg/kg bw/day in the presence of nevadensin at a dose 
reflecting their actual levels in PFS2 amounting to 6.4 or 9.6 µg/kg bw/day 
nevadensin respectively. These results demonstrate that the consequences of 
the in vivo matrix-derived combination effect are especially observed in rodent 
bioassays at estragole dose levels that cause significant cancer incidences but 
are predicted to be limited at exposure levels of estragole and nevadensin 
relevant for the daily use of PFS consisting of powdered basil material. For the 
extracts consisting of basil essential oil only the PBK predicted levels of DNA-
adducts formed upon intake of estragole at dose levels resulting from intake of 
PSF3, PSF4 and PSF5 at the recommended daily dose levels were calculated 
and were found to amount to 128, 3-13 and 55-87 in 108 nt respectively. 
BMDL
10
 analysis and updated risk assessment using the MOE approach
Table 3 presents a summary of the incidence of hepatocellular carcinomas as 
observed in a long term carcinogenicity study in which rodents were exposed 
to estragole at dose levels of 54 or 107 mg/kg bw/day without the natural 
(botanical) matrix being present (Miller et al., 1983). Based on the PBK model 
predictions for the reduction in estragole DNA-adduct formation in rat liver 
following the combined exposure to estragole and nevadensin (Table 2), 
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a refinement of the incidences of hepatocellular carcinomas as reported 
by Miller et al. (1983) was made assuming a proportional reduction in DNA-
adduct formation and hepatomas. Table 3 provides a summary of the refined 
hepatoma incidences thus obtained.  
Table 2. Overview of the PBK-predicted formation of estragole DNA-adducts in rat liver in the presence 
or absence of nevadensin at a ratio of estragole and nevadensin reflecting their occurrence in basil-
containing PFS. 
Dose estragole 
(mg/kg bw/day)
Dose nevadensin 
(mg/kg bw/day) 
Adducts in 108 nt in the 
absence of nevadensin 
as predicted by PBK 
modeling
Adducts in 108 nt 
in the presence 
of nevadensin as 
predicted by PBK 
modeling
% reduction 
DNA-adduct 
formation
Basil-containing PFS1
0 0 0 0 0
54 8 1983 688   65
107 15 4114 1385 66
Basil-containing PFS2
0 0 0 0 0
54 64 1983 214 89
107 127 4114 496 88
 
 Based on the refined hepatoma incidences obtained, a BMD analysis 
was performed resulting in BMDL
10
 values ranging between 21-25 mg/kg bw/day 
and 63-87 mg/kg bw/day when using the estragole to nevadensin ratios of PFS1 
and PFS2 respectively (Table 4) (for details on BMD analysis see Table S1 in the 
Supplementary Materials of Chapter 5). Subsequently, MOE values were calculated 
by comparing the newly defined BMDL
10
 values with the estimated daily exposure 
levels to estragole resulting from the use of the specific basil-containing PFS (i.e. 
0.005-0.014 mg estragole/kg bw/day and 0.005-0.008 mg estragole/kg bw/day 
for PFS1 and PFS2, respectively). Table 4 shows the refined MOE values that were 
obtained in this way. For PFS1 the refined MOE values vary between 2,000 and 5,000 
and for PFS2 MOE values were found to amount to 8,000-20,000 (Table 4). These 
refined MOE values are considerably higher than the MOE values of 200-1,000 and 
400-1,000 that were previously derived using the non-refined BMDL
10
 values from 
tumor data obtained in a rodent study using purified estragole without the natural 
(botanical) matrix being present (Miller et al., 1983; van den Berg et al., 2011b).
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Table 3. Overview of the incidence of hepatomas in rodents following long-term exposure to pure 
estragole (Miller et al., 1983) and the calculated incidence of hepatomas taking into account the matrix-
derived combination effect of basil-containing PFS as derived by PBK modeling. 
Dose estragole 
(mg/kg bw/day)
Dose nevadensin 
(mg/kg bw/day)
Incidence hepatomas 
in the presence of 
estragole only (Miller et 
al., 1983)
% reduction 
DNA-adduct 
formationa 
Calculated inci-
dence hepatomas 
after co-adminis-
tration of estragole 
and nevadensin
Basil-containing PFS1
0 0 0/50 0 0/50
54 8 27/48 65 9/48
107 15 35/49 66 12/49
Basil-containing PFS2
0 0 0/50 0 0/50
54 64 27/48 89 3/48
107 127 35/49 88 4/49
 
a The data used to predict the reduction in DNA-adduct formation in rat liver following the combined 
exposure to estragole and nevadensin are presented in Table 2.
Table 4. Updated risk assessment based on the MOE approach taking into account the presence of the 
SULT inhibitor nevadensin in basil-containing PFS (matrix-derived combination effect).
PFS Daily Intake 
Estragole (mg/kg 
bw/day)a (van den 
Berg et al., 2011b)
MOE using data 
from Miller et 
al.1983 (van den 
Berg et al., 2011b)
Refined BMDL
10
 taking 
into account the ma-
trix-derived combination 
effect (mg/kg bw/day)
Refined MOE taking 
into account the 
matrix-derived  
combination effectb
1 0.005 – 0.014 200 – 1,000 21 – 25 2,000 – 5,000
2 0.005 – 0.008 400 – 1,000 63 – 87 8,000 – 20,000
3 4.78 1 NDc NDc
4 0.147 – 0.589 6 – 40 NDc NDc
5 2.275 – 3.414 1 – 3 NDc NDc
 
a Using the dose of PFS intake as recommended by the manufacturer of the basil-containing PFS and the 
chemically determined levels of estragole in the PFS, daily intake estimates of estragole were obtained 
assuming a body weight of 60 kg.
b Refined MOE = refined BMDL
10
 (mg/kg bw/day) / daily intake estragole (mg/kg bw/day)
c  ND: Not Determined
Details on BMD analysis can be found in Table S1 in the Supplementary Materials of Chapter 5.  
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Discussion
In the presented chapter, the consequences of combined exposure to 
estragole and other compounds present in basil-containing PFS on the SULT-
mediated bioactivation of estragole were studied. The results demonstrated 
that methanolic extracts of PFS consisting of powdered basil material contain 
potent SULT inhibitors. In line with these findings, a significant inhibition of 
SULT activity was previously also shown for a methanolic extract prepared from 
basil as such (Alhusainy et al., 2010, 2012; Jeurissen et al., 2008). It is important 
to note that results of the present study also revealed that the level of SULT-
inhibition by PFS prepared from the essential oil of basil was markedly lower 
than that of PFS consisting of powdered basil material. In line with these 
findings, Müller et al. (1994) reported that basil essential oil, containing 88% 
estragole, was found to induce unscheduled DNA Synthesis (UDS) in the same 
concentration range as pure estragole showing that there was no protective 
effect of the remaining compounds present in the essential oil. The differences 
between the observed protective effects of PFS consisting of powdered basil 
material and PFS consisting of basil essential oils can be explained by the fact 
that PFS consisting of powdered basil material contain other compounds in 
addition to estragole that exert a substantial SULT-inhibiting activity whereas 
the presence of such modulating compounds in PFS consisting of basil essential 
oil is apparently limited. Thus, assessing the risk for human health resulting 
from the use of basil-containing PFS, one should take into account the specific 
processing and manufacturing conditions used since differences in these 
production processes can induce marked changes in composition, especially 
when extracting essential oils containing concentrated levels of individual 
(toxic) ingredients such as estragole. 
In the present study, the flavonoids nevadensin and apigenin were 
identified in the methanolic extracts of PFS consisting of powdered basil material 
as the compounds responsible for inhibiting SULT activity. In line with these 
findings, both flavonoids were previously identified as the major SULT-inhibiting 
constituents in methanolic extracts of intact basil sold in the supermarket for 
use as a herb (Alhusainy et al., 2010, 2012). Other flavonoids that are reported to 
be present in some basil varieties have also been demonstrated to exert SULT-
inhibiting activities (Alhusainy et al., 2012). These flavonoids include luteolin 
and catechin. However, it is important to realize that according to literature, 
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nevadensin is one of the major flavonoids of basil and exists in almost all varieties 
of the genus Ocimum basilicum L. whereas apigenin, luteolin and catechin are 
present in relatively low quantities or are only present in some basil varieties 
(Grayer et al., 1996, 2004; Shan et al., 2005). For example, the level of apigenin 
in different varieties of the genus Ocimum basilicum L. was estimated to be up 
to 71-fold lower compared to the level of nevadensin found in the same basil 
leaf sample (Grayer et al., 2004). In addition, the K
i
 value for SULT-inhibition by 
apigenin was shown to be 175-fold higher than the K
i
 value for SULT-inhibition 
by nevadensin (i.e. 4 nM) (Alhusainy et al., 2010, 2012) corroborating nevadensin 
to be a more important SULT inhibitor. Based on these results, the effect of 
apigenin on SULT-mediated bioactivation of estragole can be expected to be 
significantly lower than that of nevadensin. Furthermore, nevadensin was not 
only demonstrated to be a potent inhibitor of SULT activity in vitro, but it was 
recently also shown to significantly inhibit the SULT-mediated bioactivation and 
DNA-adduct formation of estragole in vivo (Alhusainy et al., 2013). 
Since nevadensin can markedly reduce estragole DNA-adduct 
formation in vivo (Alhusainy et al., 2013), the adverse effects of estragole are 
likely to be lower when estragole is consumed in a matrix of basil-containing 
PFS compared to studies administering pure estragole. Thus, performing a risk 
assessment for basil-containing PFS as described previously (van den Berg et al., 
2011b), by using the BMDL10 data obtained from a rodent study with high dose 
levels of the pure estragole (Miller et al., 1983), may result in an overestimation 
of the priority for risk management and the potential risk for human health. 
Therefore, an updated risk assessment of basil-containing PFS using the 
MOE approach was made in the present study. To this end, studies in rodents 
should ideally be performed with the botanical or the botanical preparation of 
interest, allowing the calculation of specific BMDL
10
 values. However, obviously, 
performing rodent bioassays for all basil-containing PFS is practically unfeasible 
as the generation of such data is expensive, labor-intensive and above all requires 
extensive animal testing. Therefore, the present study focused on the chemical 
identification of the most potent SULT inhibitor in basil-containing PFS and the 
use of the previously developed and validated estragole-nevadensin PBK model 
(Alhusainy et al., 2013) to predict the possible in vivo reduction in estragole 
DNA-adduct formation, taking for each PFS the relative ratio between its levels 
of estragole and nevadensin into account. To obtain this refined estimate, the 
possible reduction in the values for the incidence of hepatocellular carcinomas 
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reported by Miller et al. (1983) was predicted using the PBK model, subsequently 
allowing the calculation of refined BMDL
10
 data. Based on this approach, MOE 
values could be calculated for the individual PFS. These MOE values were found 
to be considerably higher than the MOE values that were previously calculated 
not taking the matrix-derived combination effect into account by using the non-
refined BMDL
10
 values (van den Berg et al., 2011b). The results now presented 
indicate a lower priority for risk management actions for the powdered basil-
containing PFS when considering the consequences of the botanical matrix 
on the bioactivation of estragole. These results indicate that for these PFS the 
use of BMDL
10
 data derived from long-term carcinogenicity studies using pure 
estragole results in an overestimation of the potential risk for human health. In 
contrast, it was concluded that the matrix-derived combination effect of PFS 
consisting of basil essential oil is only of minor importance suggesting that the 
use of BMDL
10
 data from studies using pure estragole accurately reflects the 
potential risk for human health resulting from the use of these PFS. 
It should be noted that the estragole doses tested by Miller et al. (1983) 
are not representative for the human situation, since these are dose levels high 
enough to cause detectable tumor incidences in groups of 50 experimental 
animals. Risk assessment by the MOE approach is done using rodent tumor 
data and is thus based on dose levels actually inducing a significant tumor 
incidence and not necessarily on realistic human intake levels. At these high 
dose levels used in the Miller et al. study the concomitant dose of nevadensin 
is also high and apparently high enough to reach nevadensin levels in the liver 
that are in the range of the Ki value of 4 nM for SULT-inhibition (Alhusainy et 
al., 2010). The presented study however also gives an estimate of the effects 
at estragole and nevadensin dose levels representing a realistic human intake. 
The matrix-derived combination effect of nevadensin on the bioactivation of 
estragole was predicted to be limited at dose levels of estragole and nevadensin 
relevant for the use of PFS consisting of powdered basil-material. At these 
dose levels the corresponding dose of nevadensin is not high enough to 
reach the K
i
 of nevadensin in vivo. This illustrates that testing compounds in 
the presence of their natural matrix in rodent bioassays may not necessarily 
provide better BMDL
10
 values for risk assessment, and that the importance of a 
matrix-derived combination effect for risk assessment of individual compounds 
should be done on a case-by-case basis also taking into account analysis of 
dose-dependent effects on the interactions detected. On the basis of the results 
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now available and our previous results showing MOE values ranging between 
200-1,000 and 1-40 for PFS consisting of powdered basil material or its essential 
oil, respectively (van den Berg et al., 2011b), it is still concluded that the use 
of some basil-containing PFS is of priority for risk management actions and a 
potential risk for human health. 
 In conclusion, compounds present in especially powdered basil-
containing PFS can modulate the bioactivation of estragole, whereas this effect 
was limited for PFS consisting of basil essential oil suggesting that the matrix-
derived combination effect for basil-containing PFS should be judged on a 
case-by-case basis. Furthermore, the present study provides an example of how 
PBK modeling can be used in the risk assessment of botanicals and botanical 
preparations, contributing to further reduction in the use of experimental 
animals. 
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Table S1. Overview of BMD analysis for the induction of hepatomas in female mice using BMDS software 
version 2.1.2, a BMD of 10% and default settings. 
Model No. of 
parameters
Log 
Likeli-
hood
p-value Accepted BMD
10
(mg/kg bw/day)
BMDL
10
(mg/kg bw/day)
Basil-containing PFS1
Null 1 -60.29
Full 3 -50.44
Gamma 1 -50.80 0.69 Yes 34.7 24.7
Logistic 2 -53.73 0.02 No
LogLogistic 1 -50.68 0.79 Yes 31.7 21.3
LogProbit 2 -50.44 1.00 Yes 13.7 ND
Multistage 1 -50.80 0.69 Yes 34.7 24.7
Multistage- 
Cancer
1 -50.80 0.69 Yes 34.7 24.7
Probit 2 -53.35 0.03 No
Weibull 1 -50.80 0.69 Yes 34.7 24.7
Quantal-linear 1 -50.80 0.69 Yes 34.7 24.7
Basil-containing PFS2
Null 1 -28.14
Full 3 -25.08
Gamma 1 -25.21 0.87 Yes 113.4 64.6
Logistic 2 -26.18 0.19 Yes 116.2 87.2
LogLogistic 1 -25.20 0.88 Yes 114.5 63.1
LogProbit 2 -25.08 1.00 Yes 185.5 ND
Multistage 1 -25.21 0.87 Yes 113.4 64.6
Multistage- 
Cancer
1 -25.21 0.87 Yes 113.4 64.6
Probit 2 -26.07 0.20 Yes 114.7 84.0
Weibull 1 -25.21 0.87 Yes 113.4 64.6
Quantal-linear 1 -25.21 0.87 Yes 113.4 64.6
ND: Not Determined. Benchmark dose computation failed. Lower limit includes zero. 
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Abstract
This chapter describes the analysis of estragole in dry fennel preparations and 
in infusions prepared from them and an associated safety assessment. A wide 
range of estragole levels of 0.15-13.3 mg/g dry fennel preparation was found. 
The estragole content in infusions was considerably lower ranging between 0.4 
and 133.4 µg/25 mL infusion prepared from 1 g dry material. Infusions prepared 
from whole fennel fruits contained about 3-fold less estragole compared 
to infusions prepared from fine cut fennel material. Safety assessment was 
performed using the Margin of Exposure (MOE) approach comparing available 
tumor data to the estimated daily estragole intakes from the consumption of 
1-3 cups fennel tea. MOE values obtained for adults generally point at a low 
priority for risk management, especially when one cup of fennel tea is used daily 
during lifetime. MOE values for use of fennel teas by children were generally 
<10,000 indicating a priority for risk management. However, limiting such uses 
to 1-2 weeks, MOE values might be 3 orders of a magnitude higher and there 
would be no priority for risk management. These results indicate a low priority 
for risk management actions for use of fennel teas especially for short-term uses 
proposed for the symptomatic treatment of digestive disorders. 
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Introduction
For many years, botanicals have formed part of the regular diet as fruits or 
vegetables, wines, tea, food supplements or as flavors and fragrances added to 
food. Additionally, numerous botanicals and botanical preparations have a long 
history of use as traditional herbal medicine. An example of such a botanical used 
to maintain health or treat symptoms of disease is fennel (Foeniculum vulgare 
Mill.). Fennel based teas are traditionally used in many parts of Europe including 
France, Germany, Austria, Czech Republic and Poland were they are often used 
for the symptomatic treatment of digestive disorders alleviating mild spasmodic 
gastro-intestinal ailments and the relief of symptoms during inflammations 
of mucous membranes of the upper respiratory tract (EMA, 2008). Resulting 
from these proposed health-promoting effects, and the natural character of 
fennel, homemade fennel tea is often used as a remedy for gastrointestinal 
complaints in infants and young children (Crotteau et al., 2006; Perry et al., 
2011). Although fennel based teas have a long history of use and are valued 
for their beneficial effects, fennel may contain active ingredients of concern, 
such as the alkenylbenzene estragole (Figure 1) (EFSA, 2012a). Estragole was 
previously indicated to be genotoxic and carcinogenic (SCF, 2001). In response 
to these findings, regulatory actions were taken within the EU restricting the use 
of estragole (Regulation (EC) No. 1334/2008 of the European Parliament and of 
the Council, 16 December 2008). The potential risks for human health related 
to the use of estragole-containing fennel based teas to relief gastrointestinal 
disorders, especially in children, have not (yet) been thoroughly studied and 
the European Medicines Agency (EMA, former EMEA) concluded that “the use 
of fennel tea is not recommended in children under 4 years of age due to the 
lack of adequate data” (EMA, 2008).
Figure 1. Structural formula of estragole.  
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A major issue in the safety assessment of estragole and estragole-
containing food items is how to provide guidance on the potential risks for 
human health resulting from the exposure to (low levels of ) food-borne 
compounds that are genotoxic and carcinogenic (EFSA, 2005). The European 
Food Safety Authority (EFSA) recently indicated that whenever genotoxic and 
carcinogenic compounds are present in a botanical or botanical preparation of 
interest, the Margin of Exposure (MOE) approach (EFSA, 2005) can be used to 
evaluate the potential risk for human health and the priority for risk management 
actions (EFSA, 2009b). The MOE is a dimensionless ratio that is obtained by 
comparing exposure levels causing malignant tumors in experimental animals 
(e.g. the BMDL10 value, the lower confidence bound of the benchmark dose that 
gives 10% extra cancer incidence) with the estimated daily intake in humans 
(EFSA, 2005). In a previous evaluation of the EFSA Scientific Cooperation (ESCO) 
working group, the MOE was applied to the use of estragole-containing tea 
prepared from bitter fennel fruits (F. vulgare Mill. var. vulgare) (EFSA, 2009a). The 
exposure to estragole was estimated to equal 1.9-15.8 mg per day corresponding 
to 33-263 µg estragole/kg bw/day for a person with a body weight of 60 kg 
(EFSA, 2009a). This theoretical exposure estimate was based on the assumption 
that 4.5-7.5 g of fennel fruits would be used on a daily basis for the preparation 
of homemade fennel tea, that fennel fruits contain 5% essential oil, that the 
essential oil contains 3.5-12% estragole and that the extraction efficiency of 
the essential oil into the infusion is equal to 25-35% (EFSA, 2009a). The ESCO 
working group calculated the MOE based on the exposure estimates obtained 
and BMDL10 values derived from the incidence of malignant liver tumors in 
female CD-1 mice exposed to estragole (EFSA, 2009a; Miller et al., 1983). The 
MOE values thus obtained were found to be relatively low (i.e. MOE values equal 
to 34-1,000) indicating that the daily use of homemade fennel tea prepared 
from bitter fennel fruits would be of high priority for risk management actions 
(EFSA, 2009a). Raffo et al. (2011) recently experimentally determined the 
estragole content in hot water extracts of commercial fennel teas providing 
a refinement of the exposure estimate made by the ESCO working group. It 
was demonstrated that the consumption of tea prepared from sweet fennel 
(F. vulgare Mill. Var. dulce), available on the Italian market, that was found to 
contain the highest estragole level amongst the preparations tested in that 
study, would result in 3-26 fold lower estragole exposures compared to those 
estimated by the ESCO working group (Raffo et al., 2011). Based on these lower 
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exposure levels, Raffo et al. (2011) calculated the MOE values to range between 
870 and 3210 which is thus higher than the MOE values of 34-1,000 calculated 
by the ESCO working group (Raffo et al., 2011). However, by being lower than 
10,000 these MOE values still point at a priority for risk management. 
In general, the use of different exposure estimates (e.g. theoretical vs. 
experimental) may result in different daily intake levels for the same exposure 
scenario and thus also might provide different advice to risk managers on the 
potential risk for human health. In fact, limitations in exposure estimates are 
a major source of uncertainty in safety assessment. Thus, the use of refined 
intake estimates for estragole is required to facilitate an accurate outcome 
of the safety assessment of fennel based tea preparations. However, the 
concentration of estragole may show considerable variations depending on the 
variety, geographical origin, harvesting techniques and processing methods 
amongst others (Smith et al., 2002) and high variability of the estragole content 
in fennel fruits are reported in literature (Dadalioglu and Evrendilek, 2004; EFSA, 
2012a; Miraldi, 1999; Ruberto et al., 2000). Although the work of Raffo et al. 
(2011) provided an important refinement of the exposure estimate of estragole 
resulting from the use of fennel tea, exposure estimates were only based on the 
use of sweet fennel obtained from the Italian market while in addition to sweet 
fennel also bitter fennel is widely used to prepare homemade fennel based 
teas. In this respect, a further refinement of exposure data of estragole resulting 
from the consumption of homemade fennel tea including different varieties 
and origins of fennel teas, but also the experimental determination of the 
extraction efficiency of estragole into the infusion could improve the accuracy 
of the safety assessment. Hence, the aims of the present study were (1) to make 
a chemical analysis of estragole in sweet and bitter fennel teas consisting of 
commercial preparations of fine cut fennel material or whole fruits derived 
from different geographical origins, and (2) to perform a safety assessment for 
estragole resulting from drinking fennel tea using the MOE approach, taking 
into account the previous work by the ESCO working group (EFSA, 2009a) and 
reported in literature (Raffo et al., 2011). 
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Materials and methods 
Chemicals and materials 
A total of 34 fennel tea preparations from different brands were purchased 
from Internet, obtained from local shops in the Netherlands, Belgium, Germany 
and Italy or provided by the European Herbal Infusion Association. Fennel tea 
preparations in the form of teabags, unpackaged fennel consisting of whole fruits 
or fine cut fennel material, and instant tea granules were included. 7 Fennel tea 
preparations consisted of sweet fennel material and 8 fennel tea preparations 
consisted of bitter fennel material. The variety of the remaining samples (n=18) 
was not specified. Product information as indicated on the label of each product 
is summarized in Table 1. Estragole (purity 98%) was supplied by Acros organics 
(Geel, Belgium). Acetonitrile (ULC/MS gradient) and methanol (HPLC supra 
gradient) were acquired from Sigma Aldrich (Steinheim, Germany). Nanopure 
water was obtained from a Barnstead nanopure Type I ultra-pure water system. 
Methanolic extracts
To allow quantification of the total estragole content in the fennel tea samples 
expressed per g dry fennel preparation, methanolic extracts were prepared 
based on the method previously described (Gursale et al., 2010; van den Berg et 
al., 2011). To correct for the amount of estragole lost in this extraction method, 
a recovery study was performed as described by van den Berg et al. (2011). The 
average percentage recovery was found to equal 90.6 ± 8.1%. This value was 
used to correct the total level of estragole in the selected dry fennel preparations 
for sample recovery. 
Hot water extracts
In addition to the methanolic extracts, hot water extracts were made to reflect 
the preparation of homemade fennel tea. Extracts were prepared based on the 
method previously described by Raffo et al. (2011) with minor modifications. In 
short, tea extracts were prepared by adding 25 mL freshly boiled water to 1 g 
of fennel tea material. The mixture of hot water and fennel tea material was 
incubated for 7 min in a covered beaker and stirred three times with a spoon.
After 7 min, all fennel material was removed from the infusion and the extract 
was cooled down to room temperature.
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Aliquots of the hot water extracts were centrifuged at 16,000g for 5 min and 
the supernatant was stored at −20 °C until ultra performance liquid 
chromatography (UPLC)-analysis.
UPLC analysis
Before UPLC analysis, aliquots of the methanolic extract solution were diluted 
in acetonitrile (1:10 v/v). Aliquots of the hot water extracts were analyzed 
undiluted. For quantification of estragole, 3.5 μl of each sample was subjected 
to UPLC analysis (n=3) as described previously (van den Berg et al., 2011). 
Estimation of daily intakes of estragole resulting from the use of fennel based teas
The exposure estimate of estragole resulting from the use of fennel teas was based 
on the estragole content in the hot water extracts as determined in the present 
study (see results) together with the assumption that 1.5-2.5 g fennel would be used 
for the preparation of a cup of fennel tea as described by the ESCO working group 
(EFSA, 2009a). Intake estimates of estragole were made for the daily consumption 
of one, two or three cups of fennel based tea assuming a body weight of 70 kg, the 
default value for adult body weight recently proposed by EFSA (2012b).
Calculation of the Margin of Exposure values
MOE values were calculated by comparing the previously calculated BMDL
10
 
values of 3.3-6.5 mg/kg bw/day (van den Berg et al., 2011) for the induction of 
hepatocellular carcinomas in female mice derived from the data of Miller et al. 
(1983), with the estimated daily intakes of estragole resulting from the use of 
fennel based teas as determined in the present study. MOE values were rounded 
to a single significant value. 
Results 
Chemical analysis of estragole in dry fennel preparations and in fennel based teas
Figure 2 presents, as an example, part of the UPLC chromatogram of a 
methanolic as well as a hot water fennel extract detecting the presence and 
level of estragole. Table 1 shows that the total estragole content in the different 
dry fennel preparations was found to vary considerably ranging between 0.15 
and 13.3 mg/g dry fennel preparation. Estragole could not be detected in two 
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samples because the instant tea granules in those specific samples only partially 
dissolved in methanol. The analysis revealed that the content of estragole in the 
hot water extracts was considerably lower than the estragole content found in 
the methanolic extracts (Figure 2 and Table 1). In fact, results for the hot water 
extracts from 1 g of fennel material, also presented in Table 1, revealed that the 
level of estragole was relatively low in these water infusions ranging between 
0.4 and 133.4 µg/25 mL infusion (Table 1). In the hot water extract prepared 
from sample 2, estragole could even not be detected (Table 1). Comparing the 
concentration of estragole in the hot water extracts to the total concentration 
of estragole in the dry fennel preparations revealed an extraction efficiency of 
estragole from fennel into the infusion equal to 0.1-2.3% (Table 1). 
Results obtained also show that the variation in the total estragole 
content as determined for the dry fennel preparations could not be attributed 
to the type of fennel (i.e. sweet or bitter) or the form (i.e. fine cut fennel material 
or whole fennel fruits). In fact, calculating the average estragole content showed 
the presence of 1.1 ± 0.4 and 1.3 ± 0.2 mg estragole/g dry weight in preparations 
of sweet (n=7) and bitter (n=8) fennel material, respectively. In addition, dry 
fennel preparations consisting of fine cut fennel material (n=23) or whole 
fennel fruits (n=7) were found to contain on average 1.3 ± 0.3 and 1.2 ± 0.2 mg 
estragole/g dry fennel preparation, respectively. In line with these findings, in 
water infusions prepared from 1 g sweet or bitter fennel material, the average 
estragole content was comparable (i.e. 9 ± 4 and 11 ± 4 µg estragole/25 mL 
infusion, respectively) indicating that the estragole content in infusions cannot 
be attributed to the type of fennel. However, the average estragole content 
in infusions prepared from whole fennel fruits (i.e. 3 ± 1 µg estragole/25 mL 
infusion) was found to be about 3-fold lower compared to the average content 
of estragole in infusions prepared from fine cut fennel material (i.e. 10 ± 2 µg 
estragole/25 mL infusion) demonstrating that the extraction efficiency of whole 
fennel fruits is lower compared to that of fine cut fennel material. 
Interestingly, it was shown that the average estragole content in water 
infusions prepared from fennel material (i.e. fine cut fennel material and whole 
fennel fruits) for which customary selections of the respective levels of estragole 
were done (samples 1-8, average estragole content of 5 ± 2 µg estragole/25 mL 
infusion prepared from 1 g dry material) was found to be about 3-fold lower 
compared to that of the remaining fennel tea preparations (samples 9-34, 
average estragole content of 14 ± 5 µg estragole/25 mL infusion). In addition, it 
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was even shown that estragole could not be detected in a water infusion that 
was prepared from sample 2. These results demonstrate that the use of fennel 
material containing low levels of estragole can have a marked eff ect on the 
estragole content in fennel teas and thus also on the potential risk for human 
health resulting from the use of fennel based teas.
Figure 2. Representative sections of UPLC chromatograms of a methanolic fennel extract (A) and a hot 
water extract (B). The insert presents the reduced scale of the same chromatogram. To allow 
chromatographic analysis, methanolic extracts were diluted in acetonitrile (1:10 v/v) whereas hot water 
extracts were analyzed undiluted. Peaks marked with an asterisk (*) were not identifi ed. Chromatograms 
were obtained at a wavelength of 225 nm.
Intake estimates and safety assessment of estragole resulting from drinking fennel 
based tea by adults
Using the estragole content in hot water extracts as determined in the present 
study, intake estimates up to 4.8 or 14.3 µg estragole/kg bw/day were obtained 
for a 70 kg person assuming the daily consumption of one or three cups of fennel 
based tea (Table 2). Table 2 presents MOE values that are equal to 200-70,000 
for the use of three cups of fennel based tea on a daily basis (i.e. 4.5-7.5 g fennel 
material) as used in the safety assessment made by the ESCO working group. 
For 10 of the 34 selected fennel preparations MOE values were calculated to be 
higher than 10,000 when assuming the use of three cups of fennel based teas 
as presented in Table 2. Interestingly, the fennel tea preparations for which MOE 
values lower than 10,000 were found all consisted of fi ne cut fennel material. 
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Assuming the daily consumption of one cup of fennel based tea throughout 
life, MOE values of 10,000 and higher were found for the vast majority (25 out 
of 34) of the selected fennel tea preparations (Table 2). In general, these fennel 
preparations consisted of whole fennel fruits or instant tea granules. It should 
be noted that also when assuming the daily use of one cup of fennel tea, 8 of 
the 9 samples for which MOE values lower than 10,000 were found consisted of 
fine cut fennel material and 1 of the 9 samples consisted of a mixture of fine cut 
fennel material and whole fennel fruits. 
Intake estimates and safety assessment of estragole resulting from drinking fennel 
based tea by infants
Infants are the main consumer group of homemade fennel based tea for 
symptomatic treatment of mild, spasmodic gastro-intestinal complaints. 
Therefore, a separate exposure estimate and subsequent safety assessment 
were made for this consumer group focusing on fennel based preparations that 
are specifically marketed for infants (i.e. sample 17, 18, 20 and 21). 
Table 3 shows the exposure estimates for estragole resulting from the 
use of homemade fennel based teas that are specifically marketed for infants. 
Exposure estimates were made based on the estragole content in the fennel 
preparations as determined in the present study in hot water extracts together 
with the amount of fine cut fennel material present in the tea bag assuming one 
cup of fennel based tea would be consumed on a daily basis (samples 17, 18 and 
21). For sample 20, consisting of instant tea granules, the weight of two whipped 
off tea spoons (the dose recommended by the respective manufacturer) was 
used to estimate the daily estragole intake. Exposure estimates reveal a daily 
intake of 0.5-6.5 µg/kg bw/day, 0.4-4.7 µg/kg bw/day, 0.3-3.6 µg/kg bw/day 
and 0.2-2.6 µg/kg bw/day for infants of 0-3 months, 3-6 months, 6-12 months 
and 12-36 months of age, respectively (Table 3). Comparing the BMDL10 values 
for estragole with the exposure estimates obtained, for samples 17, 18 and 
21 consisting of fine cut fennel material MOE values were found to generally 
be below 10,000 indicating a priority for risk management actions (Table 
3). However, it should be noted that for sample 20 consisting of instant tea 
granules MOE values of 10,000 and higher were found when tea prepared from 
this product would be consumed by infants of 6 months and older. 
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Table 3. Level of estragole in hot water extracts of fennel based tea preparations specifically marketed 
for infants, corresponding daily intake estimates and MOE values. 
Sample No.
Average ± STDEV 
(µg estragole/ 
25 mL infusion)
Daily intake fennel(g)a Daily Intake  
estragole
(µg/kg bw/day)b
MOEc
Infants 0-3 months of age
17 3.5 ± 1.1 1.5 1.1 3,000 – 6,000
18 8.8 ± 4.9 1.8 3.3 1,000 – 2,000
20 0.4 ± 0.1 6.0 0.5 6,000 – 10,000
21 15.6 ± 5.4 2.0 6.5 500 – 1,000
Infants 3-6 months of age
17 3.5 ± 1.1 1.5 0.8 4,000 – 8,000
18 8.8 ± 4.9 1.8 2.3 1,000 -3,000
20 0.4 ± 0.1 6.0 0.4 8,000 – 20,000
21 15.6 ± 5.4 2.0 4.7 700 – 1,000
Infants 6-12 months of age
17 3.5 ± 1.1 1.5 0.6 6,000 – 10,000
18 8.8 ± 4.9 1.8 1.8 2,000 – 4,000
20 0.4 ± 0.1 6.0 0.3 10,000 – 20,000
21 15.6 ± 5.4 2.0 3.6 900 – 2,000
Toddlers 1-3 years of age
17 3.5 ± 1.1 1.5 0.4 8,000 – 20,000
18 8.8 ± 4.9 1.8 1.3 3,000 – 5,000
20 0.4 ± 0.1 6.0 0.2 20,000 – 30,000
21 15.6 ± 5.4 2.0 2.6 1,000 – 3,000
 
a Daily intake of fennel is based on the weight of the respective teabags and granules assuming one cup 
of homemade fennel tea will be used on a daily basis 
b Daily intake estimates of estragole were obtained assuming a body weight of 4.8 kg, 6.7 kg, 8.8 kg, and 
11.9 kg for infants of 0-3 months of age, infants of 3-6 months of age, infants of 6-12 months of age and 
toddlers of 1-3 years of age respectively (EFSA, 2012b)
c MOE = BMDL
10
 (mg/kg bw/day)/ daily intake estragole (mg/kg bw/day)  
Discussion
In the present study, a safety assessment for estragole resulting from drinking 
fennel based tea was made using the MOE approach taking into account the 
previous work in the field by the ESCO working group (EFSA, 2009a) and reported 
in literature (Raffo et al., 2011). The results presented show that the consumption 
of fennel teas generally presents a low priority for risk management actions, 
especially when one cup of fennel tea is consumed by adults on a daily basis. 
 Based on the chemical analysis performed in the present study, 
estragole was detected in the selected 34 fennel samples in quantities equal to 
0.15-13.3 mg/g dry fennel preparation. This is comparable to the value resulting 
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from the assumption made by the ESCO working group of 5% essential oil 
containing 3.5-12% estragole which would give rise to 1.75-6 mg/g fennel material 
(EFSA, 2009a). Assuming that 4.5-7.5 g fennel material per day would be used for 
the preparation of fennel tea as described by the ESCO working group (EFSA, 
2009a) and that the extraction efficiency of the essential oil of fennel is 25-35% 
(EFSA, 2009a), the daily estragole intake would amount to 3-499 µg/kg bw/day 
for a person with a body weight of 70 kg, which is comparable to the estimate of 
33-263 µg/kg bw/day reported by the ESCO working group. However, this indirect 
worst case approach using levels of estragole in fennel material might represent 
an overestimation of the actual risk for human health resulting from the use of 
fennel tea. Raffo et al. (2011) indicated that the extraction efficiency of fennel 
essential oil into the infusion of 25-35% as used by the ESCO working group (EFSA, 
2009a) is relatively high leading to an overestimation of the estragole content 
in the infusion. In fact, Zeller and Rychlik (2006) experimentally determined the 
extraction efficiency for specific odorants occurring in fennel essential oil into an 
infusion demonstrating an extraction efficiency of 12% for estragole which is 2-3 
fold lower than the extraction efficiency of 25-35% used in the theoretical worst 
case approach reported by the ESCO working group (EFSA, 2009a). Therefore, in 
the present study hot water extracts were used representing tea preparation by 
consumers. Results revealed that the levels of estragole were indeed found to be 
remarkably lower in the hot water extracts compared to the total estragole content 
in dry fennel preparations (i.e. up to 1,000-fold). The extraction efficiencies obtained 
were 0.1-2.3% and thus lower compared to the extraction efficiency determined 
by Zeller and Rychlik (2006). This difference might be explained by the fact that 
Zeller and Rychlik (2006) prepared tea from freshly comminuted fennel fruits (2.5 
g in 150 mL hot water) while in the present study dried fine cut fennel material or 
intact fennel fruits were used. Raffo et al. (2011) previously indicated that estragole 
levels determined in water infusions prepared from intact fruits were 4-6 times 
lower compared to the levels in water infusions prepared from freshly comminuted 
fruits explaining the difference in extraction efficiency. Moreover, it is likely that 
fresh fennel fruits contain higher levels of volatile constituents including estragole 
compared to the packaged fennel materials used in the present study as a result 
of graduate losses of volatile constituents in crushed and/or powdered fennel 
material upon ageing (EMA, 2008). In fact, in teabags opened for a period of 30 days 
a 4-10% decrease in the level of essential oil was previously reported (EMA, 2008). 
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Calculation of the MOE values for the intake of estragole from fennel 
tea using the levels of estragole in the hot water extracts as determined in the 
present study resulted in MOE values that are generally above the default of 
10,000. In spite of this, for some -though not all- fennel based teas MOE values 
are still below 10,000 indicating a potential risk for human health and a priority 
for risk management actions. However, it is important to note that while the 
daily estragole exposure resulting from the consumption of tea prepared from 
1.5 to 2.5 g fennel material three times a day (i.e. 4.5-7.5 g fennel/day) might pose 
a potential risk for human health, the consumption of tea prepared from 1.5 to 
2.5 g fennel seeds one time a day does not. This is because in the latter situation 
MOE values above the default of 10,000 are obtained for the vast majority of 
samples, i.e. 25 out of 34 samples. Important to note is that for water infusions 
prepared from fine cut fennel material generally relatively low MOE values were 
obtained. In contrast, MOE values for water infusions prepared from whole 
fennel fruits or instant tea granules were calculated to be generally higher than 
10,000 indicating a low priority for risk management actions. In addition, the 
present study revealed that MOE values below 10,000 were obtained for infants 
of 0-3 years of age drinking one cup of fennel tea prepared from fine cut material 
on a daily basis indicating a priority for risk management. However, it should be 
noted that for infants of 6 months and older also MOE values above 10,000 were 
obtained for one sample consisting of instant tea granules. In fact, the label of 
the respective fennel based tea product recommends to use the product only 
for infants of 6-36 months of age which, based on the calculated MOE values 
of 10,000-30,000, would be a low risk. However, it must be emphasized that 
in the present chapter MOE values are calculated assuming lifetime exposure 
while homemade fennel based teas are generally only used during periods of 
gastrointestinal complaints. For this reason, calculation of the MOE values using 
the intake estimates as daily intake estimates might overestimate the potential 
risk for human health. However, a general framework for taking intermittent 
and/or short-term instead of lifetime exposures to genotoxic carcinogens into 
account in the safety assessment is currently not in place. Felter et al. (2011) 
recently proposed a framework for assessing the risk from less-than lifetime 
exposures to carcinogens. They proposed to use the principle of Haber’s Rule 
provided that chemical-specific carcinogenicity data are available and that data 
support a linear dose-response relationship (Felter et al., 2011). Haber’s Rule 
assumes that the acceptable cumulative lifetime exposure can be averaged 
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over the duration of short-term exposure, suggesting that higher daily intakes 
are acceptable when short-term exposure is considered (Felter et al., 2011). 
EMA previously indicated that fennel based teas should not be used for more 
than two weeks by adults and less than one week by children under the age 
of 12 (EMA, 2007). Applying Haber’s Rule to assess the potential risk for short-
term estragole exposure during a period of one week (children) and two weeks 
(adults) on an estimated life expectancy of 75 years might result in MOE values 
that are 3 orders of a magnitude higher than those obtained when assuming 
lifetime (75 years) daily use of fennel based tea. These results indicate that there 
may be no reason for risk management actions, when consuming three cups of 
fennel based tea on a daily basis for only two weeks. 
Obviously, the calculation of MOE values is based on BMDL10 data that 
are obtained from a long-term carcinogenicity study in which pure estragole 
was administered to rodents (Miller et al., 1983). However, the presence of a 
natural botanical matrix might modulate the bioactivation of estragole thereby 
lowering the potential cancer risk. In fact, Alhusainy et al. (2012) previously 
demonstrated that methanolic extracts from different herbs and spices were 
able to inhibit the sulfotransferase-mediated bioactivation of estragole. The use 
of such carcinogenicity data in safety assessment of fennel based teas might 
thus overestimate the actual risk. However, in the study of Alhusainy et al. (2012) 
it was shown that among the tested alkenylbenzene-containing herbs and 
spices, fennel did not show any effect on the sulfotransferase enzyme activity. 
Moreover, it was previously shown that matrix-derived combination effects may 
be limited at lower dose levels which are relevant for the use of botanicals and 
preparations made thereof (van den Berg et al., 2013). On the basis of these 
findings it can be concluded that the used BMDL10 values represent an adequate 
basis for the safety assessment of fennel based teas. 
As shown in the present study, the level of estragole in water infusions 
prepared from fennel can vary considerably depending on the estragole content 
present in the fennel material used. In addition, the estragole content in the 
water infusion might also depend on the preparation method used. Raffo et al. 
(2011) demonstrated that the extent of dilution has only a limited effect on the 
level of estragole extracted in the infusion. In contrast, squeezing the teabag 
to remove any residual water following the preparation of a fennel infusion 
was found to result in a considerable increase in the estragole content and 
was previously experimentally determined by Raffo et al. (2011) to equal 15% 
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and Zeller and Rychlik (2009) even demonstrated an increased extraction of 
estragole into the infusion equal to 45% (Zeller and Rychlik, 2009). In addition, 
the use of freshly comminuted fennel fruits was shown to increase the estragole 
content in the infusion by 4-6 fold compared to the use of intact fennel fruits 
(Raffo et al., 2011). It should be noted that reduction of the estragole content 
in fennel and fennel based teas is technically possible (Pank, 2003). This can be 
done by removing estragole from instant teas through fractionated distillation 
(Pank et al., 2003). Moreover, Zeller and Rychlik (2006) indicated that reduction 
of the estragole content in fennel tea would not influence the overall flavor 
of fennel tea. Reducing the estragole content is thus recommended to lower 
the potential risk for human health, if any, resulting from the use of fennel 
based teas. In fact, the estragole content of one of the analyzed fennel teas 
consisting of instant tea granules that was specifically marketed for infants of 
6 months and older (i.e. sample 20) was relatively low indicating that such a 
technology might have been applied to reduce the estragole content. However, 
although fractionated distillation can markedly reduce the estragole content 
in instant teas, this procedure cannot be applied to the fennel fruits in their 
original form which is the form most commonly used in the preparation of 
fennel based teas (Pank et al., 2003). Breeding new cultivars without estragole 
is not (yet) possible (Pank et al., 2003). Moreover, breeding new fennel cultivars 
with reduced estragole levels was found to result in reduced total essential 
oil contents including trans-anethole, which gives the characteristic flavor to 
fennel tea, meaning that these cultivars are of lower quality. 8 Of the 34 selected 
samples were prepared from fennel material obtained by customary selections 
of the levels of estragole. The average estragole content in the water infusions 
prepared from the respective fennel tea preparations (samples 1-8) was found to 
be about 3-fold lower compared to that of the remaining fennel teas. Moreover, 
estragole could even not be detected in fennel based tea prepared from sample 
2. This indicates that the use of fennel material with relatively low estragole 
levels can have a marked effect on the estragole intake resulting from the use 
of fennel based teas. 
In addition to estragole, the EFSA compendium indicates trans-anethole 
as a substance of possible concern for human health present in F. vulgare Mill. 
(EFSA, 2012a). For trans-anethole the Joint FAO/WHO Expert Committee on 
Food Additives (JECFA) derived a temporary acceptable daily intake (ADI) of 
0-2.0 mg/kg bw (JECFA, 1998), which can be used to define whether exposure 
27938 Berg, Suzanne vd.indd   195 24-04-14   12:58
Chapter 6
196
resulting from proposed uses and use levels will be safe. Zeller and Rychlik (2006) 
previously demonstrated that trans-anethole is the most abundant odorant in 
fennel fruit and in fennel based tea (i.e. 3600 µg trans-anethole in an infusion 
extracted from 1 g fennel material). Based on the level of trans-anethole detected 
by Zeller and Rychlik (2006) and assuming the daily consumption of one cup of 
fennel tea prepared from 1.5 to 2.5 g fennel material the daily intake of trans-
anethole would equal 77-129 µg/kg bw/day for a 70 kg person. Since this value 
is well below the ADI it can be concluded that the exposure to trans-anethole 
resulting from the use of fennel based tea is not of concern for human health.
Altogether, the present study showed that extraction efficiencies of 
estragole into the infusion were considerably lower than the 25-35% extraction 
efficiency used in the worst case exposure assessment performed by the ESCO 
working group. In general, extraction efficiencies were found to be lower for 
samples consisting of whole fennel fruits compared to that of samples consisting 
of fine cut fennel material indicating that exposure assessments should be done 
on a case-by case basis taking into account the physical characteristics of the 
product of interest. In fact, estragole levels were 3-fold lower in water infusions 
prepared from whole fennel fruits compared to that in water infusions prepared 
from fine cut fennel material. Also the use of fennel material with relatively 
low estragole levels obtained by customary selection to prepare fennel based 
teas resulted in reduced estragole levels of about 3-fold. The results obtained 
generally point at a low priority for risk management actions for the use of 
fennel teas, especially when consuming one cup of fennel tea on a daily basis 
prepared from 1.5 to 2.5 g fennel material. Moreover, assessing the risk from less-
than lifetime exposures to estragole resulting from the use of fennel based teas 
during a period of one to two weeks resulted in MOE values that are 3 orders of a 
magnitude higher indicating low priorities for risk management actions. Taken 
together, these results indicate a low priority for risk management actions and 
a low risk for human health for the use of fennel based teas especially for the 
short-term proposed uses of fennel based teas for the symptomatic treatment 
of digestive disorders alleviating mild spasmodic gastro-intestinal ailments. 
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General discussion 
To adequately support the safe use of plant food supplements (PFS), uniform 
and well accepted procedures for risk and safety assessment are essential. While 
many consumers equal ‘natural’ with ‘safe’, PFS may contain compounds that 
are of concern for human health. One of the main bottlenecks in the safety 
assessment of botanicals and botanical ingredients and thus also for PFS is the 
fact that some botanicals may contain compounds that are both genotoxic and 
carcinogenic. The risk assessment of such compounds is complicated and an 
international scientific agreement on the best practices for risk assessment of 
these type of compounds is currently lacking (EFSA, 2005). Therefore, the present 
thesis aimed at testing and validating new concepts that could be of use for the 
risk and safety assessment of PFS focusing on finding adequate ways to judge 
the risk or safety of PFS that may contain compounds that are both genotoxic 
and carcinogenic (Chapter 1). This work should ultimately give a better idea 
on when risk management actions would be needed, but also for which PFS 
there is no reason for concern even though they do contain limited amounts of 
compounds that may be genotoxic and carcinogenic. The new concepts tested 
and the results obtained are discussed below in some more detail. 
Selection of the PFS and compounds to be included 
Since a major unsolved issue in safety assessment of botanicals is how to deal with 
PFS that contain compounds that may be genotoxic and carcinogenic (Chapter 
2), the work started by making a thorough selection of botanical compounds that 
may be present in PFS and that exert genotoxic and/or carcinogenic properties. 
This work was described in detail in Chapter 3. Compounds were selected based 
on (1) information on genotoxic and carcinogenic botanical ingredients in the 
European Food Safety Authority (EFSA) compendium (EFSA, 2012a), (2) evidence 
of genotoxicity and/or carcinogenicity of plant constituents described in studies 
performed by the National Toxicology Program and (3) the expert judgment 
from partners collaborating under the PlantLIBRA project (acronym PLANT food 
supplements: Levels of Intake, Benefit and Risk Assessment) which is a European 
collaborative project under the Seventh Framework Programme. Based on 
this inventory, 30 compounds were selected. Two major groups of botanical 
genotoxic carcinogens were identified including the group of alkenylbenzenes 
(e.g. estragole, methyleugenol, safrole, β-asarone and elemicin) and the group 
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of unsaturated pyrrolizidine alkaloids (e.g. riddelliine and monocrotaline). Based 
on consultation with PlantLIBRA partners it was concluded that unsaturated 
pyrrolizidine alkaloids are currently already regulated and not allowed in PFS 
and that therefore further work should focus on the group of alkenylbenzenes. 
Testing the Margin of Exposure (MOE) concept for risk and safety assessment of PFS
For risk and safety assessment of genotoxic carcinogens, expert groups of 
EFSA, the Joint FAO/WHO Expert Committee on Food Additives (JECFA) and 
the International Life Sciences Institute (ILSI) have recommended the use of the 
Margin of Exposure (MOE) approach (Chapter 2). The MOE is a ratio between (1) a 
reference point from an animal experiment (e.g. a BMDL
10
, the lower confidence 
limit of the benchmark dose resulting in 10% extra cancer incidence) and (2) 
the estimated daily intake in humans (EFSA, 2005). MOE values lower than 
10,000 are considered as a priority for risk management actions and a concern 
for human health (EFSA, 2005). In Chapter 3 the use of the MOE approach was 
tested in the safety assessment of PFS containing the alkenylbenzenes which 
were selected as the model compounds of interest. For the alkenylbenzenes 
estragole, methyleugenol, safrole and β-asarone carcinogenicity studies were 
available in the literature from which BMDL10 values could be derived that 
are required for the MOE approach. MOE values were calculated by dividing 
these BMDL
10
 values by the estimated intakes of the compounds of interest. 
These intake estimates were based on experiments in which we analyzed the 
levels of the alkenylbenzenes in PFS obtained on the Dutch and Italian market 
and via Internet consisting of basil-, fennel-, nutmeg-, sassafras-, cinnamon-, 
or calamus-containing PFS. Using the results of these chemical analyses and 
the dose of the PFS recommended by the respective manufacturer, intake 
estimates were made and compared with the BMDL
10
 values to calculate MOE 
values. These calculations showed that many PFS contain alkenylbenzenes in 
such low amounts that the corresponding daily intakes result in MOE values 
up to 200,000 and are thus far above an MOE of 10,000. For these PFS one can 
conclude that although they contain compounds that are both genotoxic 
and carcinogenic they do not present a safety concern. However, for other 
basil-, fennel-, sassafras-, nutmeg- and calamus-containing PFS, MOE values 
lower than 10,000 were derived and for a few PFS even MOE values below 10 
were found indicating that the estimated daily intake of the alkenylbenzenes 
resulting from use of these PFS is in the range of dose levels causing liver tumors 
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in experimental animals. From this study it became clear that the MOE approach 
is highly useful to perform the risk assessment of PFS that contain compounds 
that are both genotoxic and carcinogenic, especially because it defines priorities 
for risk management showing that some PFS are safe whereas others may raise 
concerns. 
Testing the mode of action based concept for risk and safety assessment of PFS
A major limitation of the MOE approach is the fact that this approach requires 
carcinogenicity data to define the BMDL
10
, whereas for many botanical 
ingredients that are genotoxic and carcinogenic such carcinogenicity data are 
not available. Therefore, in Chapter 4 it was investigated whether a mode of 
action based approach could be used to do a read across from one compound to 
another and perform a risk assessment by the MOE approach for a compound for 
which tumor data are absent. To this end a mode of action based physiologically 
based kinetic (PBK) modeling approach was used to quantify the relative 
importance of bioactivation and detoxification of the model alkenylbenzene 
elemicin, for which no tumor data are available. The results obtained were 
compared to those obtained from the structurally related alkenylbenzenes 
estragole and methyleugenol for which tumor data are available. Based on this 
approach, a BMDL10 could be estimated for elemicin. Comparing this estimated 
BMDL
10
 with the estimated daily intake of elemicin from nutmeg-containing 
PFS resulted in high MOE values, suggesting that the exposure to elemicin due 
to use of PFS is of low priority for risk management actions. 
Testing the matrix-derived combination effect concept for risk and safety assessment 
of PFS
Safety and risk assessment of PFS is generally performed using data obtained 
from studies with pure compounds administered in the absence of the natural 
botanical matrix. However, the toxicity of the botanical compounds of interest 
may be modulated by the botanical matrix and this may affect the outcomes 
of the assessment. Therefore, in Chapter 5 a new science-based approach 
was applied to take matrix-derived combination effects into account. To this 
end the effects of compounds present in the matrix of basil-containing PFS 
on the bioactivation of estragole were characterized and quantified. Basil-
containing PFS, for which relatively low MOE values ranging between 1 and 
1,000 were obtained (Chapter 3), were selected as a showcase. Results revealed 
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that methanolic extracts of PFS consisting of powdered basil material could 
considerably inhibit sulfotransferase (SULT)-activity required for estragole 
bioactivation, whereas this effect was found to be limited for methanolic 
extracts of PFS consisting of basil essential oil. Nevadensin was identified as 
the major compound responsible for the SULT-inhibiting activity of methanolic 
extracts of PFS consisting of powdered basil material. Next, PBK modeling was 
performed to predict the in vivo effects of nevadensin on estragole DNA-adduct 
formation in rat and human liver. A considerable matrix-derived combination 
effect was predicted to occur in vivo when estragole would be tested in an 
animal experiment in the presence of the SULT inhibitor nevadensin at 
ratios detected in PFS. Based on the outcomes, a refined risk assessment was 
performed resulting in MOE values that were significantly higher than the MOE 
values derived using the tumor data obtained in the rodent study in which 
pure estragole was used without the natural botanical matrix being present. 
PBK modeling also revealed that the matrix-derived combination effects were 
dose dependent. At dose levels relevant for the use of PFS, which are lower than 
the levels tested in rodent bioassays, matrix-derived combination effects may 
be limited. The results provide an example of how PBK modeling can be used 
to study matrix-derived combination effects and how to take such effects into 
account evaluating the risks and safety of PFS. 
Safety assessment of botanical preparations other than PFS
The model compounds of the present thesis, alkenylbenzenes, are not only 
present in PFS but consumer exposure may also result from the use of herbal 
teas instead of PFS. Therefore, in additional studies of the present thesis safety 
assessment was also performed for botanical preparations in the form of herbal 
teas that may contain alkenylbenzenes. In Chapter 6, an analysis of the levels 
of the genotoxic and carcinogenic alkenylbenzene estragole in dry fennel 
preparations and in infusions prepared from packaged fine cut fennel material, 
whole fennel fruits or instant tea granules were quantified and an associated 
safety assessment was performed. Based on available tumor data from 
literature and the estimated daily intakes of estragole that would result from 
use of fennel based teas with the estragole levels determined in the present 
study, a safety assessment was performed using the MOE approach. For adults, 
the MOE values obtained were generally higher than the default of 10,000 
indicating a low priority for risk management, especially when consuming 1 
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cup of fennel tea on a daily basis during lifetime. However, when calculating 
the MOE values for use of fennel teas specifically marketed for children, values 
were obtained that were generally below 10,000 indicating a priority for risk 
management. However, one could argue that these MOE values are based on 
lifetime exposure whereas for use of fennel based teas for the symptomatic 
treatment of digestive disorders shorter exposure periods (1-2 weeks) may 
be more realistic. Assessing the potential risk for human health resulting from 
short-term exposure to estragole-containing fennel based teas (i.e. 1-2 weeks) 
on an estimated life expectancy of 75 years, may result in MOE values that are 
3-orders of magnitude higher than those obtained assuming lifetime exposure. 
The results obtained point towards a low priority for risk management and a 
low risk for human health, especially when considering the short-term use of 
fennel based teas proposed for the relief of gastrointestinal complaints. These 
results illustrate how to perform a safety assessment for botanical preparations 
other than PFS, also taking into account short-term exposure relevant for the 
botanical preparation of interest. 
Conclusions
The new concepts tested in this thesis focus on some of the major bottlenecks 
in risk assessment of PFS in order to improve the scientific basis for risk and 
safety assessment. The use of the MOE was found to be a valuable approach in 
the risk and safety assessment of PFS that can be used to set priorities for risk 
management actions. Moreover, the integrated approach of in vitro studies and 
mode of action based PBK modeling that was applied in this thesis was found 
to be a very useful addition to the risk and safety assessment of PFS based on 
the MOE approach since it facilitates read across thereby contributing to the 
reduction of the number of experimental animals used for the safety testing of 
PFS and it also provides a way to take matrix-derived combination effects into 
account. 
Future perspectives
This thesis presents the use of some new concepts in risk assessment of PFS. In 
the next sections some suggestions are given for steps to be taken in the near 
future for a further improvement of risk and safety assessment of PFS. Such 
steps include developing better models for extrapolation in risk assessment 
of PFS, and incorporating the matrix effects on absorption, distribution, 
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metabolism and excretion (ADME) characteristics and dynamic characteristics 
of active chemical substances in the risk assessment minimizing uncertainties 
in the MOE approach. Moreover, suggestions are given for the regulation of 
alkenylbenzene-containing PFS and a selection of the preferred concept in risk 
and safety assessment of botanicals and botanical preparations is made. 
Importance of better models for extrapolation in risk assessment of PFS
In risk assessment of genotoxic carcinogens a variety of qualitative and 
quantitative approaches is used (Barlow and Schlatter, 2010). Quantitative 
approaches often include dose-response data which are generally obtained 
from rodent bioassays since epidemiological data are often lacking (EFSA, 
2005). However, the use of such data requires quantitative extrapolation to 
realistic human exposure levels occurring in daily life which are usually much 
lower than the high dose levels used in standard 2-years rodent bioassays. For 
example, to quantitatively assess the potential risk for human health linear 
extrapolation can be applied to obtain a virtual safe dose (VSD) at which the 
additional lifetime cancer risk would be one in a million. However, low-dose 
cancer risk extrapolation has been widely discussed (EFSA, 2005) and is currently 
not generally accepted. In fact, it is often unknown if the mathematical model 
used for low-dose extrapolation actually describes the biological mechanisms 
underlying the toxic effect (EFSA, 2005) introducing uncertainties in the risk 
assessment. Better approaches for low-dose extrapolation are thus required. 
EFSA previously advised to use the MOE approach for compounds that are both 
genotoxic and carcinogenic (EFSA, 2005). Although in the present thesis the 
MOE approach was found to be highly useful to perform the risk assessment 
of PFS containing compounds that are both genotoxic and carcinogenic, the 
MOE does not quantify the risk for human health (Barlow et al., 2006). Therefore, 
future developments should still work on also developing accepted models to 
do quantitative risk assessment and quantify risks at low dose levels. This may 
require that sensitivity of endpoints may need to be increased since for example 
one in a million cancer risks cannot be experimentally determined. In other 
words, models and assays are required which are sensitive enough to detect 
effects in humans at realistic exposure levels already occurring in daily life. An 
example of a new method in risk assessment is the development of genomics-
derived biomarkers of effect which could provide insight into responses 
occurring at low exposure levels relevant for humans which are generally not 
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detected using conventional toxicity studies (Paules et al., 2011). However, it 
should be noted that it is unknown whether or not such -omics effects actually 
represent adverse effects. In addition, PBK models may help to reduce the 
uncertainty in low-dose extrapolation. PBK modeling allows studying effects at 
low dose levels relevant for the human situation. In fact, using PBK modeling, 
the occurrence of (non-)linear effects and/or thresholds can be studied at 
relatively low dose levels, which often remain undetected in animal experiments. 
Moreover, PBK models might be extended to physiologically based dynamic 
(PBD) models to predict tumor incidences occurring at low realistic intake levels 
to quantify the ultimate carcinogenic effect. The development of such a PBD 
model requires the description of dynamic characteristics in addition to the 
kinetic characteristics used in a PBK model. Dynamic characteristics that can be 
included to describe the mode of action of the compound of interest, such as 
the alkenylbenzenes, are DNA-adduct formation, DNA repair, gene and protein 
expression, mutation modulation and ultimately tumor formation (Paini, 2012). 
Another issue is that the relevance of the carcinogenicity findings in rodent 
bioassays for human cancer risks may be questioned. To adequately perform risk 
assessment it is of importance to take various uncertainties into account such 
as interspecies differences in kinetics and dynamics. To address this bottleneck 
in risk assessment of genotoxic carcinogens, PBK and PBD models can be used 
in the near future to quantify species-dependent differences in the kinetics and 
dynamics of the compound of interest allowing a more reliable interspecies 
extrapolation. These insights may result in definition of compound specific 
uncertainty factors that can be used to refine the risk assessment.
In addition, in the present thesis the incidences of hepatomas as 
observed in a long-term carcinogenicity study were refined based on the 
outcomes of the PBK model assuming a linear relationship between the reduced 
formation of estragole DNA-adduct formation predicted by the PBK model and 
the reduction in the hepatoma incidence. However, such a relation has not yet 
been established and the PBK models used in this study do not present full 
insight in such a relationship introducing uncertainties in the risk assessment. 
Moreover, DNA-adduct formation is often considered as a biomarker of exposure 
and not as a biomarker of effect (Brink et al., 2009; La and Swenberg, 1996; Paini 
et al., 2011; Swenberg et al., 2008). To address these uncertainties, PBD models 
can be developed and used in future risk assessment to provide insights in the 
relationship between DNA-adduct formation and tumor formation facilitating 
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better risk and safety assessments of compounds that are both genotoxic and 
carcinogenic. In fact, based on the insights in the relationship between the 
reduced formation of estragole DNA-adduct formation and the reduction in 
the hepatoma incidence obtained by applying PBD models, uncertainty factors 
used to describe inter- and intraspecies differences in dynamics can be adjusted. 
For example, to take into account interspecies differences, a default uncertainty 
factor of 10 is normally used which can be divided into a factor of 4 for kinetics 
and 2.5 for dynamics (IPCS, 2010). The outcomes of PBK modeling can provide 
scientific evidence to increase or decrease the default of 4 for kinetics, and 
the outcomes of PBD modeling can provide scientific evidence to increase or 
decrease the default of 2.5 for dynamics. 
Matrix–derived combination effects in risk and safety assessment of botanicals
Whereas risk assessments generally address the potential risks for human 
health based on toxicity studies that are performed using individual chemicals, 
botanicals generally are complex mixtures consisting of numerous chemicals 
including primary metabolites such as carbohydrates, lipids and proteins, as 
well as secondary metabolites such as, for example, compounds belonging to 
the groups of alkaloids, terpenoids, steroids, saponins, phenolics and flavonoids 
which occur in a wide variety of botanicals (Vanisree et al., 2004). Botanicals 
may also include smaller groups of secondary metabolites such as the 
alkenylbenzenes. In principle, the numerous chemicals present in botanicals 
and botanical preparations may result in interactions that could affect the 
absorption, distribution, metabolism and excretion (ADME) characteristics as 
well as the toxicity of the individual active substance. Thus, the use of toxicity 
data of individual active substances might not represent an adequate starting 
point for risk assessment of botanicals and botanical preparations. In fact, 
Schilter et al. (2003) previously described that the use of toxicity data obtained 
from experiments in which individual active substances were used could be 
questioned when used in the risk assessment of complex botanical materials 
(Schilter et al., 2003). Possible consequences and examples of botanical matrix-
derived combination effects on the ADME characteristics of active chemical 
substances are described below.
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Matrix-derived combination effects on absorption
An aspect that needs consideration is that the botanical matrix can modulate 
the rate and extent of absorption of the active substance altering its toxicity. 
For example, as a consequence of the slow and/or incomplete release of the 
active substance from its botanical matrix the level of bioavailability might be 
reduced compared to the situation in which the pure compound is administered 
(Schilter et al., 2003). For example, Al-Subeihi et al. (2012) demonstrated that 
PBK model based predicted venous blood levels of methyleugenol assuming 
100% bioavailability were an order of magnitude higher compared to the 
bioavailability of methyleugenol from gingersnaps served as a breakfast 
together with orange juice observed in a human intervention study (Al-Subeihi 
et al., 2012). The PBK based prediction would actually fit the observed data when 
the bioavailability of methyleugenol from the gingersnaps and orange juice 
breakfast would have been 13.8%. Another example of reduced bioavailability 
due to matrix interactions was demonstrated for β-carotene (van het Hof et al., 
1999). Van het Hof et al. (1999) reported that the bioavailability of β-carotene 
present in a matrix of mixed vegetables equals 14% compared to that of purified 
β-carotene. In addition, Adam et al. (2002) showed that the bioavailability of 
ferulic acid is considerably lower in the presence of a food matrix (e.g. cereals). 
In fact, in rats only 3% of the ingested dose of ferulic acid was recovered in 
urine following the exposure to ferulic acid in a complex cereal matrix of 
Triticum durum whereas about 50% of the ingested dose was recovered in urine 
following the exposure to ferulic acid enriched semipurified diets (Adam et al., 
2002). In contrast, Chen et al. (1997) demonstrated that the rate of absorption of 
(-)-epigallocatechin-3-gallate (EGCG) was about 4-fold higher in rats following 
the combined exposure to EGCG and decaffeinated green tea (equivalent dose 
of EGCG of 15 mg/kg) in comparison to the situation in which pure EGCG (75 mg/
kg) was intragastrically administered to the rats (Chen et al., 1997). Moreover, it 
is of importance to note that several flavonoids have been reported to inhibit 
various transporters located in the basolateral or apical membrane in cells of the 
intestinal epithelial barrier affecting the bioavailability of chemical compounds 
upon oral uptake (Brand et al., 2006). Inhibition of apical transporters that 
transport compounds out of the intestinal cells back to the intestinal lumen may 
facilitate systemic uptake, whereas inhibition of basolateral transporters that 
transport compounds from the intestinal cell to the systemic circulation may 
oppose bioavailability. Flavonoids are present in a wide variety of botanicals 
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and therefore it is likely that these compounds may affect the bioavailability 
of substances of concern occurring in the botanical or botanical preparation 
of interest. 
 
Effects on distribution 
Matrix-derived combination effects can also occur at the level of distribution. 
Chen et al. (1997) revealed that the distribution of EGCG was different when 
pure EGCG (10 mg/kg) was administered intravenously to rats than when given 
intravenously in combination with decaffeinated green tea (equivalent dose of 
EGCG of 1.8 mg/kg) (Chen et al., 1997). Results showed that the concentrations of 
EGCG found in the plasma and the area under the plasma concentration versus 
time curve of total EGCG (i.e. free and conjugated EGCG) were lower following 
the intravenous exposure to pure EGCG compared to the exposure to EGCG in 
a matrix of decaffeinated green tea. In addition, a larger distribution volume 
was observed following the treatment with pure EGCG than in the situation in 
which rats were exposed to decaffeinated green tea consisting of EGCG. The 
authors concluded that these differences might be due to a faster distribution 
of EGCG in the body following exposure to pure EGCG compared with the 
exposure to EGCG in a matrix of decaffeinated green tea (Chen et al., 1997). An 
underlying reason for this observation could be that the parent EGCG is more 
rapidly conjugated, which may result in a faster distribution and excretion of 
metabolites, when exposed to pure EGCG compared to EGCG administered in 
a matrix of decaffeinated green tea (Chen et al., 1997). 
 
Effects on metabolism
In addition to the possible alterations in the rate and extent of absorption and 
distribution, the botanical-derived matrix may have an effect on the metabolism 
of the active chemical substance(s) of interest. Effects can occur at the level of 
phase I and phase II metabolism. Previous studies demonstrated the inhibitory 
effects of some flavonoids (e.g. naringin, naringenin, kaempferol and quercetin) 
and furanocoumarin (e.g. bergamottin and 6’,7’-dihydroxybergamottin) 
occurring in grapefruit juice on the activity of cytochrome P450 3A4 (CYP3A4) 
(De Castro et al., 2006; Ho et al., 2001). The grapefruit juice-mediated inhibition 
of human CYP3A4 activity in the small intestine or the liver, may reduce the 
level of pre-systemic metabolism of prescription drugs by CYP3A4 thereby 
increasing their oral bioavailability (Bailey et al., 1998). 
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Another example of botanical ingredients that can interact with the 
pharmacokinetics of prescription drugs are compounds present in St. John’s 
wort. When concomitantly consumed, St. John’s wort can induce CYP3A4 
activity resulting in a decrease of plasma levels of several prescription drugs 
including alprazolam, irinotecan and indinavir (Gurley et al., 2005; Markowitz et 
al., 2003; Mathijssen et al., 2002; Piscitelli et al., 2000). In addition, St. John’s wort 
may interfere with the efficacy of oral contraceptives (Hall et al., 2003; Murphy 
et al., 2005). 
Furthermore, a matrix-derived combination effect was previously 
shown for the bioactivation of the alkenylbenzene estragole at the level 
of sulfotransferase mediated bioactivation. Estragole and its structurally 
related analogues are not genotoxic or carcinogenic as such, but have to 
be metabolized into a 1’-sulfoxymetabolite that can covalently bind to DNA 
(Boberg et al., 1983; Phillips et al., 1981; Phillips et al., 1984; Randerath et al., 1984; 
Wiseman et al., 1985; Wiseman et al., 1987). Jeurissen et al. (2008) showed that 
the level of estragole bioactivation and DNA-adduct formation was significantly 
reduced in incubations with rat and human liver S9 and in the human HepG2 
liver cell line following co-exposure to 1’-hydroxyestragole, the proximate 
carcinogen of estragole, and a methanolic basil extract (Jeurissen et al., 2008). 
The flavonoid nevadensin was identified as the major compound responsible 
for this observed in vitro inhibition of estragole bioactivation and subsequent 
DNA-adduct formation by the methanolic basil extract (Alhusainy et al., 2010). 
In a subsequent study in which rats were simultaneously dosed with estragole 
and nevadensin it was shown that nevadensin is also able to significantly inhibit 
DNA-adduct formation in vivo (Alhusainy et al., 2013). The results obtained in this 
thesis also indicate that data derived from carcinogenicity studies administering 
pure estragole to rodents in the absence of other botanical compounds may 
result in an overestimation of the adverse effects (Chapter 5). However, it should 
be noted that the matrix-derived combination effect may be dose-dependent. 
In fact, in Chapter 5 it was shown that while the matrix-derived combination 
effect was observed at dose levels used in rodent bioassays, the effect may be 
only limited at realistic human exposure levels resulting from the use of PFS. 
The effects observed when botanicals and botanical preparations including PFS 
would be tested in rodent bioassays would thus not be representative for the 
human situation and does not provide a good starting point for risk assessment. 
Based on the results of the present thesis it may even be concluded that the 
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experiments with the pure compound may provide a better starting point for 
the risk assessment than testing of the botanical itself. This indicates that the 
incorporation of the matrix-derived combination effect in the risk assessment 
of botanicals and botanical preparations should be done on a case-by-case 
basis taking into account analysis of the dose dependency of the interactions 
detected. 
 
Effects on excretion 
Combined exposure may not only affect the level of formation of the metabolites 
responsible for induction of adverse effects but may also alter formation of 
metabolites that can be excreted. Although limited studies are available in 
literature describing matrix-derived effects on excretion, an example of such an 
effect can be found in the study reported by Chen et al. (1997) who showed that 
the presence of a matrix of decaffeinated green tea influenced the elimination 
rate of EGCG in rats. In fact, in rats EGCG was found to be more rapidly eliminated 
following the intravenous or intragastric administering of pure EGCG compared 
to that following the concomitant exposure with decaffeinated green tea (Chen 
et al., 1997). Competition for the binding sites in metabolizing enzymes by 
polyphenols present in decaffeinated green tea might result in lower metabolic 
conversion and consequently a decreased level of elimination compared with 
pure EGCG (Chen et al., 1997). 
In addition, also in the process of excretion of several botanical 
ingredients transporters might be involved. As a result, compounds that exert 
an effect on transporters may also affect excretion. 
 
Conclusion  
Based on these findings, it can be concluded that matrix-derived combination 
effects can have a marked effect on ADME characteristics of chemical substances 
potentially affecting toxicity. Therefore, risk assessment should not only focus on 
individual substances but should take into account possible consequences of 
the botanical matrix-derived combination effects on the ADME characteristics 
and on dynamic processes to accurately determine the risk for human health. An 
example of how matrix-derived combination effects at the level of metabolism 
can be included in the risks and safety assessment of PFS is provided in Chapter 
5 of the present thesis. 
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Uncertainties in the MOE approach
The results of the present thesis demonstrate that the MOE approach can be of 
use in risk assessment and setting priorities for risk management of PFS. When 
applying this MOE approach an MOE value of 10,000 or above is generally 
considered as a low priority for risk management actions. This value of 10,000 
is based on the following considerations and uncertainties; (1) a factor 100 to 
take into account species differences and human variability in kinetics and 
dynamics, (2) a factor of 10 for inter-individual human variability in cell cycle 
control and DNA-repair and (3) a factor of 10 for the reason that the reference 
point is not equivalent to a no observed adverse effect level (NOAEL) and effects 
can occur at lower doses (EFSA, 2005). EFSA previously stated that the safety 
factors used to describe species differences and human variability in kinetics 
and dynamics can be adjusted based on the availability of appropriate chemical 
specific data (EFSA, 2005). However, a clear guidance on how this should be 
done is not provided. The results obtained in the present thesis indicate that 
species-dependent effects in the metabolism of the compound of interest can 
be obtained by developing PBK models for different species allowing a reliable 
interspecies extrapolation. The PBK model outcomes obtained in Chapter 4 of 
the present thesis revealed that the relative extent of bioactivation of elemicin 
in human was 3.8-fold lower than in rat at concentrations relevant for the daily 
human exposure to elemicin through the daily diet. Resulting from the fact that 
the bioactivation of elemicin in human was lower compared to that of rat, using 
the default approach can be considered as too conservative and the default 
factor of 4 for species differences in kinetics (IPCS, 2010) can thus be removed 
from the total MOE default factor of 10,000. As a result, a default MOE of 2,500 
could be considered assessing the risk for human health resulting from the daily 
exposure to elemicin through the human diet. In fact, one could argue if the 
uncertainty factor for interspecies differences can even be 3.8-fold lower since 
bioactivation of elemicin in humans is not 4-fold higher or equal compared 
to rat but even 3.8-fold lower. This would result in a relatively low MOE value 
of about 650. This presents an example how PBK modeling can be integrated 
in risk assessment to provide a scientific basis on whether or not and how to 
adjust the default value of 10,000 used in the MOE approach, using so-called 
compound specific uncertainty factors. 
 Another issue to consider is that although EFSA previously stated that a 
lower MOE presents a higher priority for risk management actions, guidance on 
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banding MOE values is not provided. ILSI previously proposed to use logarithmic 
intervals (i.e. 1–100; 100-1,000; 1,000–10,000; and 10,000-100,000) for banding 
MOE values (ILSI, 2009). However, an international consensus is still lacking. 
Banding MOE values might improve communication between risk assessors 
and risk managers facilitating better priority setting for risk management 
actions. For example, based on the results obtained in Chapter 3, it can be 
concluded that in some cases the daily dose of estragole resulting from the use 
of basil-containing PFS was equivalent to the dose causing malignant tumors 
in experimental animals (i.e. MOE of 1). In addition, also considerably higher 
MOE values of 3,000-7,000 were found for fennel-containing PFS consisting of 
estragole. Although being all lower than the default of 10,000, and leading to 
the conclusion there is a priority for risk management, it may be considered 
that these MOE values indicate a different priority for risk management actions. 
To facilitate such a differentiated approach, banding of MOE values would be 
required to indicate if the priority for risk management actions is for example 
very high, high, moderate, low or negligible. 
Generally, MOE values are calculated using BMDL10 data obtained from 
long-term carcinogenicity studies. EFSA previously indicated that the use of 
such long-term carcinogenicity studies to derive an MOE might be conservative 
when short-term exposure is considered (EFSA, 2005). Assessing the potential 
risk for human health resulting from short-term exposure might be challenging 
as a general framework for the safety assessment of short-term exposures 
to genotoxic carcinogens is lacking. Nonetheless, based on a workshop by 
a committee of the ILSI Health and Environmental Sciences Institute held in 
2009, a framework for assessing the risk from less-than lifetime exposures 
to carcinogens was proposed (Felter et al., 2011). Based on the framework 
proposed, the potential risk for human health resulting from less-than lifetime 
exposures to carcinogens can be assessed using the principle of Haber’s Rule 
(Felter et al., 2011). Applying Haber’s Rule, the availability of chemical-specific 
carcinogenicity data and data that support a linear dose-response relationship 
are a prerequisite (Felter et al., 2011). Haber’s Rule assumes that the acceptable 
cumulative lifetime exposure can be averaged over the duration of short-term 
exposure, suggesting that higher daily intakes are acceptable when short-term 
exposure is considered (Haber, 1924). Chapter 6 of this thesis describes the 
application of Haber’s Rule in the MOE approach to assess the potential risk 
for short-term estragole exposure via fennel based tea for the symptomatic 
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treatment of digestive disorders alleviating mild spasmodic gastro-intestinal 
ailments. MOE values were estimated to be three orders of a magnitude 
higher when fennel based tea would be used for a period of only 1 or 2 weeks 
relevant for the use of fennel based tea, compared to lifetime (75 years) daily 
use of fennel based tea. These results indicate that assuming life-time daily 
exposure in safety assessment of fennel based teas might overestimate the 
actual risk. The framework proposed can also be applied in the risk assessment 
of alkenylbenzene-containing PFS. It is important to note that the duration 
of consumption of (specific) PFS remains unclear adding uncertainty to the 
exposure assessment. Assuming that a PFS is used for a period of only 6-months 
on an estimated lifetime expectancy of 75 years, MOE values would be derived 
that are 150-fold higher than those presented in Chapter 3. Table 1 shows 
the MOE values obtained assuming lifetime exposure and those assuming 
short-term exposure (6-months) obtained by applying Haber’s Rule. The 
results obtained indicate that there may be no reason for risk management 
actions for the vast majority of PFS (19 out of 24) when consumed for only 
6-months daily during lifetime (Table 1; bold figures). However, results clearly 
show that even when assuming short-term exposure especially the use of PFS 
consisting of essential oils is of priority for risk management actions and is a 
potential risk for human health. Thus, in cases where the duration of exposure 
is much shorter than lifetime exposure, the use of the MOE based on lifetime 
exposure estimates might overestimate the actual risk for human health. 
These results demonstrate the need for an internationally agreed scientific 
framework to assess the short-term dietary intakes of genotoxic carcinogens 
present in botanicals and botanical preparations using the MOE approach. 
 Based on the considerations described above it is concluded that 
it should be encouraged to further refine the MOE approach to minimize 
uncertainties, ultimately improving the quality of risk assessment. 
Suggestions for regulation of alkenylbenzene-containing PFS
Within the EU, the addition of pure estragole, methyleugenol (Regulation (EC) 
No 1334/2008 of the European Parliament and of the Council 16 December 
2008), safrole and β-asarone (Council Directive 88/388/EEC of 22 June 1988) 
to food is currently prohibited. In addition, for several food categories 
including dairy products, fish products and non-alcoholic beverages maximum 
levels of these alkenylbenzenes, naturally present in flavorings and food 
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ingredients with flavoring properties have been defined (Regulation (EC) No 
1334/2008 of the European Parliament and of the Council 16 December 2008). 
Table 1. MOE values for different alkenylbenzene-containing PFS assuming lifetime exposure or short-
term exposure. MOE values lower than 10,000 are printed in bold.
Botanical in supplement MOE assuming lifetime exposure 
(75 years)
(van den Berg et al., 2011)
MOE assuming short-term  
exposure (6-months)
Basil
1* E: 1 E: 150
ME: 700-3,000 ME: 100,000-500,000
2* E: 6-40 E: 900-6,000
S: 400-5,000 S: 60,000-800,000
ME: 5,000-7,000 ME: 800,000-10,000,000
3 E: 200-1000 E: 30,000-200,000
ME: 20,000-200,000 ME: 3,000,000-30,000,000
4* E: 1-3 E: 200-500
ME: 700-5,000 ME: 100,000-800,000
5 E: 400-1,000 E: 60,000-200,000
ME: 1,000-10,000 ME: 200,000-2,000,000
Fennel
1 E: 200-300 E: 30,000-50,000
2 E: 200-700 E: 30,000-100,000
3 E: 40-80 E: 6,000-10,000
4 E: 90-200 E: 10,000-30,000
5 E: 2,000-7,000 E: 300,000-1,000,000
6 E: 3,000-7,000 E: 450,000-1,000,000
7 E: 700-1,000 E: 100,000-200,000
Sassafras
1 S: 2,000-10,000 S: 300,000-200,0000
2 S: 100-300 S: 20,000-50,000
ME: 20,000-70,000 ME: 3,000,000-10,000,000
3 S: 600-2,000 S: 90,000-300,000
4 S: 600-5,000 S: 90,000-800,000
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Botanical in supplement MOE assuming lifetime exposure 
(75 years)
(van den Berg et al., 2011)
MOE assuming short-term  
exposure (6-months)
Nutmeg
1 S: 50-400 S: 8,000-60,000
ME: 1,000-10,000 ME: 200,000-2,000,000
2 S: 9-100 S: 1,000-20,000
ME: 200-6,000 ME: 30,000-900,000
3 S: 200-400 S: 30,000-60,000
ME: 2,000-8,000 ME: 300,000-1,000,000
4 ME: 2,000-9,000 ME: 300,000-1,000,000
Calamus
1 BA: 600-4,000 BA: 90,000-600,000
2 BA: 1,000-7,000 BA: 200,000-1,000,000
3 BA: 20-30 BA: 3,000-5,000
4 BA: 600-1000 BA: 90,000-200,000
* Botanicals consisting of essentials oils  
E, estragole; ME, methyleugenol; S, safrole; BA, β-asarone 
In contrast, such regulations are not in place for the use of alkenylbenzene-
containing PFS. This is remarkable since some of the PFS selected and analyzed 
in Chapter 3 such as the PFS consisting of basil essential oil were found to 
contain highly concentrated levels of estragole (i.e. 32.71-241.56 mg estragole/g 
PFS). For these PFS, MOE values below 10 were derived indicating that the 
daily exposure to estragole resulting from the use of these PFS is in the range 
of dose levels causing liver tumors in experimental animals. Moreover, even 
when considering short-term exposure of only 6-months throughout lifetime, 
relatively low MOE values would be derived (i.e. 150-6,000) for PFS consisting 
of basil essential oil indicating a priority for risk management actions (Table 1). 
These results point towards the need for better regulation and quality control 
of PFS containing alkenylbenzenes. In line with regulation (EC) No 1334/2008 
of the European Parliament and of the Council, maximum levels could also 
be established for the presence of alkenylbenzenes in PFS to protect human 
health. Such a regulation would restrict the use of PFS containing highly 
concentrated levels of alkenylbenzenes such as PFS consisting of the essential 
Table 1 (continued). MOE values for different alkenylbenzene-containing PFS assuming lifetime 
exposure or short-term exposure. MOE values lower than 10,000 are printed in bold.
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oils of alkenylbenzene-containing botanicals. This would facilitate authorities 
to take regulatory actions to remove alkenylbenzene-containing PFS from the 
market that are of concern for human health. 
Selection of the preferred approach in risk and safety assessment of botanicals and 
botanical preparations
In the present thesis different concepts that could be of use for the risk and safety 
assessment of PFS were tested which included the MOE concept, the mode 
of action based concept and the matrix-derived combination effect concept. 
Consequently, various advantages of the use of these concepts were defined. 
Moreover, some limitations came across when testing the MOE concept, the 
mode of action based concept and the matrix-derived combination effect 
concept for risk and safety assessment of PFS. 
Table 2 summarizes the advantages and limitations that were 
encountered when using the MOE approach in the risk assessment of PFS. The 
main limitations of the MOE concept seem to be related to data availability 
and variability, introducing uncertainties up to one or even more orders 
of magnitude in the MOE approach or even making use of the approach 
impossible. However, whenever data are available the MOE concept proved to 
provide an easy way to set priorities in the risk management of genotoxic and 
carcinogenic botanical ingredients for (1) different compounds, (2) different 
sources of exposure including PFS and teas amongst others and (3) different 
groups within the population e.g. children and adults.
Table 3 provides an overview of the advantages and limitations that were 
met when using the mode of action concept using PBK models to evaluate the 
risks of low dietary exposure levels. The main limitation of PBK modeling seems to 
be related to the validation of the developed model in the absence of appropriate 
in vivo data quantifying the concentrations of the formed metabolites in blood 
or urine. Despite this limitation, PBK models were found to be a useful method 
in evaluating the possible risk for human health resulting from the exposure 
to elemicin since the developed models can quantify the relative importance 
of bioactivation and detoxification facilitating a read across from rat to human 
and from one compound to another. The use of such models can considerably 
contribute to further reduction in the use of experimental animals and provides 
a way to obtain clear insights in bioactivation and detoxification at relatively low 
exposure levels which remain undetected in animal studies. 
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Some advantages and limitations were defined in the incorporation of 
the matrix-derived combination effects in the risk assessment of PFS by means 
of PBK modeling which are presented in Table 4. The major limitation to the 
use of PBK models to take matrix-derived combination effects into account in 
the risk assessment of PFS seems to be related to the fact that only few PBK 
models have currently been developed for botanical ingredients. In spite of 
this limitation, PBK models were found to be a valuable tool in incorporating 
the matrix-derived combination effect for the bioactivation of estragole from 
basil-containing PFS in the risk assessment of these products. 
Another approach that can be used in the risk assessment of genotoxic 
carcinogens is the Threshold of Toxicological Concern (TTC) concept that is 
based on setting a generic human exposure threshold value for chemicals below 
which there is a low probability of adverse effects on human health (Kroes et al., 
2004). According to this approach, a level of exposure below the TTC represents 
an insignificant risk for human health and the approach can be applied to many 
chemicals with the relevant TTC being defined on the basis of available toxicity 
data from structurally related compounds (Kroes et al., 2004). Therefore, the 
TTC approach can even be applied for chemicals of unknown toxicity on the 
condition that their chemical structure is known. For substances containing a 
structural alert for possible genotoxicity a TTC of 0.15 µg/day is suggested which 
equals 0.0025 µg/kg bw/day for a 60 kg person (Kroes et al., 2004). However, a 
TTC should not be considered for high potency genotoxic chemicals including 
aflatoxin-like compounds, N-nitroso-compounds and azoxy-compounds since 
compound-specific risk assessment is required for these groups (Kroes et al., 
2004). Table 5 shows the estimated daily intake of estragole, methyleugenol, 
safrole and β-asarone resulting from the use of PFS as determined in Chapter 
3. Comparing these estimated daily intakes of the alkenylbenzenes with the 
TTC value of 0.0025 µg/kg bw/day for a 60 kg person, it can be concluded that 
the use of such alkenylbenzene-containing PFS exceeds the defined TTC for 
genotoxic compounds thus suggesting that the absence of a potential risk for 
human health cannot be assumed. EFSA previously stated that “it is possible 
to make an approximate comparison between the MOE approach and the TTC 
approach.
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For a substance with an MOE of 10,000 based on a tumor incidence of 10%, and 
assuming the dose-response is linear, the human exposure would correspond 
to an upper bound risk of less than 1 in 100,000 (10-5 risk). The TTC value of 
0.15 µg/day is derived by linear extrapolation down to a 1 in a million risk (10-6 
risk). Thus, substances with an exposure below the TTC value, if they were to 
be tested and were shown to be genotoxic carcinogens, they can be expected 
to have MOE values of 100,000 or more.” (EFSA, 2012b). In line with this, Table 
5 shows that whenever the TTC for genotoxic compounds was found to be 
exceeded, MOE values of 100,000 or lower were generally found. Moreover, 
in line with the results from the MOE concept, results obtained using the TTC 
concept indicated a priority for risk management actions at the proposed 
use levels of PFS containing the alkenylbenzenes estragole, methyleugenol, 
safrole or β-asarone. However, some differences can be indicated for specific 
PFS especially for methyleugenol-containing PFS. For example, the exposure to 
methyleugenol resulting from the use of a sassafras containing PFS is suggested 
to be a low concern for human health based on the MOE approach. On the 
contrary, making use of the TTC approach, the exposure to this compound 
was found to exceed the TTC of 0.0025 µg/kg bw/day indicating the need for 
compound-specific toxicity data. These discrepancies can be explained by 
the fact that the MOE uses 1 in 10-5 risk while the TTC uses 1 in 10-6 risk as the 
cut off. An additional reason for this discrepancy is the inclusion of data from 
carcinogenicity studies when using the MOE approach, while the TTC approach 
does not make a distinction between the carcinogenic potencies for specific 
compounds. Table 6 describes several advantages and disadvantages of the 
use of the TTC approach in safety assessment of botanicals and/or botanical 
preparations that contain compounds that are genotoxic and carcinogenic. In 
general, the TTC concept can be a practical approach for the safety assessment 
of botanical ingredients. However, the use of the TTC approach, but also 
the use of the MOE approach, greatly depends on the quality of daily intake 
estimates for a particular chemical reflecting the major drawback of the use 
of these approaches in the risk assessment of the consumption of botanicals 
and botanical preparations including PFS since appropriate human exposure 
estimates resulting from the use of such products are scarce.
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However, when sound intake estimates are available, the TTC approach can be 
used as a “preliminary step in the risk assessment process to aid in the assessment 
of whether chemical-specific toxicity data are necessary” ultimately resulting in 
a reduction of time, costs, expertise and animal use when human intakes are 
found to be below the TTC for the respective chemical of interest (Kroes et al., 
2004). Since a major limitation of the MOE approach was found to be the lack 
of carcinogenicity studies, the TTC approach could be used to conclude on the 
safety of the intake of PFS containing genotoxic and carcinogenic ingredients 
in the absence of carcinogenicity data. 
Altogether, the concepts tested in the present thesis were found 
to provide adequate ways to judge the risk or safety of PFS that contain 
compounds that are both genotoxic and carcinogenic. The MOE concept is 
a practical approach that can be used to set priorities for risk management 
actions. Moreover, to perform risk assessment of PFS containing genotoxic 
carcinogens, various approaches such as mode of action based PBK modeling 
and read across can even be integrated in the MOE concept. This facilitates risk 
assessment for compounds for which the toxicological database is only limited 
and the incorporation of matrix-derived combination effects in risk assessment 
on a case-by-case basis. Whenever carcinogenicity studies are lacking and read 
across from one compound to another is not possible, safety assessment of genotoxic 
and carcinogenic botanical ingredients can be performed using the TTC approach. 
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To date, the consumption of botanicals and preparations made thereof, such as 
plant food supplements (PFS) is increasing. Although such products generally 
have a high acceptance by consumers, PFS may contain compounds that are of 
possible concern for human health (EFSA, 2012). For example, some botanicals are 
known to contain compounds that are both genotoxic and carcinogenic (EFSA, 
2012). However, the risk assessment of PFS containing genotoxic carcinogens is 
accompanied with difficulties (EFSA, 2005). Moreover, an international scientific 
agreement on the best testing strategy for risk assessment of such compounds 
is not (yet) in place (EFSA, 2005). Therefore, the aim of this thesis was to test 
and validate new concepts for the risk assessment of PFS containing genotoxic 
carcinogens. 
Chapter 1 provides a general introduction to PFS, an introduction to 
the concepts tested, and an introduction to the model compounds tested in 
the present thesis. Moreover, Chapter 1 presents the aim and outline of the 
present thesis. 
An overview of the different approaches currently in use for risk 
and safety assessment of botanicals and botanical preparations is presented 
in Chapter 2. In addition, examples are provided of botanical compounds 
that are of potential concern for human health because of their genotoxic 
and carcinogenic properties or other mode of actions, neurotoxic effects or 
interactions with prescription drugs. 
Chapter 3 describes the application of the Margin of Exposure 
(MOE) concept for the risk assessment of PFS from Internet and the Dutch 
and Italian market. First, 30 botanical compounds with genotoxic and/or 
carcinogenic characteristics were selected based on available literature data. 
Most compounds that were judged to be both carcinogenic and genotoxic 
could be classified into two categories of botanical ingredients, namely the 
alkenylbenzenes and unsaturated pyrrolizidine alkaloids. In a next step, BMDL10 
values (i.e. the lower confidence limit of the benchmark dose resulting in a 10% 
increase in tumor incidence) were calculated for the alkenylbenzenes estragole, 
methyleugenol, safrole and β-asarone. In addition, intake estimates were made 
based on results from chemical analyses together with the recommended daily 
dose levels of the respective PFS indicated on the label. Finally, risk assessment 
was performed based on the MOE approach dividing the BMDL
10
 values by 
the estimated daily intakes. For several PFS, MOE values higher than 10,000 
were found indicating a low priority for risk management. In addition, for other 
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PFS MOE values lower than 10,000 were obtained indicating a priority for risk 
management. For PFS consisting of basil essential oil MOE values were even 
found to be lower than 10. This means that the daily estragole intake resulting 
from the use of such basil-containing PFS is comparable to the dose levels 
at which tumor incidences were detected in rodents. These PFS should be a 
priority for risk management actions. 
In a next step, mode of action based physiologically based kinetic (PBK) 
models were made for the alkenylbenzene elemicin in rat and human for which 
limited toxicity data is available (Chapter 4). Based on the results obtained, it was 
concluded that interspecies differences in bioactivation of this compound were 
limited. Moreover, the differences in the formation of the ultimate carcinogenic 
metabolites of elemicin and its structurally related analogues estragole and 
methyleugenol were also found to be limited. Based on these data and read 
across from available animal data for estragole and methyleugenol, BMDL10 
values were estimated for elemicin. Next, a risk assessment was performed 
using the MOE approach indicating that the elemicin intake resulting from use 
of herbs and spices and products made thereof such as PFS is of lower priority 
for risk management actions compared to the priority for risk management 
actions as defined for its structurally related analogues. Based on the results 
described in Chapter 4, it can be concluded that PBK modeling can provide a 
scientific basis for read across from one botanical compound to another thereby 
facilitating risk assessment. As a result, risk assessment can be performed for 
compounds for which only limited toxicity data are available without the need 
of performing animal bioassays. 
Subsequently, the effects on the bioactivation of estragole by 
compounds present in basil-containing PFS was studied (Chapter 5). Methanolic 
extracts of several PFS consisting of powdered basil material or basil essential 
oil were tested for their effect on in vitro sulfotransferase (SULT)-inhibiting 
activity. Interestingly, all methanolic extracts from basil-containing PFS were 
found to be able to inhibit SULT activity. However, the level of SULT-inhibiting 
activity was found to be more pronounced in PFS consisting of powdered basil 
material compared to that of PFS consisting of basil essential oil. Nevadensin 
was identified as the botanical compound responsible for SULT-inhibition 
in powdered basil PFS. Subsequently, the in vivo effect on estragole DNA-
adduct formation was predicted by PBK modeling. The PBK model predictions 
thus derived were used to refine the incidence of liver tumors reported in 
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literature which we used in our previous risk assessment for basil-containing PFS 
as described in Chapter 3. Results obtained revealed that the effects of estragole 
will be reduced in rodent bioassays when high doses of estragole and nevadensin 
would be administered simultaneously at ratios detected in PFS. However, results 
also revealed that the matrix-derived combination effect may be limited at lower 
dose levels of estragole and nevadensin relevant for the use of PFS indicating that 
the effect of the botanical matrix on the bioactivation of estragole should be tested 
at realistic intake levels. 
In a next step, a chemical analysis and safety assessment was performed for 
estragole in fennel based teas (Chapter 6). In dry fennel preparations estragole levels 
of 0.15–13.3 mg/g dry fennel preparation were found whereas the estragole content 
was found to be much lower in water infusions (i.e. 0.4-133.4 µg/25 mL infusion 
prepared from 1 g dry material). Based on these findings, the extraction efficiency of 
estragole into the infusion was determined to equal 0.1-2.3%. Interestingly, estragole 
levels were found to be about 3-fold lower in water infusions prepared from whole 
fennel fruits compared to water infusions prepared from fine cut fennel material. In a 
next step, an estimate of the daily intake of estragole resulting from the use of fennel 
teas was made based on chemical analysis and assuming the daily use of 1-3 cups 
fennel tea. Subsequently, MOE values were calculated by dividing the BMDL10 values 
for estragole, as obtained in Chapter 3 of this thesis, by the estimated estragole 
intakes resulting from the daily use of fennel teas. Results reveal that the daily use 
of fennel based teas is generally of low priority for risk management (MOE >10 000), 
especially when consuming one cup of fennel tea on a daily basis throughout life. 
However, the use of fennel based teas by children was found to be a priority for risk 
management. Nevertheless, when fennel based tea is used for a short period of 1-2 
weeks, proposed for the symptomatic treatment of digestive disorders, MOE values 
would be higher than 10,000 indicating a low priority for risk management. 
Chapter 7 of this thesis presents a general discussion of the results 
obtained. In addition, future perspectives are raised to further improve risk and 
safety assessment of PFS. 
Overall, the work presented in this thesis shows that the MOE concept 
is a useful approach in risk and safety assessment of PFS containing genotoxic 
carcinogens that can be used to prioritize risk management actions. In addition, 
integrating various approaches such as mode of action based PBK modeling and 
read across in the MOE concept was found to facilitate risk and safety assessment of 
botanical compounds even in the absence of a full set of toxicity data. 
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Momenteel neemt in Europa het gebruik van planten en plantaardige 
producten zoals plantaardige voedingssupplementen toe. Hoewel zulke 
producten doorgaans een hoge acceptatiegraad hebben bij de consument, 
kunnen plantaardige voedingssupplementen toxische ingrediënten bevatten 
en dat geeft reden tot zorg (EFSA, 2012). Zo kunnen bijvoorbeeld natuurlijke 
ingrediënten aanwezig zijn die zowel genotoxisch als carcinogeen zijn (EFSA, 
2012). De risicobeoordeling van plantaardige voedingssupplementen die 
genotoxische en carcinogene ingrediënten bevatten is niet gemakkelijk. Zo is 
er momenteel geen internationale overeenkomst over de beste strategie voor 
de risicobeoordeling van dergelijke plantaardige ingrediënten en preparaten 
(EFSA, 2005). Het doel van dit proefschrift was het testen en valideren van 
nieuwe concepten die gebruikt kunnen worden in de risicobeoordeling 
van plantaardige voedingssupplementen die genotoxische en carcinogene 
ingrediënten bevatten. 
 Hoofdstuk 1 geeft een algemene inleiding over voedings-
supplementen, een introductie over de in het proefschrift geteste methoden 
voor risicobeoordeling van plantaardige voedingssupplementen en een 
introductie over de in het proefschrift onderzochte genotoxische en carcinogene 
ingrediënten. Hoofdstuk 1 presenteert tevens het doel van dit proefschrift en 
geeft een overzicht van de hoofdstukindeling. 
 Een overzicht van de verschillende benaderingen die momenteel 
in gebruik zijn voor de risico- en veiligheidsbeoordelingen van planten en 
plantaardige producten is beschreven in hoofdstuk 2. Tevens worden er in 
hoofdstuk 2 een aantal voorbeelden gegeven van plantaardige ingrediënten 
die aanleiding geven tot zorg vanwege hun genotoxische en carcinogene 
eigenschappen of andere werkingsmechanismen, zoals neurotoxische effecten 
of interacties met geneesmiddelen. 
 Hoofdstuk 3 beschrijft de toepassing van de zogenaamde Margin 
of Exposure (MOE)-methode in de risicobeoordeling van plantaardige 
voedingssupplementen die verkregen zijn via internet en de Nederlandse 
en Italiaanse markt. Allereerst werden er 30 stoffen met genotoxische en/
of carcinogene eigenschappen geselecteerd op basis van de beschikbare 
literatuur. Het overgrote deel van deze stoffen behoorde tot een van twee 
belangrijke categorieën van toxische plantaardige ingrediënten, te weten de 
alkenylbenzenen en de onverzadigde pyrrolizidine alkaloïden. Vervolgens 
werden BMDL10-waarden (dat wil zeggen het laagste betrouwbaarheidsinterval 
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van de benchmark dosis die resulteert in een stijging van 10% van het aantal 
tumoren) berekend voor de alkenylbenzenen estragole, methyleugenol, 
safrole, en bèta-asarone. Ook werden er innameschattingen gemaakt. Deze 
innameschattingen waren gebaseerd op de resultaten verkregen via een 
chemische analyse en de aanbevolen dagelijkse dosis van het betreffende 
plantaardige voedingssupplement zoals aangegeven op het etiket. Gebruik 
makend van deze gegevens werd er een risicobeoordeling uitgevoerd met 
behulp van de MOE-methode door de BMDL
10
-waarden te delen door de 
dagelijkse innames. Voor een aantal plantaardige voedingssupplementen 
was de MOE-waarde >10.000, wat een lage prioriteit voor risicomanagement 
impliceert. Echter, voor andere supplementen werden MOE-waarden <10.000 
verkregen, wat een prioriteit voor risicomanagement impliceert. Voor 
plantaardige voedingssupplementen bestaande uit de essentiële oliën van 
basilicum werden zelfs MOE-waarden <10 gevonden. Dit wil zeggen dat de 
dagelijkse estragole-inname als gevolg van het gebruik van zulke supplementen 
vergelijkbaar is met de dagelijkse dosis estragole waarbij levertumoren in 
proefdieren zijn gevonden. Deze plantaardige voedingssupplementen zijn een 
prioriteit voor risicomanagement. 
 Vervolgens werd een zogeheten physiologically based kinetic (PBK) 
model geconstrueerd voor de alkenylbenzeen elemicine (hoofdstuk 4). Voor 
elemicine zijn in de literatuur slechts weinig toxicologische data beschikbaar. 
Op basis van de verkregen resultaten kon geconcludeerd worden dat de 
speciesverschillen in de bioactivering van elemicine slechts beperkt zijn. Ook 
de verschillen tussen de vorming van de uiteindelijke carcinogene metaboliet 
van elemicine en de vorming van de vergelijkbare carcinogene metabolieten 
van de structuurgerelateerde analogen estragole en methyleugenol, bleken 
beperkt. Gebruik makend van deze gegevens en van read-across naar de 
aanwezige data uit dierstudies uitgevoerd met estragole of methyleugenol, 
werd een schatting van de BMDL10-waarde voor elemicine gemaakt. Vervolgens 
werd een risicobeoordeling uitgevoerd met behulp van de MOE-methode. 
Op basis van deze risicobeoordeling werd geconcludeerd dat de inname van 
elemicine door het gebruik van kruiden en specerijen, en producten die daarvan 
gemaakt zijn, zoals plantaardige voedingssupplementen, een lagere prioriteit 
voor risicomanagement hebben in vergelijking met de structuurgerelateerde 
analogen estragole en methyleugenol. Gebruik makend van de resultaten zoals 
verkregen in hoofdstuk 4, kan geconcludeerd worden dat het gebruik van PBK-
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modellen een wetenschappelijke basis vormt voor read-across van het ene 
plantaardige ingrediënt naar het andere, structureel verwante, plantaardige 
ingrediënt waardoor een risicobeoordeling uitgevoerd kan worden voor een 
bestanddeel waarvoor slechts weinig toxicologische data aanwezig zijn, zonder 
dat er gebruik gemaakt hoeft te worden van proefdieren. 
 Hoofdstuk 5 beschrijft de effecten op de bioactivering van estragole 
door andere bestanddelen in basilicum-bevattende supplementen. Van 
elk van de geselecteerde basilicum-bevattende supplementen werd een 
methanolextract gemaakt. Deze extracten werden vervolgens getest op het 
effect op de sulfotransferase (SULT)-activiteit. SULT-activiteit werd door alle 
geteste extracten geremd. Echter, SULT-activiteit werd sterker geremd door 
supplementen die basilicum in poedervorm bevatten in vergelijking met 
supplementen die de essentiële oliën van basilicum bevatten. In supplementen, 
bestaande uit basilicum in poedervorm, werd nevadensin geïdentificeerd als 
het plantaardige bestanddeel dat verantwoordelijk was voor de remming van 
SULT-activiteit. Vervolgens werd PBK-modellering toegepast om de in vivo 
effecten op estragole DNA adductvorming te voorspellen. Deze voorspellingen 
werden gebruikt om de incidentie van levertumoren, zoals beschreven in de 
literatuur, te verfijnen. De verkregen resultaten lieten zien dat de effecten van 
estragole lager zullen zijn wanneer hoge concentraties estragole en nevadensin 
gelijktijdig toegediend worden in ratio’s zoals ze ook voorkomen in plantaardige 
voedingssupplementen. Echter, de resultaten toonden ook aan dat dit effect 
beperkter is wanneer concentraties estragole en nevadensin gebruikt worden 
die worden bereikt bij het gebruik van plantaardige voedingssupplementen. 
Dit benadrukt dat de effecten van de plantaardige matrix op de bioactivering 
van estragole voor realistische innames getest zou moeten worden. 
Hoofdstuk 6 beschrijft de chemische analyse en veiligheids-
beoordeling voor estragole in venkelthee. De concentraties estragole in droge 
venkelpreparaten waren gelijk aan 0.15-13.3 mg/g droog venkelpreparaat. De 
hoeveelheid estragole was veel lager in waterinfusies, namelijk 0.4-133.4 µg/25 
mL infusie gemaakt van 1 g droog venkelmateriaal. De extractie-efficiëntie 
van estragole in de infusie is dus gelijk aan 0.1-2.3%. De hoeveelheden 
estragole in waterinfusies, gemaakt van intact venkelmateriaal, was 3 keer 
lager dan de hoeveelheid estragole in waterinfusies gemaakt van fijngesneden 
venkelmateriaal. In een vervolgstap werd er een schatting gemaakt van de 
dagelijkse inname van estragole als gevolg van het drinken van venkelthee. 
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Dit werd gedaan door gebruik te maken van de resultaten verkregen via 
chemische analyse en ervan uitgaande dat er dagelijks 1-3 koppen venkelthee 
geconsumeerd worden. MOE-waarden werden berekend door de BMDL
10
-
waarden voor estragole, zoals verkregen in hoofdstuk 3 van dit proefschrift, 
te delen door de geschatte estragole-inname via het gebruik van venkelthee. 
Op basis van deze veiligheidsbeoordeling werd geconcludeerd dat het 
dagelijks gebruik van venkelthee over het algemeen van lage prioriteit voor 
risicomanagement is (MOE >10.000), voornamelijk wanneer dagelijks 1 kop 
venkelthee geconsumeerd wordt. Het gebruik van venkelthee door kinderen is 
wel een prioriteit voor risicomanagement. Echter, in het geval van de behandeling 
van symptomatische klachten als gevolg van spijsverteringsstoornissen wordt 
meestal geadviseerd venkelthee te gebruiken voor een periode van 1-2 weken. 
De MOE-waarden voor een dergelijk kortdurend gebruik van venkelthee zouden 
3 orden van grootte hoger zijn en dus >10.000 hetgeen een lage prioriteit voor 
risicomanagement impliceert.
 Hoofdstuk 7 presenteert een discussie van de verkregen resultaten. 
Daarnaast worden toekomstige perspectieven beschreven om de risico- en 
veiligheidsbeoordeling van plantaardige voedingssupplementen verder te 
verbeteren. 
 Alles bijeen laat het werk, zoals gepresenteerd in dit proefschrift, zien 
dat de MOE-methode geschikt is voor de risico- en veiligheidsbeoordeling 
van plantaardige voedingssupplementen die carcinogene en genotoxische 
bestanddelen bevatten. De MOE-methode kan gebruikt worden om prioriteit 
voor risicomanagement aan te geven. Bovendien kan met name de combinatie 
van verschillende methoden, zoals het gebruik van PBK modellering en read-
across met de MOE methode, van nut zijn voor de risico- en veiligheidsbeoordeling, 
en de mogelijkheid bieden een risico- en veiligheidsbeoordeling uit te voeren 
zelfs voor plantaardige voedingssupplementen waar geen toxicologische 
informatie voor aanwezig is. 
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